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Objective. There is an on-going worryingly low patient entry to Cancer Clinical Trials (CCTs) 
in the UK. The doctor-patient communication difficulties have been highlighted as a significant 
reason for this low entry. The purpose of this study was to explore the role of interprofessional 
communication in seeking informed consent (IC) and how this may impact on patient uptake 
to CCTs. The use of overarching concepts assisted in framing the aims of the study. Research 
questions focused on the experience of interprofessional responsibility as shaped by time, the 
experience of gaining trust and its association with the patient’s best interest, and the 
experience of facilitating patient’s autonomy.  
Methods. The research design encompassed a qualitative phenomenological approach within 
a case study to ascertain the experiences of 26 clinical and non-clinical professionals who 
directly or indirectly communicated with CCT adult patients. The research methods used to 
collect data comprised in-depth semi-structured interviews. Data were complemented by the 
practitioner researcher’s research diary which contributed to the analytical approach.  
Results. The findings of the study have shown how interprofessional communication impacts 
on obtaining IC to CCTs. The medical professionals were primarily positioned for their 
responsibility for IC, although when explored from an interprofessional and nursing standpoint, 
the role of time as a process became increasingly significant. Both professionals viewed trust 
as integral to obtaining IC to CCTs, but there were differences between how trust was initially 
gained and subsequently maintained. While participants considered facilitating patient 
autonomy a prerequisite, the possibility of valid consent if relied solely on patient autonomy 
was questionable.  
Conclusion. Above all else, it was found that interprofessional communication over time 
maintained the professional-patient trusting relationship wherein facilitating the relational 
component of autonomy defined valid and lasting IC to CCTs.  
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Glossary of Terms 
Equipoise: An ethical basis for the clinician to assign patients to different arms of a study 
(Freedman, 1887). The clinician does not know the efficacy of the trial treatment choice, which 
is often blinded. 
Haematology: The medical speciality of blood diseases / dyscrasias. 
Informed Consent (IC) in Clinical Research: The voluntary patient authorisation of 
participation in a clinical trial as a result of adequate information disclosure. To ensure IC is 
valid and real, 3 critical and essential elements are required; voluntarism, information 
disclosure, and decision-making capacity (Gupta, 2013).  
Multi-disciplinary Team (MDT): A multi-professional or interprofessional team referred to 
as involved in the patient’s care and decision-making.  
Oncologist: A medical doctor who specialises in cancer care and treatments. 
Phase 1 & 2: Earlier phase trials designed to ascertain the drug safety via dose escalation. 
Phase 3 & 4: Randomised or Later phase trials designed to ascertain the efficacy of a new drug 
against a standard treatment. 
Randomised Controlled Trials (RCTs): A trial which ascertains the efficacy and safety of a 
new drug when compared to a standard treatment drug (Sedgwick, 2011). The computer 
randomly assigns the patient to a study arm. RCTs are considered the ‘Gold standard’ in study 
design available (Grossman, 2005).  
Relational autonomy: This type of autonomy seeks to take into consideration the social and 
political structures, and forms of oppression within decision-making, often due to social 
restrictions on an individual’s ability to act autonomously. Relational autonomy challenges the 
assumptions found in the bioethical literature that views autonomy as an individual endeavour 
(Mc Leod and Sherwin, 2000). 
Research diary: Refers to the reflective journal kept by the researcher which captures the 
assumptions and the reflectivity between the researcher and the study. 
‘Therapeutic error’: When  patients are susceptible to ‘therapeutic misconception’ (confusing 
the context of the trial), ‘unrealistic optimism’, and ‘therapeutic mis-estimation’ due to their 
prior research understanding (Jansen, 2014, p.7). 
Trust: A psychological contract gained by the interaction between two parties involving a 
social dimension (Gilson, 2003; Hurd et al., 2017). 
Shared decision-making (SDM): A partnership in decision-making between the physician or 
healthcare professional and the patient (Barton and Eggly, 2009).  
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Chapter One: The Introduction  
________________________________________________________ 
1.0 Introduction 
The focus of this thesis is the interprofessional experience of obtaining / seeking informed 
consent to Cancer Clinical Trials (CCTs) and the role of communication within this. The study 
pertains to the adult cancer patient population assumed to have mental capacity as opposed to 
children. From my previous practitioner researcher and educator experience within the high-
risk cancer treatment and research, I have developed a long-standing interest in finding out 
why there are on-going difficulties with obtaining informed consent from cancer patients to 
clinical trials. My particular interest lies in the value of interprofessional communication within 
a contemporary setting.  
CCTs are necessary for the advancement of cancer treatment, yet ‘slow accrual to CCTs 
impedes the progress of effective cancer treatments’ (Brown et al., 2011, p. 1). It is estimated 
internationally that less than 5% of adult cancer patients enter CCTs (Unger et al., 2016). The 
UK National Cancer Patient Experience Survey (NCPES, 2018) evidenced that CCTs are 
discussed with less than 30% of cancer patients. However, there has been some advancement 
in the UK CCT recruitment since improvements to research networks within the National 
Health Service (Jenkins et al., 2010). Clinical trials have long since been known to cause 
communication difficulties for clinicians obtaining informed consent from cancer patients 
arising from the way information is delivered by physicians and understood by patients 
(Fallowfield et al., 2002; Jenkins et al., 1999). The interprofessional experience of 
communication difficulties is under researched. It is intimated that there are shortcomings in 
professional-patient communication in cancer research. Sankar asserts that the social context 
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of communication is ‘overlooked’ in relation to “what, how and by whom it is said” (Sankar, 
2004, p.1). 
To fully understand the communication practices at play the experience of all 
professionals involved needs exploration. The introduction begins with a brief overview of 
obtaining informed consent to CCTs from the traditional standpoint. Following on from this, 
the importance and aims of the study are presented within the context of the chosen research 
method. The structure of the thesis is outlined indicating the content of the subsequent Chapters 
2-9.  
1.1 An overview of informed consent to cancer trials 
Put simply, informed consent (IC) is the voluntary patient authorisation of participation in a 
clinical trial as a result of adequate information disclosure. To ensure IC is “valid and real, 3 
critical and essential elements are required; voluntarism, information disclosure and decision-
making capacity” (Gupta, 2013, p. 1). The medical profession has traditionally held the 
responsibility for information-disclosure prior to obtaining informed consent and subsequently 
their quality of communication with patients is paramount. Low recruitment has been attributed 
to the physician’s communication or lack of patient understanding owing to an inability to 
achieve informed consent in the first instance (Butow et al., 2014; Brown et al., 2004; Jenkins 
et al., 2010; Brown et al., 2011). The majority of the sociological research pertains to these 
medical challenges or is aimed at improving communication practices for the medical 
profession.  
There has been uncertainty about how much information doctors ought to provide to 
patients to enable patient understanding and to achieve informed consent. Despite training 
programmes to address and improve doctors’ communication strategies, Brown et al. (2011) 
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found shortcomings relating to doctors poorly explaining information. Furthermore, Brown et 
al. (2011) showed that trust in the physician was a defining factor necessary that enabled 
patients to follow the physician recommendation, sometimes favouring a paternalistic 
physician approach to deciding on the clinical trial, potentially negatively on achieving 
consent.  
Where patient understanding is questionable, the validity of informed consent could be 
undermined owing to a lack of patient autonomy. The practice of obtaining informed consent 
that encompasses vast quantities of information delivery may be problematic when limited to 
a single patient encounter, or when limited to one professional encounter. It is speculated that 
obtaining informed consent is an interprofessional process of interaction with patients 
(Corrigan, 2003).  
1.2 The importance of the thesis 
The central purpose of this thesis is to explore the role of interprofessional communication in 
seeking informed consent and how this may impact on adult patient uptake to CCTs. The role 
of interprofessional communication was explored through the experiences of the professionals 
involved. Contributing to the achievement of this purpose, this thesis will detail the 
interprofessional experience (to include nurses, doctors and clinical managers) of obtaining 
informed consent to CCTs by exploring aims set out as individual research questions:  
1. How professional responsibility is experienced as determined by time spent with 
patients for its impact on obtaining of informed consent to CCTs. 
2. The experience of how trust is gained or lost by professionals within an ongoing 
process of informed consent, and how perceptions of patients’ trust are associated 
with maintaining the patients’ best interest. 
3. How professionals experience facilitating diverse patients’ autonomy when 
obtaining ‘valid’ informed consent to CCTs. 
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4. Whether an enhanced way of interprofessional working improves the 
communication difficulties that underlie poor informed consent to CCTs.  
It is speculated that this exploration will build on the sociology of professions to gain a better 
understanding of interprofessional communication practices needed to improve obtaining 
informed consent to CCTs. In Chapter two, the background to the study is presented.  
1.3 The conceptual approach 
The key concepts underpinning the focus of this research are outlined and interlinked with each 
other in Chapter three. The concept of communication as a central focus within professionalism 
is linked to the trust and autonomy needed to achieve informed consent to CCTs.  
1.4 The methodology 
The methodological approach was set against the lens of the conceptual framework wherein 
the key concepts of informed consent, communication, professionalism, trust and autonomy 
are interlinked. See Glossary of terms on page 10. A qualitative phenomenological approach 
was used to explore the aims as set out as research questions. Data were collected by 
undertaking 26 semi-structured interviews with nurses, doctors and clinical managers and by 
keeping a research diary. As the researcher was also a professional and manager within the 
setting, a phenomenological approach described by Heidegger (1962) was chosen allowing for 
the interpretation of more than one truth.  
1.5 Data analysis 
Data were analysed by categorising into codes and subsequent themes from the language, 
words and phrases the participants used to relay their experiences with patients. The data were 
interpreted from the insider researcher’s perspective as aligned with the concepts identified. 
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The practitioner researcher and participants view is later explained as a fusion of one 
constructing the other (Munhall, 1989). 
1.6 The results and discussion of the findings 
There are three analysis / discussion chapters spanning Chapters six to eight. In Chapter six 
there is a focus on how professionals experienced their responsibility. In Chapter seven the 
professional experience of gaining, and losing trust is explored, and its association with 
patients’ best interest. In chapter eight, the difficulties with facilitating patients’ autonomy is 
explored in relation to specific diverse cancer patient needs. In the final Chapter, a summary 
of the findings and the conclusions are provided along with the strengths and limitations of the 




Chapter Two: The Background 
__________________________________________________________________ 
2.0 Introduction 
Since the early nineties, CCTs have led the way in clinical trial progression in the UK, and it 
was then that doctors’ communication practices first received attention (Fallowfield, 1995). 
Low recruitment to CCTs has continued to be attributed to difficulties with doctor-patient 
communication (Brown et al., 2011). Yet the field of clinical trial contemporary practice is 
advancing to encompass nursing and interprofessional practice. It is necessary to outline the 
origin of informed consent to clinical trials since its inception. It will be explained how 
professionals need to meet regulatory and ethical requirements to ascertain informed consent. 
Furthermore, the significance of clinical trial phases in relation to CCT patient consent is 
illustrated.  
2.1 The origin of informed consent 
The doctrine of informed consent as we know it today is based on moral philosophy and law. 
In the aftermath of the Nazi War crimes in World War 11, the Nuremberg Code was created in 
1947 laying down regulations for ethical conduct in research (Jefford and Moore, 2008). The 
Declaration of Helsinki in 1964 established an ethical set of principles internationally requiring 
that participants entering research are adequately informed to include research risks and are 
given the right to refuse or withdraw from the research at any time and to provide written 
informed consent (World Health Association, 2008).  
The 1970’s brought about a detailed framework of clinical trial conduct which required 
all professionals undertaking research to adhere to Good Clinical Practice (GCP) and 
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International Harmonisation (IHC). This framework of clinical trial conduct was formalised by 
the Belmont Report (1979), issued by the National Commission for the Protection of Human 
Subjects of Biomedical and Behavioural Research. Central to the framework is the emphasis 
on the responsibilities of researchers to protect and respect  individual patients / participants 
from harm and to ensure transparency for the sharing of research information. 
2.2 The components of informed consent to CCTs 
Arising from the need to respect and protect patients / participants from harm as a primary goal 
in clinical practice, four bioethical principles are commonly referred to. These are  beneficence, 
non-maleficence, respect for autonomy and justice (Beauchamp and Childress, 2001). The 
principle of beneficence holds that the trial benefit is greater than the side-effects, moreover, 
ensuring against non-maleficence (harm). The provision of information about the trial is 
necessary for the patient to attain an understanding that is sufficient for him / her to consent to 
the trial. In order to achieve informed consent, the primary focus is to attain the individual’s 
autonomous and voluntary authorisation to participate in research (del Carmen and Joffe, 
2005).  
While advocating for individual autonomy according to Beauchamp and Childress 
(2001), it could be perceived that autonomy trumps other principles, however, in reality there 
is often a preference among patients for shared decision-making or ‘relinquishing autonomy’ 
respectively (Biedrzychki 2011; Sinding, 2010). Furthermore, Corrigan (2003) speculates that 
the reliance on ‘individual autonomy’ underestimates the importance of the social dimension 
when obtaining consent. In more recent years and pertinent to CCTs, the quality of informed 
consent received attention, possibly due to questions about the lack of quality of informed 
consent that is achievable or the difficulty in achieving it.  
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2.3 The progression of informed consent to CCTs 
As the field of clinical trial practice has expanded it is possible that professional boundaries 
are being challenged or even eroded. The nursing profession have sought professional role 
advancement within clinical research although their responsibility for IC remains often 
unclearly defined or evaluated, requiring exploration.  
2.3.1 The medical and traditional standpoint 
Commonly oncologists (cancer specialist doctors) hold a dual responsibility as a researcher 
and as a clinician, which Barton and Eggly (2009) identified as a central ethical issue due to 
differing role priorities relating to upholding patient autonomy or using a shared decision-
making model. Medical communication was found to be problematic because the way doctors 
delivered information could be persuasive, for example placing ‘value judgements’ on the trial 
(Barton and Eggly, 2009; Weinfurt et al., 2003; Albrecht et al., 2003; and Butow et al., 2014). 
Even after doctors training in consent, still the language used continued to be arguably 
persuasive, yet consent improved if more time was given to patients (Brown et al., 2004; Brown 
et al., 2007, Bergenmar et al., 2011). 
2.3.2 The process of informed consent as a social endeavour 
Although seeking consent is evidenced by the patient signing the consent form, Corrigan 
(2003) asserts that in reality consent is unlikely a ‘one-time event’ and concurs with Brown et 
al. (2007) that consent is a process over time. Owing to the complexity of information delivery 
needed, particularly in relation to randomised controlled trials (RCTs), sufficient time is 
essential to meet consent requirements. Integral to incorporating patient choice, more time 
afforded patients with an opportunity to express preferences (Brown et al., 2004; Hietanen et 
al., 2007). In more recent times the notion of shared decision-making (SDM) has been shown 
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as the preferred approach because it involves patients in decision-making and patients have 
shown preferences for sharing the responsibility of the decision to enter a trial as opposed to 
the referred to ‘loneliness’ of an autonomous patient consent decision (Madsen, 2007).   
The problem with obtaining consent over time is that the traditional role of the medical 
profession may be constrained in the achievement of clinical trial consent. Once informed 
consent is achieved, the continuation of care must prevail throughout the duration of the clinical 
trial which can take several months and longer for the follow up, which arguably may span 
interprofessional practice.   
2.3.3 The emergence of the interprofessional role 
The doctor-patient relationship holds particular significance because of the power dynamic 
created where trust is needed before the medical recommendation for the clinical trial is 
accepted by the patient. Even when informed consent is obtained there is the possibility that it 
may not be of reliable quality, notwithstanding the possibility that consent can be lost during 
the duration of the trial. There may be care gaps that doctors are challenged to fulfil. The 
possibility of the interprofessional social interaction with patients may bring about an 
improvement.   
In the studies that have included the interprofessional perspective nurses play a 
significant role in spending time providing comprehensive information to patients (Loh et al., 
2002; Burke et al., 2014; Beadle et al., 2011). However, the role of nurses to date within 
informed consent has not received sufficient recent acknowledgement in the UK. Meanwhile 
external to the UK, particularly in the USA and Australia, important frequent nursing activities 
centred around the achievement of informed consent denoting that the nurse’s role holds value 
in the achievement of informed consent (Wilkes et al., 2012; Nagel et al., 2010; Catania et al., 
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2012). There is room for more recent insight into the interprofessional experience in the 
informed consent process in the UK which may highlight role advancement as the medical 
standpoint is challenged or supported.  
2.4 The significance of clinical trial phases for cancer patients 
It is necessary for the development of a therapeutic drug to undergo some years of phased 
clinical trial research to realise standard treatment status. Drug research is commonly divided 
into 4 phases (mainly 1- 1V). The characteristics of the most commonly offered trials and the 




Table C1.0 Trial phases at a glance (adapted from CRUK, 2019) 
Phase Number of patients 
Cancer type /stage 
of disease / 
prognosis 
Aims / objectives of trial / 
characteristics 
Randomised? 
(RCT) Patient Issues 
Professional 
Issues 
0 Small,10 to 20 people 
Many cancer types 
/ Later stages / Poor 
prognosis  
Checking if drug is harmful  No Same as Phase 1  Same as Phase 1 
1 Small, 20 to 50 people 
Many cancer types 
/ Later stages / Poor 
prognosis  
Find outside effects (by dose 
escalation) / Effect on body. 
Drug safety / Early 
pharmacological actions 
(Sedgwick, 2011) 














(Van der Biessen 
et al., 2017) 




from 10’s to 
over 100’s 
1-2 Cancer types / 
Earlier or Later 
stages 
Safety is advanced & more 
information on the therapeutic 
efficacy  
Sometimes 
Not RCT - 
Same as phase 1  
If RCT - same 
as phase 3 
Not RCT - Same 
as phase 1  








Usually one cancer 
type / Earlier stage 
/ Better - Good 
prognosis 
Comparing the safety & 
efficacy of new treatment to 
the standard treatment / drug, 
pre-licensing (Sedgwick, 
2011) 
Assigned to different arms 
Yes 
 
Most scientific / 






















Albrecht et al., 
2003) 
? Validity of 
consent 
4 Medium to  Large One cancer type 
Finding out more about long-
term benefits / Side effects / 
Marketing 
No Not seen often Not seen often 





In this chapter, the origin of informed consent is outlined in relation to the ethical principles 
professionals need to meet. It has been indicated that the traditional medical role has had 
difficulties with the delivery of information to patients. The potential difficulty for upholding 
patient autonomy is highlighted. The more recent social dimension of seeking consent as a 
process appears to span the professions. In the next chapter, the philosophical concepts that 
underpin obtaining informed consent to CCTs are presented. 
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Chapter Three: The conceptual framework 
___________________________________________________________________ 
3.0 Introduction 
In this chapter, the foundations for this research study are presented by looking through the 
lens of the main concepts (ideas). The conceptual framework has underpinned the study as 
connections were formed between interrelated concepts, which Polit and Beck (2012) highlight 
as ‘illuminating relationships’ between the main concepts, theory, practice and the insider 
practitioner researcher’s assumptions. This relationship can oscillate between higher level 
theoretical ways of understanding and some lower level theories as derived from research 
studies, although the literature review focuses on lower theoretical findings. The 
interconnections derived from the main concepts has led to the appropriate methodology 
chosen from which the theory is interpreted for practice. As the phenomenon explored is multi-
faceted, there will be a breakdown of how the main concepts relate to informed consent in the 
CCT setting.  
The theory sought is aimed at the experience of professional communication within 
informed consent in the CCT setting. The concept of professionalism for the relevant 
professions is set out, indicating how professional identities impact on interprofessional 
practice. The relevance of the concepts of power and time within the concept of professional 
responsibilities is presented. Following on from this; the concepts of trust and patient autonomy 
within CCTs is outlined. But first, informed consent is the voluntary patient authorisation of 
participation in a clinical trial as a result of adequate information disclosure. Three critical and 
essential elements are required to ensure validity; “voluntarism, information disclosure and 
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decision-making capacity” (Gupta, 2013, p. 1). The way professionalism interacts with 
informed consent is now outlined. 
3.1 The concept of Professionalism 
Understanding what it means to be a professional not only relies upon the regulatory 
components to be met to fulfil informed consent, for example the requirements of the relevant 
professional governing bodies, namely the General Medical Council (GMC) or the Nursing 
and Midwifery Council (NMC). Professionalism is also informed by the experience of practice 
at a given time. The professional communication mostly thought to be involved in obtaining 
informed consent to CCTs is derived from mainly the doctor-patient relationship and possibly 
the nurse-patient communication, notwithstanding the interaction between these professions in 
relation to the patient. The social structure and norms of the professions bears relevance to how 
both standard practice is experienced and challenged. There may be a gap or a disconnect 
between what is the norm experienced and how that is deconstructed by the contemporary 
experience to formulate a new reality or ‘truth’.  
The medical profession has held the power and responsibility over this traditional role 
of obtaining informed consent. Friedson (2001) emphasised that a professional is ‘self -
regulating’ and can act on knowledge and skills to formulate judgment to make decisions, 
arguably competencies required to recommend a trial treatment for a patient. It is known that 
the physician is dominant in the informed consent discussions with patients (Butow et al., 2014; 
Brown et al., 2004). It has been recognised that within the forum for decision-making known 
as the Multidisciplinary team (MDT), there is a lack of nursing involvement and the MDT can 
be medically dominated (Lamb et al., 2011). On the other hand, nurses have not traditionally 
held the responsibility for informed consent and are believed by Davis (2000) to be adjuncts to 
the medical profession. Indeed, more traditionally nurses were marginalised as having lower 
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status by having less knowledge and autonomy (Carpenter, 1993). However, Stein (1967) 
believed that the nurse could influence the doctor’s decision covertly by providing information 
rather than challenging. More recently, Banks and Gallagher (2009) described the general 
nursing responsibility as a ‘duty of care’. However, to encompass care for a patient Davis’ 
notion of professional identity as emotional detachment may not fit with what is inherent to 
nursing or what is needed / experienced in clinical trial practice.  
The interprofessional experience of communication with CCT patients may provide 
reason to challenge the traditional norms and what has been taken for granted of the 
responsibilities for informed consent. To this end, it is worth considering Foucault’s (1979) 
post-modern approach to power affecting society in a good or a bad way. He asserts that placing 
oneself in a discursive practice can change throughout history. He proposes a concept around 
sexuality as opposed to feminism which may affect nursing as mainly a female profession. In 
addition, the distribution of power needs to not take only a top down approach but is prevalent 
in all levels of society (Hoy, 1986) possibly challenging the known interprofessional power 
dynamics. Possible challenges within or between professional groups may have relevance for 
how professions exercise their power and responsibility through communication. Furthermore, 
external forces due to the potential for pharmaceutical and managerial target influences within 
the CCT setting may threaten what Evetts (2011) calls the ideology of a profession because of 
control from organisational objectives in contemporary practice.  
In more recent years interprofessional practice has emerged as professionals 
complementing each other’s role (Hammick et al., 2009), where roles overlap and professional 
boundaries have been extended, which may be relevant to CCT practice. While Hammick et 
al. (2009) recognised interprofessional practice as care professionals complementing each 
other’s roles, there is potential for tension or challenges to roles due to overlap and separation 
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of roles. The possibility for role overlap may arise because both doctors and nurses may assume 
responsibility for information giving or play a part in decision-making by advocating for the 
patient. Possible challenges to the norm may prove morally burdensome to uphold 
responsibility yet work interprofessionally where boundaries are blurred in keeping with Engel 
and Prentice (2013). However, to understand the experience of practice it is essential to find 
out how the professions socially orientate themselves. It may be that the professional 
socialisation is in a state of continuous change because of what Abbott (1988) asserts as arising 
from competition over the division of labour. The way labour is defined may relate to how the 
availability of time impacts on roles.  
3.2 The significance of time as a concept 
The existing sociology emphasised the importance of professionals, namely doctors gaining 
consent as a ‘process’, ‘over time’ as opposed to gaining consent in a ‘given moment of time’ 
or ‘one-time event’ (Corrigan, 2003, p.786, 788; Jansen et al., 2014, p.30). In the context of 
high-risk lung cancer patients, one reason for obtaining consent over time given was that 
patients need time to deliberate, requiring ‘slow construction’ of information that is ‘explained 
and reformulated’ (Pujol et al., 2016, p.1). The professional duty to provide ‘an adequate 
information base’ supports informed consent, allowing enough time to enable an understanding 
of the risk-benefit in order to facilitate patient autonomy (Beauchamp and Childress ,2001, p. 
321; Herring, 2006). Providing an ‘adequate information base’ requires professionals to spend 
time with patients. Strazdins et al. (2016, p.1) suggests that time is ‘socially shaped’. 
Furthermore ‘qualitative time’ is the ‘quality’ of social time, ‘derived from a group’s beliefs 
and customs’ Merton (1937, cited in Hassard, 2001) whereas, quantitative time is regulated by 
the ‘quantity’ of time, Sorokin and Merton  (1937 cited in Hassard 2001). It is argued that 
‘quantitative time’ ‘understates qualitative time’ which can be operated ‘within irregular self-
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determined temporal patterns’ (Hassard 2001, p.136,137). It would be insightful to find out 
how ‘quantitative time’ and ‘qualitative time’ impact on obtaining informed consent.  
The research in general practice has mainly explored generally how time is lived in 
medical practice, thereby impacting interactions with patients (MacBride-Stewart,2013; 
Horobin and McIntosh, 1983; Armstrong, 1985). It is  noted that for doctors time is constructed 
in ‘units’ in relation to both the ‘task’ and ‘socio-temporal structures’ in keeping with Hall, 
(1989 cited in Deery 2008). The example used by Deery (2008) refers to doctors exercising 
their responsibilities within the time boundaries of outpatient appointments. Conversely, 
‘process time’ was argued in the nurse midwifery context as ‘the plural’ and ‘relational’ 
‘context-linked’ to the nature of time’ involved in care, which is ‘relationship-governed’ 
according to Davies (1994 cited in Deery, 2008). ‘Relationship-governed’ time may also have 
a function in achieving trust within a power dynamic between the professional and the patient 
underlying informed consent.  
3.3 Trust for diverse cancer patients 
Within the sociological literature, the most prevalent components of the concept of trust is that 
the ‘trustor (the patient) has positive expectations regarding both the competence of the 
professional (competence trust), the trustee, and that they (the trustee) will work in their best 
interest (intentional trust)’ (Calnan and Rowe, 2008, p7). Indeed, there is a bioethical view that 
informed consent relies upon trust (Eyal, 2014). Sociological theory has suggested a power 
dynamic between the trustor and the trustee where the offer of the trial facilitated the 
expectation of hope for cancer patients by using positive language (Brown et al. 2015). 
However, the facilitation of patient trust and hope could be challenging for relationship 
building because the trial outcome is uncertain and carries the risk of unpleasant or even life-
threatening side-effects. Professional-patient interactions are important for the development of 
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trust needed for informed consent because of the CCT clinical uncertainty. Indeed, 
demonstrating informed consent would require for the ‘trustor’ to display ‘active’ trust as 
opposed to ‘passive’ trust (Giddens,1990;1994), who describes ‘active’ trust as enabling a 
patient to take an active ‘leap’ by ‘bracketing out’ the uncertainty of the CCT outcome (Brown 
et al., 2015). As professional-patient interactions are the focus of experience, the ‘micro’, as 
opposed to ‘macro’ organisational trust experience requires exploration (Gilson, 2003).  
Informed consent to CCTs is needed to span a prolonged process of trial treatment 
which involves patient care across professional teams. However, Hurd et al. (2017) found that 
trust can be most vulnerable to disruption during transition of care between teams. Patients 
may have initial trust where unconditional or what Calnan and Rowe called ‘blind trust’ (2008) 
in the doctor’s expertise and knowledge is experienced, which Greener (2003) said can mitigate 
the degree of risk involved in patients’ choices. ‘Unconditional trust’ can be based on 
dependency, hope and ‘faith’, which can be non-rational arising from an affective or emotional 
bond (Lewis and Weiger,1985). However, Calnan and Rowe (2008) found that trust was also 
conditional and rationally based, derived from the experience of good care, competency and 
effective communication skills. With regard to maintaining trust, Hurd et al. (2107) argued that 
the on-going ‘traditional trust’, is apart from the ‘initial trust’, a combination of emotional 
(affective) and knowledge-based (competency-based) trust, in an advanced stage. The 
possibility of the disruption of on-going trust is important and could avoid patient attrition from 
the trial. Furthermore, patients already on the trial have an expectation of hope (Simpson, 
2004), which Barbalet (2008) proposed professionals are required to honour, possibly by 
upholding trust.  
The definition of trust as dependent on acting in the patients’ best interest according to 
Calnan and Rowe (2008) may have implications for professional interactions with patients. It 
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is possible that gaining patients’ trust is likely to be influenced by what professionals believe 
is in a patients’ best interest. Professionals aim to work in collaboration following the 
Multidisciplinary Team best interest decision. However, Wood et al. (2007) and Blazeby et al. 
(2005) asserted that medical discordance with MDT decisions in cancer care was attributed to 
different medical perceptions about the patients’ best interest and ‘unknown factors’ causing 
practice to unfold differently outside of the MDT. Trial design, for instance was highlighted 
by Jenkins and Fallowfield (2000) as a communication barrier to cancer patient’s trial 
recruitment after the MDT recommendation. Gaining and sustaining a trusting relationship 
based on good interprofessional communication may help to alleviate the possibility of the loss 
of trust and ensure improved patient understanding, arguably needed for patient autonomous 
decision-making. 
3.4 Autonomy as central to obtaining informed consent 
Previous theorists have examined the value of autonomy extensively in relation to an 
individual’s ability to determine freedom of choice and display rationality (Dworkin, 1988, p. 
103; Kant, cited in Paton, 2001; Mill, cited in Collini, 1989). Indeed, Mackenzie (2008) 
considers respect for autonomy as a ‘cardinal moral value’. In the healthcare setting, day-to-
day practice encompasses the duty of professionals to enable patients’ autonomous choice and 
patients’ decision-making. O’Neill (2002) says that facilitating what she refers to as ‘individual 
autonomy’ is a professional duty, while Beauchamp and Childress (2001, p. 64) assert that 
‘respect for autonomy’, ‘obligates the professional, to foster adequate decision-making’, by 
ensuring information disclosure, understanding and ‘voluntariness’. However, facilitating the 
patient’s autonomy to enable consent could be problematic if the patient struggles to 
understand the information disclosed which could place doubt over the possibility of respecting 
‘full’ autonomy as alluded to by O’Neill (2002). It may be necessary for the professional to 
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consider the validity of consent by assessing the amount of autonomy that the patient displays, 
depending on the patient’s ability, knowledge or desire to make a decision about a trial 
treatment.  
It has been previously recognised that the ‘validity’ of informed consent depends on 
the patient’s moral power and freedom to decide or ‘voluntariness’ (Chwang, 2016; Bergenmar 
et al., 2008). Insider researcher assumptions question the validity of informed consent in the 
CCT setting because of the patients’ emotional and cognitive perceptions about the trial. The 
patients’ ability and freedom to consent could be impacted upon because of an asymmetry in 
physician/patient knowledge or a distorted understanding of information by patients. For 
instance, Jansen (2014, p.7) refers to ‘therapeutic error’, where patients are susceptible to 
‘therapeutic misconception’ (confusing the context of the trial), ‘unrealistic optimism’; and 
‘therapeutic mis-estimation’ (due to their prior research understanding). The patients’ illness 
stage can also impact on their emotional desire to enter the trial. Dolly et al. (2016) highlights 
that a feeling of patient ‘desperation’ impacts on informed consent for advanced cancer patients 
embarking on trials. Additionally, a lack of the patients’ understanding of information could 
pose difficulties for facilitating respect for autonomy. Known associated language factors are 
often related to socio-economic and illiteracy barriers to informed consent in ethnic minority 
populations resulting in patients’ lacking trial understanding (Schrank et al., 2016; Durant et 
al., 2014). Patients’ lack of understanding of the trial could cause professionals to doubt 
patients’ autonomous ability to choose a treatment because patients may be perceived as 
lacking sufficient knowledge needed to decide.  
Contemporary healthcare practice is characterised by endeavouring to respect 
‘individual’ autonomy (Corrigan, 2003). In this study, mental capacity is assumed of the adult 
cancer patients from whom consent is sought. However, it has been recognised that there are 
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‘limits’ to individual autonomy based on patient and physician factors (Van Kleffins, 2004), 
for example, professionals’ preconceived view of lack of patient’s trial understanding. It has 
been recognised that there can be physician bias or selection bias, or professionals precluding 
patients from trial entry or ‘gatekeeping’,(Melisko et al., 2005; Jansen and Wall, 2017; Sharkey 
et al., 2017). Some sociologists object to individual autonomy because of assumptions made 
by professionals about the patient’s independence and self-sufficiency (Sherwin,1998). 
Facilitating individual autonomy could therefore be problematic in some ethnic minority 
groups where the influence of the family could undermine or restrict the patient’s independence 
and capacity (Bell and Balgeaves, 2015). However, some sociologists have perceived the 
criticality of relational autonomy which they explain encompasses an appreciation for the 
family structure in decision-making as opposed to focusing on individual autonomy (Corrigan, 
2003; Donchin, 1988). Differences in the way patient autonomy is viewed by professionals 
may impact on contemporary practice.  
3.5 Summary 
The theoretical linkage of the concepts has provided a lens through which the experience of 
practice can be viewed. The purpose of the research is to find out how these concepts may be 
experienced in daily practice, not only because they are integral to informed consent, but 
because the experiences may challenge traditional professional socialisation. The conceptual 
framework has formulated an approach to the methodology and how data were collected and 
analysed. Furthermore, these concepts guided the research studies selected on informed 
consent highlighting the theoretical gaps as seen in the literature review chapter. 
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Chapter Four: A review of the Literature 
____________________________________________________________ 
4.0 Introduction 
The aim of this thesis was to explore the interprofessional experience of communication that 
impacts on obtaining adults’ informed consent to CCTs. In this review, a synthesis of previous 
research and literature is provided. The structure of the review is guided by the conceptual 
framework in order to find out the interprofessional-patient communication gaps. The review 
focuses on exploring how informed consent is verbally obtained from adult cancer patients as 
opposed to exploring forms of written communication given to patients. The themes found in 
the literature are then presented according to three main sections; namely, professional roles as 
determined by time; gaining patient trust and facilitating patient autonomy. The conceptual 
framework has underpinned the categorisation of these sections. Finally, drawing the literature 
together the review culminates in three research questions by highlighting the gaps for 
exploration in this study.  
4.1 The Review Process 
The method used to undertake this literature review involved a critical review of peer reviewed 
empirically based research studies predominantly in the CCT setting, together with some grey 
literature on policies / standards that guide practice. Although qualitative studies were 
prioritised, quantitative and mixed method studies were reviewed in order to find out what is 
already known about the interprofessional experience of obtaining informed consent from adult 




The four databases chosen from which to review the literature were Cinahl plus, 
Medline, Science Direct: Social Sciences and Psych-info. These were chosen because they are 
widely used for their contribution to medical, nursing and psych-social research. The word 
search terms comprised of three terms / word sequences per search spanning three main 
categories as seen in Table C4.0. When reviewing the breath of literature pertaining to more 
broad concepts, for instance; ‘uncertainty, communication, informed consent’ and ‘trust, and 
risk’, large yields were generated, thereby necessitating a 3-5-year date range search. Literature 




Table C4.0 Word search sequences by categories (concepts) 
Communication, Professions, Time 
1 Communication Informed consent (IC) Cancer clinical trials (CCTs) 
2 CCTs IC Roles & responsibilities 
3 CCTs IC  Time 
4 IC CCTs Process 
5 CCTs IC  Doctors 
6 CCTs IC  Nurses 
7 CCTs IC Interprofessional 
 
Trust 
8-9 CCTs Trust Doctors / Nurses 
10 CCTs Trust Interprofessional 
11 Trust  Cancer Medicine 
12 Building trust CCTs Oncology 
13 Fears IC Cancer 
14 CCTs Best interest Medical 
15 CCTs Trustworthy IC 
16 Uncertainty Communication  IC 
17 Trust  Risk Uncertainty 
18 Trust Hope Medicine 
19 Motivation Patients CCTs 
20 CCTs Risk Trust 
 
Autonomy 
21 Participation Perspective CCTs 
22 Patient autonomy CCTs IC 
23 Decision making  IC CCTs 
24 Relational autonomy Decision making CCTs 
25 Autonomy  Cancer CCTs 
26 Paternalism Patient CCTs 
27 Autonomy Cancer  Physician 
28 Cancer patient IC Autonomy 
29 Autonomy  Cancer  Doctor 
 
The inclusion criteria comprised International adult English-speaking peer reviewed 
studies on informed consent mainly in CCTs, and some cancer treatment consent studies 
between 2003-2018. Those that were excluded were too general, meta-analysis, non-cancer 
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specific, child-specific, cancer screening or those that were not pertaining to the overarching 
research aim but focused on technical and scientific aspects of individual trials. In total, 1213 
studies were found. The final number of papers selected for review were 77, which included 2 
literature reviews, 5 discussion papers. 32 studies were reviewed in depth, while 38 were 
referred to, in order to demonstrate similar findings and show the breath of research considered. 
See Appendix C4, The Cumulative search history for breakdown of reviewed papers. Grey 
literature considered were local policies for Consent Taking (Appendix C5.6) and professional 
regulatory body codes of practice guidance; and books pertaining to consent practices.  
The synthesis of the studies was guided by the use of the Critical Appraisal Skills 
Programme (CASP) Table, showing an appraisal of the methods, the findings, themes and 
study limitations. See sample in Table 4.1. Attention is given to interprofessional qualitative 
studies as shown in Appendix C4.3 and C4.4. As many themes were dispersed throughout 
different search categories, a study is reviewed once when pertaining to the main theme taken 
from that study, otherwise that study is referred to. First, the perceptions of professional roles 
and how time contributes to seeking IC in the CCT is reviewed. 
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Table C4.1 Sample of Synthesis of Literature: Medline 8 (CASP adaptation, Nice, 2014) 
Author and 
Journal 
Design Aim & Findings / Themes 
highlighted 
Limitations  Strengths Additional- 
Referred to 

















To ascertain views of data 
managers (sometimes nurses) of 
the nature and challenges of their 
role and differences between 
physician’s role.  
3 roles identified: 
Information provision-clarification of 
questions post consultation, RCT 
explained, detail not provided by 
doctor i.e. logistics and practicalities, 
but unable to provide some info  
Gave quality assurance-ensured true 
IC, verifying understanding, non-
coercive, rights confirmed, gave 
balanced view, comfortable speaking 
to patients, felt IC still medical 
prerogative, patients valued on-going 
nursing support & QL discussions, 
inconsistent team messages,  
Negotiated time-to discuss difficult 
patient issues, needs, cultural, 
language, misconceptions, ethical 
concerns  
No doctors’ 
views on their 
perception of 
nurse’s roles 




















accrual- due to 
physicians- 






Other roles  
Penman et al. 
(1984) old, Cox 
(2002) Patient 












4.2 Professional roles and time 
The main sub-themes identified within searches 1-7 were the professional / researcher role 
dilemma, information-giving, and the impact of time on professional roles. First, the 
communication challenges encountered by mainly doctors when undertaking research is 
reviewed. 
4.2.1 The professional / researcher role 
The way doctors understand their research role may have significance for how their practice is 
undertaken. In a study of 22 oncology physician consultations, Barton and Eggly (2009) 
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identified that there is a central ethical issue in relation to the role of the oncologist as a 
researcher. They described how the researchers’ role is governed by contemporary bioethics, 
where according to Beauchamp and Childress (2001) consent to research demands that the 
researcher ensures the autonomous patients’ consent; whereas the clinician’s role is governed 
by professional medical ethics which they describe as modelled on shared decision-making 
(SDM). While Barton and Eggly (2009, p297) found that these combined identities often had 
the effect of the clinician researcher uttering statements of persuasion in favour of the trial, 
they viewed such communication as ‘an ethical strategy in guided decision making’. The 
approach to their analysis was particularly effective in identifying the physicians’ main topics 
of information given spanning several trial phases. The discourse was analysed by assessing 
the statements used according to a positive or negative valence, as transcribed by trained 
assistants. One of the drawbacks of this study was that the cohort of doctors was small and 
within one interview a repeated statement accounted for one theme. Repeating positive 
statements may well have an influence on how consent was obtained, together with skewing 
the statistical analysis. Furthermore, Iltis (2005) outlines an ethical argument where clinicians 
sought preliminary consent from patients which may cause pressure to participate in the trial 
because of the patient’s previous relationship with the doctor (clinician). She likens the 
clinician in a research role to two moral equivalents because patients do not see the physician 
in different roles and therefore could feel pressured. 
In a mixed methods study, Easter et al. (2006) highlighted that when undertaking 
professional role/s, one needs to have a particular relationship with the patient. Doctors 
distinguished between the caring and the research role. For nurses and study coordinators their 
caring role sometimes conflicted with research role. For them caring entailed relationship 
building over time. The strength of this study was that professionals could describe their role 
qualitatively by the open-ended interview question format undertaken. Quantifying the themes 
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was useful due to the large number of participants comprising 82 multi-professionals. The 
focus of this study was obtaining consent to phase 1 studies which may have influenced an 
increased caring role for a potentially more vulnerably ill patient group. Both professional 
groups integrated the caring and research roles, where physicians referred to the role integration 
as wearing ‘two hats’. Differing role identities for nurses is reviewed later.  
4.3.2 Information-giving 
The giving of information to patients was shown to be problematic as studies indicated 
depending on the trial phase offered. The 90’s was a time of seminal work highlighting doctor-
patient communication difficulties. Fallowfield (1995) revealed that there was a need for 
physicians to give more information to patients to achieve better accrual, especially to 
randomised controlled trials (RCTs). Albrecht et al. (2003) in a discussion paper found that 
there was a potential for doctors to give too much information making it difficult for patients 
to emotionally cope. An influential early observational small-scale study (of 5 Oncologists) by 
Jenkins et al. (1999) found that physicians were unsure how much or how little information to 
provide because of patients’ lack of comprehension of the trial information. They found that 
risky information about RCTs was communicated to patients as unclear analogies; likening 
RCTs to ‘a lottery’ or ‘tossing a coin’ in almost 35% of discussions. A strength of this study 
was the authors did establish a grid matrix to match statements of information-giving against 
assisting with the analysis of the study. In a later large multi-centre patient study, Jenkins et al. 
(2010) found that most patients were willing to enter a trial, although only half would enter a 
RCT. Interestingly, the amount of participation in RCTs increased significantly if patients were 
given more information in the consent discussion.  
Various studies form the non-medical perspective reported that physicians gave 
insufficient information about the trial detail (Loh et al., 2002; Burke et al., 2014). Burke et al., 
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(2014) observed in an ethnographic study that the initial presentation of information posed a 
challenge to RCT consent. There was a lack of information clarity contributing to patient 
misconception of the trial. The strength of this study was the qualitative information found 
from the interviews, as analysed by an objective anthropological perspective. They found that 
patient questions were not always answered clearly at the point of trial recommendation, but 
were evaded, seeming to resemble achieving patient assent (a more passive agreement) as 
opposed to consent, although the focus was solely on entry to RCTs. Interestingly, it was 
following this initial recommendation stage that navigators (assumed nurses) took on the role 
of patient advocacy and the provision of missing information. 
4.3.3 The quality of information 
The language used by doctors while explaining the information was seen to have a specific 
effect in relation to phase I trial consent. In a qualitative study of 16 informed CCT discussions, 
an Anthropologist, Sankar (2004) shows how the way the trial was presented by physicians 
‘imposed expectations’. She relayed that doctors on the one hand explained that the trial could 
have no benefit, but on the other could bring about a ‘wonderful response’. These constituted 
expressions of hope and belief in the trial, although the primary objective was to assess the 
dosing toxicity only. The positive language used in relation to the trial had the effect of what 
she called ‘framing’, where the trial benefits were over-emphasised. She concluded a strong 
likelihood for trial information misconception or therapeutic misconception as a result. 
Although there was a small number of participants, the study was well designed by objectively 
observing consent discussions and data coding were checked 3 times.  
Similarly, Weinfurt et al. (2003) presented a case study of a phase 1 trial patient 
discussion to demonstrate the effect of doctors using ‘multi-vocalarity’ expressions. Multi-
vocalarity referred to doctors mixing ‘frequency-type statements’ that referred to the 
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percentage benefit of a trial or by uttering ‘belief-type’ statements or questions to describe the 
trial or to seek a response from the patient. One example given was doctors saying, “What do 
you think your chances are?”, where the use of ‘chance’ intimated a positive trial outcome. 
One of the difficulties found was that the patient’s belief response statement did not reflect the 
factual lack of benefit of the phase 1 trial. The patient’s response seemed to resemble a 
therapeutic mis-conception (that they would benefit from a phase 1 trial, which is factually 
incorrect). However, Weinfurt et al. (2003) pointed out that there were other reasons why the 
patient may respond with belief statements, for instance because of conflicting information 
given and the patient using high expectation statements communicating reassurance to relatives 
listening. The study drawback was that findings were based on a single case study, possibly 
undermining the generalisability of the study.  
More recently, from US behavioural sciences Dept, Brown et al. (2011) in small US 
study focusing on phase 1 clinical trial consent found shortcomings in physician 
communication strategies. The manner by which the information was communicated was in 
some cases highlighted as persuasive and paternalistic physician approaches to recommending, 
limiting the possibility of the patient’s choice or SDM. However, only 6 oncologists’ 
communication was examined, and their discussions were not limited to phase 1 trial entry. 
The study identified  important themes highlighting the need for additional strategies for phase 
1 clinical trial discussions. The lack of clarification of phase 1 trial intent chimes with the study 




4.3.4 Physician training strategies 
Borne out of the impetus to increase CCT recruitment and the subsequent need to improve 
physician communication, mostly physician communication training was assessed using 
interventional studies that analysed the efficacy of training using physician questionnaires. 
Fallowfield et al. (2002) assessed the efficacy of 160 Oncologists training sessions resulting in 
definite improvements in communication. The reason was that doctors gave more time to 
provide patient information, showed more empathy and encouraged patient participation, 
although doctors mostly did not check information was understood. However, it is difficult to 
rely on or generalise these findings because in effect this was a ‘staged environment’, not 
reflecting the time pressures doctors would be under in reality. However, these findings set a 
landmark for studies that followed.  
In a series of Brown et al. (2004 a & b; 2007) studies a sequenced step-by-step 
communication process of information-giving was assessed. Overall, it was found that 
communication was poor. Only 24% of doctors included patient participation in the decision 
(Brown et al., 2004a), with less than a third offering another treatment option and a small 
minority checked if patients understood the information. In the second of the Brown et al. 
(2004b) studies qualitative statements observed in cancer trial consultations were quantified 
into 4 ethical domains (themes) as follows: giving more time to seek preferences, moving 
through sequencing and autonomy steps, clarifying information and avoiding coercion. This 
study was extremely beneficial as it categorised communication techniques that mapped with 
facilitating the ethical components necessary to obtain informed consent. Comparison between 
baseline prior to training and post was ascertained by a team of mixed disciplines including 
psychologists, epidemiologists and doctors. However, the study lacked nurse communication 
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and only focused on phase 2 and 3 clinical trial consent. The ethical domains identified were 
used as a basis for assessing clinical practice and devising future communication training.  
Later, Brown et al. (2007) examined only 10 doctors’ communication strategies based 
on training in the 4 ethical domains. Doctors demonstrated more patient involvement in the 
consent and were less coercive by not favouring the trial leaving patients more satisfied about 
their decision, although some patients wanted the doctor to make the decision. Both Hietanen 
et al., (2007) and Brown et al., (2007), found that the trained group gave more time to patients 
which engendered better SDM allowing time for patient preferences. However, the lack of 
checking patient understanding of information is supported by Brown et al., (2004) and Butow 
et al., (2000), who highlighted that doctors not checking patient understanding of information 
was unresolved. Kao et al. (2017) reviewed that post communication skills training patients 
had no more knowledge about the trial, although the impact of time given in the consent 
discussions impacted on patients’ decisions and gave patients more satisfaction. The 
experience of the non-medical team is taken into consideration next.  
4.4 The role of the non-medical team 
There has been a paucity of communication studies on non-medical professionals involvement 
in CCT consent in the UK, although Avis et al., (2006) recognised involvement needed to span 
the professions.  
In a qualitative US study by Davis et al. (2002) nurses provided clarity about their 
advocacy role in CCTs. As a patient advocate, nurses identified with protecting the patients’ 
interests and welfare, while as a study advocate their responsibility extended to the research 
goals, and as a subject advocate they were conscious of the patients’ rights and understanding 
of the trial. The strength of the methodology used was that it was designed to elicit potentially 
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sensitive information about nurses’ roles by means of first running pilot vignettes that were 
structured to avoid personal references. The questions in the focus groups that followed 
addressed what their responses would be to particular patient dilemmas, however some 
questions may have been leading because of stating a dilemma which sought their response as 
opposed to the nurse or coordinator describing a dilemma. However, the qualitative analysis 
did provide insight into role conflicts experienced, although it is unclear how these conflicts 
changed the way they communicated with patients.  
The clinical trial nurse questionnaire (CTNQ) developed and validated in the US and 
Canada by Ehrenberger and Lillington (2004) was used in several studies to ascertain the nurses 
experience of their role, which they say is undergoing significant ‘transformation’. The CTNQ 
assessed the frequency and subjective importance of activities clinical trial nurses performed. 
Activities frequently performed centred around the comprehensive communication of  
information to patients, checking that information and managing the trial throughout on-going 
informed consent (Ocker and Plank, 2000; Mori and Mullen, 2007). Another important role 
within consent was that nurses viewed themselves as a patient advocate, facilitating patient 
decision-making (Mori and Mullen, 2007; Catania et al., 2012). In more recent years, the 
importance of their involvement in consent was rated the most important of their activities 
(Nagel et al., 2010; Wilkes et al., 2012; Catania et al., 2012), although Catania et al. (2012) 
rated their actual involvement with IC as the third most frequent activity. Wilkes et al. (2012) 
found that the involvement in IC was the most important and most frequent activity for 
Australian nurses. However, the drawbacks of this study was that physicians were required to 
contact nurses to take part potentially favouring nurses who were more actively involved in the 
IC process. Mainly, the nurse role in research was acknowledged. The CTNQ questionnaire 
used for most of these studies arguably provided a limited form of enquiry, potentially guiding 
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nurses’ answers, and the results did not give a guide for how informed consent could be 
improved. 
The UK is lacking exploration of the nurses’ experience of their role in IC. However, 
Tomlin et al. (2014) did acknowledge nurses as information advocates in RCT consent, 
prioritising patient suitability and eligibility questions although nurses arguably led patients by 
what was termed their ‘empathetic preferences’ (what nurses felt was the best choice of trial 
arm). Only 3 out 5 were cancer trials discussions, and there was great variety in nurse training 
and clinical backgrounds. Tomlin et al. (2014) found a discordance between what nurses views 
were and how they interacted with patients. Nurses did not always align information correctly 
or answer patient concerns; which they felt limited patient empowerment in decision-making; 
while some nurses felt consent, discussions were restrictive. The methodology used varying 
qualitative tools, while the uptake of some was poor. Only 7 nurses undertook audio recordings, 
and only 9 individual interviews, while 30-34 attended group interviews. Although various 
common communication themes were identified, the data from the focus group may have been 
restrictive as often participants do not contribute equally within a group. Spilsbury et al. (2008) 
found through nurse focus groups that research nurses lacked confidence in the UK and did 
echo the conflict of role between their clinical and research responsibilities. However, these 
nurses were not from the cancer speciality. It may be that specialist cancer nurses are more 
certain of their role in IC in the UK, although this remains unclear. Interestingly, in the UK, 
Cox (2002) from the patient perspective found that nurses who communicated using positive 
trial language had an impact on gaining trial consent. 
In a European survey of almost 200 cancer nurses, Beadle et al. (2011) found that nurses 
felt informed consent discussion fell short of ethical standards (considering physician talks). 
They attributed shortcomings in information-giving to a lack of patient understanding, even 
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coercion, because patients did not have enough time to decide. The questions and statements 
generated did encompass specific domains of communication, from which participants ticked 
and were evaluated in focus groups of 6 oncology nurses, although it is unclear if they were 
involved in research. The design could have led the participants to a choice of answer. Loh et 
al. (2002) revealed through qualitative focus groups that the nurses’ role centred around 
information provision including answering questions in more detail than the doctors. They also 
ensured high quality consent by checking information was understood and verifying that the 
patient did not feel coerced by overestimating the trial benefits. The Burke et al. (2014) study 
chimes with the notion of research nurses (as navigators) exercising patient advocacy which 
they term ‘competing ethics’. Nurses answering key questions avoided misleading patients’ 
understanding of the trial from the start of the consent process.  
4.5 Informed consent as a process 
While informed consent is often understood as a contractual agreement / paper signing between 
the physician and the patient, much of the literature has referred to obtaining informed consent 
to CCTs or RCTs as an on-going process over time (Brown et al., 2004; Brown et al., 2007; 
Corrigan, 2003; Kao et al., 2017). These studies pointed towards both physicians and patients 
mostly needing more time in the clinical trial discussions.  
The nursing perspective highlighted by Beadle et al. (2011) relayed the that 19% nurses 
felt that there was not enough time given in the physician discussions to enable patient 
understanding to decide on the trial decision. As previously reviewed seeking RCT consent 
and shared SDM particularly necessitated more time (Brown et al., 2004; Bergenmar et al., 
2008; Jenkins et al., 2010); although this did not always take place (Brown et al., 2007). In a 
later study, Bergenmar et al. (2011) discovered although patient understanding could be 
improved with more consultation time for instance over 30 minutes time yielded higher patient 
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perceived understanding of the risks and benefits, yet there was no significant patient 
knowledge increase with more time. One of the strengths of this study was the use of a validated 
measurement tool (QuIC- the Quality of Informed consent), although the data were collected 
retrospectively after the patients were consented to the trial, which may well have distorted the 
data due to the possibility of poor patient memory recall. Importantly, these efforts to provide 
more time to patients yielded improved communication.  
The benefit of giving more time to patients as a consent process was also found to yield 
an improved relationship with patients as nursing studies acknowledged (Loh et al., 2002; and 
Burke et al., 2014), demonstrating that such a rapport with patients alleviated their 
misunderstandings. However, Sankar (2004) attributes this professional-relationship 
improvement to the way information was delivered as opposed to the time spent, while Brown 
et al. (2004) acknowledged the benefit of the process of physicians ‘sequencing the 
information’ over time as a social process of interaction with patients. Easter et al. (2016) found 
that spending more time with CCT patients significantly improved patient care, described as 
‘closeness’, although the focus of the study was care as opposed to obtaining informed consent. 
Easter et al. (2016) and Mc Grath-Lone et al. (2015) found that care was an important 
component in research practice, which chimes with the NMC Code of practice (2016). Easter 
et al. (2016) also suggest that this improved interprofessional care may influence recruiting 
patients in trials, although research was often referred to in negative terms while care was 
referred to in positive terms, suggesting a professional moral challenge for professionals 
undertaking research.  
4.6 Interprofessional roles as influenced by time 
Overall, professionals experience role dilemmas between care and research advocacy. Nurses 
and trial coordinators appear to have complemented the doctors’ role in obtaining consent to 
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CCTs by spending more time giving detailed information to patients using appropriate 
language and checking patient understanding of the information. Many of the studies were of 
a quantitative design, leaving room for an exploration of how the experience of the 
professional-patient interaction could be impacted by time, particularly in the UK. 
Consequently, the following research question can be asked: How does the experience of 
interprofessional responsibility as determined / shaped by time influence obtaining informed 
consent to CCTs? The focus of the literature now shifts to trust within the professional-patient 
communication. 
4.7 The impact of trust 
Within search sequences 8-20 there were 3 main categories, namely, trust motivating patients, 
trust undermined, and distrust and the amount of trust needed in uncertainty. It is note-worthy 
that in many studies that assessed doctors’ or nurses’ communication strategies trust was not 
the main focus.  
4.7.1 The patient motivation 
Many theorists found that patient trust in the physician was a key motivating factor influencing 
the decision to enter a CCT (Jenkins et al., 1999; Cox, 2002; Loh et al., 2002; Madsen et al., 
2007; Kass et al., 2009; Comis et al., 2009; Catt, 2011; Brown et al., 2011). Patients were 
motivated to trust in the physician because of a belief that the physicians’ recommendation was 
in their best interest or due to the doctors’ competence (Jenkins et al., 1999; Cox, 2002; Catt, 
2011, Mechanic, 2000; Comis et al., 2009; Townsley et al., 2006; Daughterty et al., 2005; 
Brown et al., 2011). Even though patients were motivated by trust in the best treatment offer, 
many nurses perceived that patients felt that they had no other option (Shannon-Dorcy, 2011), 
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or patients were unable to refuse (Catt, 2011), raising questions as to whether patient trust was 
freely placed in the physician.  
Certain groups of patients demonstrated trust differently. Price et al. (2012) found that 
older patients preferred to be guided especially when the treatment was uncertain, while Cox 
(2002) and Nurgat et al. (2005) found that patients were motivated to participate in trials due 
to self-interest and trust. In the Madsen et al. (2007) study, there was a shortcoming in the study 
design because only female patients who had a response to treatment were contacted for ethical 
reasons. The responders may have had more trust in the doctors’ competence. However, 
interestingly, patients did experience a lack of trust when they saw too many physicians, 
highlighting the value of one-to-one trust relationships.  
Patients often associated hope with trust. Although only in a small study of 13 patients, 
Brown et al. (2015) found that patients interweaved trust with hope, because of trust in the 
doctors’ competence and hope in the trial drug, while the doctor fostered hope. A more 
physiological approach was undertaken by Yang et al. (2010) who found that patients had an 
affective response to positive statements by using the Risk Information Seeking and Processing 
(RISP) tool to assess patients. Such an assessment was counselling specific and would 
potentially require careful patient support if it were undertaken again. Similarly, Lee et al. 
(2016) found breast cancer patients had trust in the doctor and placed hope in the trial, even 
though only Asian women were assessed. Biedrzychi et al. (2011) and Godskesen et al. (2015) 
found from questionnaires that enabling patients hope was a predictor of trial entry for patients, 
although patients had more trust in the healthcare system than doctors.  
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4.7.2 Trust undermined and distrust 
Gaining the patients’ initial trust appeared crucial and involved rapport-building with the 
doctor. In a meaningful literature review, Hurd et al. (2017) developed an integrated model of 
care as applied from the business field but could be useful in CCT practice. They proposed that 
the consent contract required an initial ‘swift’ trust to enable the recruitment or consent to the 
trial, while the ‘traditional’ trust sustained the duration of the trial. Interestingly, they felt that 
professionals could modulate trust by ambivalent behaviour within their relationship with the 
patient. Such ambivalence and the previously reviewed negative potential of the doctor’s 
positive approach, could have potential for undermining trust. Positive language used by 
doctors to recommend the trial was intimated as coercive and termed ‘framing’ (Brown et al. 
2015; Sankar, 2004); which could lead to distrust. Thorne et al. (2013) advocated the value of 
nurses ‘sitting down’ with patients to allay distrust by deciphering too much information, albeit 
given positively by doctors. The nurses’ role seemed to have the effect of allaying patient fears, 
or alleviating the possibility of coercion, thereby possibly maintaining trust (Cox, 2002; Loh 
et al., 2002).  
Studies on Ethnic Minority Groups indicated that distrust was linked to patient fear, 
uncertainty and suspicion. Some of the common findings were that African-American patients 
worried about being guinea pigs and showed lower trust than white patients (Meng et al., 2016; 
Somayaja et al., 2015). An important study was undertaken by Durant et al. (2014) which 
sought the interprofessional perspective on barriers to trial entry for minority groups. The 
findings were most valuable as they were attained from qualitative interviews with doctors and 
research nurses. The main findings were that these patients were sceptical because of fear 
caused by distrust, negative trial connotation and the language used by professionals. The 
language barrier often caused stereo-typing of patients assuming they were not intelligent, 
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exacerbated by interpreter problems. It was reported that this group required ‘tailor-made’ 
communication and that nurses were integral to the reviewing process to identify eligible 
patients.  
In a similar UK study, Hussain-Gamble et al. (2006) assessed the interprofessional 
views of research staff regarding the participation of Asian women in CCTs. The value of this 
study was the face-to-face private interviews. Healthcare professionals did not feel patients 
were excluded because physician tendencies to ‘cherry-pick’ patients was excused due to lack 
of professional time. While mistrust was found as a potential barrier to trial entry, there was 
emphasis on the building of a professional-patient trusting relationship, although the 
professions struggled to find enough time to nurture a relationship disadvantaging patients. The 
findings of this study could be transferrable to other ethnic minority populations. Importantly, 
Fisher and Kalbaugh (2012) among others pointed out that minority groups were 
underrepresented in CCTs. 
4.7.3 More or less trust and uncertainty 
Uncertainty about the trial outcome or doctors not knowing the outcome (equipoise) was cause 
for patient distrust. Physicians felt communicating the uncertainty of RCT outcomes could 
impact on patients trust in them, potentially losing trust or bringing about distrust, respectively 
(Jenkins et al., 1999; Fallowfield et al., 1998; Featherstone and Donovan 2002; Thorne et al., 
2013). However, the ethical communication strategies and sequencing developed over various 
interventional studies did prove beneficial in allaying such uncertainty, thereby as a bi-product 
built trust (Brown et al., 2011). One of the most influential studies on how patients dealt with 
uncertainty was undertaken by Brown et al. (2015) who found that patients could ‘bracket out’ 
the uncertainty of the trial outcome to maintain trust and hope enabling consent to the trial.  
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There is an argument in the literature in relation to the notion of patients having more 
or less trust where Yin-Yang et al. (2010) found that more trust achieved better patient trial 
compliance, while passive (arguably less trust) was found to have the effect of patients handing 
over their trust to the clinician (Kraetschmer et al., 2004). Although a sociological discussion, 
Zinn (2008) argued that more trust was needed for risky decisions. In a later paper, Zinn (2016) 
developed the notion of ‘in-between’ patient strategies for example hope and faith that enabled 
trust formation. Interestingly, Zinn points out that all patients are not autonomous, although 
professionals tend to frame passive hope negatively. 
4.7.4 Interprofessional trust 
While trust was essential for informed consent to occur, maintaining trust could be perceived 
as more challenging. Hillen et al. (2011) concluded that from 45 studies the trusting physician-
patient relationship facilitated decision-making, often by decreasing the patient’s fear. 
However, the role of the doctor and the nurse differed in trust formation and maintenance, 
because it is not certain how they experience it or how collaborative roles impact trust. Mostly, 
patients trusted doctors because of a belief that doctors acted their best interest. Therefore, the 
questions can be asked: What is the interprofessional experience of gaining trust to CCTs, and 
how does acting in the patients’ best interest impact on trust? Finally, attention now shifts to 
patient autonomy positioned as one of the bedrocks of attaining informed consent. 
4.8 Autonomy as a deciding factor 
The studies from searches 20-29 including over-lap from previous studies were focused 
on how professionals experienced patient autonomy, sometimes seeking data from patients to 
inform practice. There are 3 main focus areas of the literature, as follows: patient understanding 
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and consent validity; relinquished autonomy; the role of advocacy / ‘gate-keeping’ and 
individual autonomy.  
4.8.1 Patient understanding and consent validity 
One of the major drawbacks of most of the studies undertaken assessing doctors’ 
communication excluded non-English speaking patients (Brown et al., 2004; 2007; Hietanen, 
2007; Jenkins,1999; Albrecht et al., 2003). However, a number of previous studies have 
focused on problems with patient understanding as a reason for questioning the validity of 
consent or have caused barriers to obtaining informed consent (Jenkins et al., 1999; Joffe et al., 
2000; Gattellari et al., 2002; Hietanen et al., 2004, and the Brown et al. 2004; 2007). The main 
reasons for poor understanding are outlined in relation to trial phase specific lack of 
understanding, therapeutic misconception, and difficulties with information disclosure and 
interpreter problems (Hussain-Gamble and Leese, 2006).  
Clinical trial phase 1 patient misunderstanding and misconception has been examined 
widely (Jefford et al., 2011; Kass et al., 2009). Jensen et al. (2011) used a measurement of 
understanding post the decision to enter the trial developed by Joffe et al. (2001). It was found 
that patients had a significantly higher level of subjective as opposed to objective 
understanding of the trial information which correlated with a high level of satisfaction for 
entering in the trial. Patients particularly struggled with understanding the benefit and dose 
escalation of phase 1 trials. The strength of this study is attributed to the validated measurement 
tools used, however these perspectives were gained after consent had taken place. There is no 
data on patients who did not consent to the trial.   
Levels of patient knowledge and understanding also differed. Bergenmar et al. (2008) 
reported that patients had a high level of understanding, but their knowledge resulted in only 
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50% understanding of the trial risks. In both studies, the patients perceived that they understood 
more than they actually did understand. Although these studies were multi-centred and used 
measurement tools, non-English-speaking patients were excluded. The disparity between the 
perceived understanding and actual knowledge level of patients is similar to the findings of 
other studies (Brown et al., 2004; Jenkins et al., 1999). The way information was delivered 
could be misleading for patient understanding. However, as explained, perceived patient 
misconception may not be cause for invalid consent (Weinfurt et al., 2003). Next, many studies 
found that patients resist decision-making arguably needed for valid informed consent. 
4.8.2 Relinquished autonomy 
A common theme in the literature was patients not wanting to decide for themselves, thereby 
possibly ‘relinquishing’ their autonomy. Cox (2002) examined the patient experience of 
recruitment to trials; wherein it was found that 80% of patients wanted the healthcare 
professional to advise them, possibly relying on the doctor to decide for them. Interestingly, a 
number of patients made an immediate decision, and a question about professionals facilitating 
autonomy arises because 40% of patients had difficulty in asking questions. A major strength 
of this study was that the experiences of patients related to their interactions with both nurses 
and doctors, highlighting that trial nurses were essential to information checking and the 
continuation of trial communication.  
Another reason for patients making passive decisions was because they had unrealistic 
hope. Dolly et al. (2012) found that 80% of phase 1 patients were motivated by clinical benefit, 
when in fact this perceived benefit was incorrect. These findings related to patient trial mis-
conception and the lack of professionals offering alternative treatment options. Of the 400 
patient questionnaires given, only ¾ were returned post doctor consultation, possibly because 
of insufficient time given to patients to rationalise for their decision / indecision. What directly 
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impacted on achieving informed consent was the patient loss of locus of control, displayed as 
ignoring the information, found by van der Biessen (2017) in a study of 135 phase 1 patients 
who found that desperate patients were motivated by hope arguably not wanting to activate 
their autonomy.  
However, doctors did not refer to ‘respect’ for autonomy or lack of; but referred to 
persuasive language or patients’ willingness. Generally, in the cancer setting, it is note-worthy 
that patients were seen to off-set decision-making (Sinding et al., 2010), or take a passive role 
due to lesser knowledge (Mancini et al., 2014); or as van Kleffens et al. (2004) point out refusal 
was a choice. As a result of patients ‘off-setting’ autonomy, there was a dilemma for 
professionals to act paternalistically. Often while assisting patient autonomy, professionals 
exercised patient advocacy. 
4.8.3 Advocacy or gate-keeping 
Studies previously showed that professionals saw the role of communicating as a patient 
advocate or decision-maker. Positively framing the information however could be coercive and 
cherry-picking could constitute ‘gate-keeping’ (selecting or excluding patients), both with a 
leaning towards deciding for the patient (Brown et al., 2004; Barton and Eggly, 2009; Sankar, 
2004; Burke et al., 2014; Hussain-Gamble and Leese, 2009). Melisko et al. (2005) and Lee et 
al. (2010) found physician bias existed against the trial itself. While selection bias is found 
against trial design, it was a predictor of participation, although as Fayter et al. (2007) pointed 
out that such bias is difficult to assess due to the lack of reporting of such data.   
It was found that nurses recognised their patient advocacy role in pre-emptying patient 
questions and clarifying possible ‘framed’ information. However, activating this role could be 
problematic (Tomlin et al., 2014; Spilsbury et al., 2008) although Fisher and Kalbaugh (2012) 
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found that nurses used the goal of altruism to cope with this dilemma. Importantly, Tomlin et 
al. (2014) found that nurses became active in assessing the suitability of RCT patients as part 
of their advocacy role. These UK nurses voiced their concerns about restricted recruitment 
practices, and consent discussions were inhibited due to misleading information or patient 
therapeutic misconception, proposing that valid consent was difficult to achieve. Gaining 
patients’ autonomous decision to obtain informed consent as emphasised by Beauchamp and 
Childress (2001) could be threatened by professionals taking on the role of advocacy. Mostly, 
studies sought professional and patient experiences of CCT consent that relied on the individual 
patients’ autonomy. 
4.8.4 Autonomy for the ‘individual’ 
Achieving valid consent is pointed out as ‘more difficult than guidelines and policies imply’ 
(Corrigan, 2003, 789) and is often reduced to a tick-box exercise to evidence that the patient 
made an autonomous individual decision (O’Neill, 2002; Twomey, 2015). Local policies 
reviewed on ‘Taking Consent’ were focused on gaining consent from the individual patient.  
In a qualitative study, Corrigan (2003) found that informed consent can be reduced to 
‘individual’ autonomy which ignores the necessary cultural dimension. She seeks to advocate 
informed consent as a relational (including the family) over an individual concept. She suggests 
that professional training needs to better reflect the patient population an institution serves. 
This is a valuable study of 25 phase 1 patients, as it shows the professionals’ opinion of trial 
rigidity and assumptions made about informed consent associated with the autocratic medical 




The main studies reviewed highlighted the barriers to CCT recruitment within the 
ethnic minority groups (Hussain- Gamble and Leese, 2006; Durant et al., 2014), although they 
did not strongly focus on the need for considering autonomy in a relational way. Datta et al. 
(2016) and Hussain-Gamble and Leese (2006) recognised medical training as opposed to 
interprofessional training to incorporate relational autonomy into clinical trial consent. In 
general oncology, Datta et al. (2016) found doctors and nurses recognised the value of the 
shared and supportive role of family, while balancing patient autonomy with the relatives’ 
desire to withhold bad news brought other challenges. In addition, Biedrzycki (2011) surveyed 
197 patients, most of whom preferred SDM (83%), which included the role of asking if patient 
preferred the family involvement, a role that nurses valued within their collaboration. When 
autonomy was considered differently, Asiedu et al. (2018) found that of 33 ovarian cancer 
patients’ decision-making was ultimately the patients’ choice, but was decided upon within the 
context of relationships, suggesting the social construction of autonomy.  
Given the challenges outlined with basing informed consent on patient autonomy 
within the context of a diverse cancer population given poor understanding and lack of active 
decision-making; the question ought to be asked: what is the interprofessional experience of 
facilitating autonomy in the diverse CCT setting?  
4.9 Summary 
The dual role of researcher and clinician has been problematic for both professions. Mainly the 
doctors’ communication difficulties were researched, and to a lesser extent the nurses’ role 
within informed consent discussions. Overlapping roles emerged as well as individual 
identities. The more or lack of time (as a process) professions spent with patients impacted on 
information-giving and patient understanding. Overall, the nurses and trial coordinators roles 
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appear to have complemented the doctors’ role. It would be interesting to find out if the 
traditional medical role of taking consent has advanced and is challenged.  
While trust appears essential for IC to occur, maintaining trust could be perceived as 
more challenging. There is a need to explore the way trust was gained or differed between the 
professions and how collaborative roles impact trust. One resounding message is that patients 
trusted doctors because of a belief that doctors acted in their best interest.  
It is uncertain if autonomy can always be truly achieved due to the patient issues 
professionals face, thereby questioning obtaining informed consent at all. It would be insightful 
to find out if IC relies on the policy requirement of patient autonomy, or if IC more relies on 
an interprofessional social endeavour. To bring about an answer to the research questions raised 
in the literature review, the methodology undertaken is next discussed in Chapter 5. 
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Chapter Five: The Methodology  
___________________________________________________________________ 
5.0 Introduction 
In this chapter, the methodological approach undertaken to answer the research question is 
presented. The overarching research question is: What is the interprofessional experience of 
communication that impacts on obtaining informed consent to cancer clinical trials? To begin 
with, the research setting is outlined. Following on from this, the rationale for choosing the 
philosophical approach, case study and the reflective approach is explained. The approval for 
the research application including ethical considerations are described. In the next section, the 
research methods are presented and discussed, followed by an explanation of the data analysis. 
Finally, the validity of the study is presented.  
The conceptual framework and the literature review have provided more clarity and 
highlighted gaps within seeking informed consent, culminating in supporting questions as 
follows: What is the professional experience of responsibility as shaped / determined by time? 
What is the interprofessional experience of trust? And what is the interprofessional experience 
of facilitating autonomy? An explanation of the chosen research methods supports the purpose 
of finding out why, so few potentially eligible cancer patients are recruited to CCTs, as guided 
by the supporting research questions.  
5.1 The research setting 
This research was undertaken within the CCT department setting comprising two day-care 
units and 4 wards in an NHS tertiary Trust specialist centre in London, delivering cancer 
treatment to 1.5 million people, many from the local diverse community or referred patients. 
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For each speciality, there were 1-3 research nurses (RN), supported by non-nurse practitioners 
and assistants, 1-3 clinical nurse specialists (CNS), 8 clinical managers covering different sub-
departments and 1-7 consultants; each quantity depended on the speciality. The Trust has 
turnover of in excess of £1.1 billion and has approximately 16,000 employees. Medical and 
nursing specialist education is supported by the affiliated University or by the neighbouring 
Universities respectively. The Cancer Research Delivery Team sit within the Cancer Academic 
Group (CAG), comprising specialist nurses and doctors, some sharing University academic 
posts or with the UK Experimental Cancer Medical Centre.  
5.2 The Philosophical approach 
The purpose of this case study was to explore and analyse the interprofessional experience of 
communication that impacts on obtaining informed consent to CCTs. A phenomenological 
approach was undertaken originating from hermeneutic philosophy (Heidegger, 1962; 
Gadamer 1976) as will be explained. 
5.2.1 Consideration of previous research methodologies 
The previous research reviewed was used to consider how well quantitative interventional 
methods ascertained the efficacy of communication improvement strategies (Fallowfield et al, 
1995; Jenkins et al, 1999; Kao et al, 2017; Brown et al, 2004; 2007; Hietanen et al., 2007). 
Professional perceptions of their roles via nursing surveys or questionnaires (Beadle et al., 
2011; Catania et al.; 2012; Wilkes et al., 2012) confirmed role identities. While these studies 
demonstrated reliability through validated methods, they lacked an in-depth exploration of how 




Dated qualitative studies ascertained the experience of IC, providing more rich data. 
Davis et al. (2002) used interviews which gave insight into how CCT nurses struggle with their 
role. An ethnographic approach was illuminating by finding out only doctor’s communication 
shortcomings via their consent talks (Sankar, 2004), while Burke et al., (2014) observed 
professional-patient interactions during consent, contributing to defining different role 
identities. Focus-groups for nurses provided insight on how non-medical research professionals 
viewed their role (Loh et al., 2002). Interprofessional and patient interviews found 
communication themes within the diverse cancer population (Durant et al., 2014). There were 
limitations to the UK’s Tomlin et al. (2012) and Spilsbury et al. (2007) studies; which of both 
relied heavily on data from focus groups, comprising 3 out of 5 cancer trials and non-cancer 
research for the latter. Considering these contributions, it would seem timely and important to 
undertake a qualitative approach to seek the experience individually from all involved 
professionals.  
5.2.2. Phenomenology: a rationale 
This study falls into the qualitative research family. Blaxter et al. (2010) further describe 
qualitative research within the context of a naturalistic phenomenological mode where the 
subjective experiences of individuals are sought in a real-life setting. The 
conceptual/philosophical approach chosen was based on the work of Heidegger (1962) and 
Gadamer (1976). The phenomenological approach was most appropriate in order to explore 
and understand (give meaning) to the ‘lived experiences’ of the participants (Polit and Beck, 
2012, p. 494; van Manen, 1990). Qualitative is preferred over quantitative methodology 
because it seeks to explore the personal meanings of experiences often through interviews. A 
qualitative observational (ethnographic) approach was not taken because I perceived that 
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observing an already contentious ethical context could cause disruption to patients or alter 
professional behaviour.  
Seeking the ‘lived-experience’ in the natural practice setting as a case study where the 
researcher was also a practitioner is intended to add value to the meaning and make sense of a 
phenomenon (Smith and Osman, 2015). The type of phenomenology engaged insider 
practitioner interpretation as opposed to eliciting solely descriptive data. The use of descriptive 
phenomenology developed by Husserl (1859-1938) may limit the meaning of the data because 
it brackets the practitioner’s interpretation and reflection. Interestingly, Dewey (2010) explains 
that the facts become meaningful when linked to knowledge, performance or role, even 
judgement, which is part of the epistemological focus of enquiry through the research 
practitioners’ interpretation. In keeping with Heidegger (1889-1976) the aim was to account 
for suppositions and assumptions by exercising reflexivity in a research (reflective) diary. The 
research diary included the researchers’ world and life experiences in keeping with Creswell 
(2007). Within the data analysis, the interaction as a practitioner sought to bring about as 
complete a meaning  as was possible. The researcher was aware of certain assumptions about 
the culture of professional responsibility that needed to be understood, ‘viewed as truth without 
conscious or explicit testing’ (Rebar et al., 2008, pp.221). 
 Reflexivity is addressed in two places in the thesis. First, within the Methodology 
Chapter as an approach to guiding the research, and later within Chapter Nine within the 
limitations of the study. To assist with reflexivity, from the outset, I set out my different 
identities/positionalities and assumptions in hierarchical order informally in my diary, as 
Thurairajah (2019) recommends. The meanings of these identities and how each one interacted 
with the data unfolded during and within the writeup phase of the research. See Table 5.0 which 
illustrates my different identities which also became my reflexivity tool.   
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Table C5.0 Reflexivity Tool for Insider research practitioner 
Adapted from Thurairajah (2019) 
(Hierarchy from top down) 
 Positionality / 
Identity 
Motivations Oppositions 




• Patient advocacy as means of 
protection 
• Partial, caring role 
• Improve practice 
• Therapeutic, empathy  
• Collegial support  
• Examples: 
• Assumed nurses’ lack of value / 
doctors’ hierarchy 
• Assumed inability to validate 
consent  
• Unable to directly protect 
• Maintaining objectivity 
• Re-experiencing own difficulties in 
practice / life due to constraints 
• Unable to judge 
• Nursing bias that they play a key 
role 
2 Manager  • Improve practice 
• Non-threatening  
• Maintain patient safety 
• Improve patient access to trials 
• Service benefit 
• Examples: Assumed Limitations 
in raising issues 
• Protect participants 
• Refrain from taking sides 
• Maintain confidentiality 
• Refrain from interviewing line 
managed (prevent data skew) 
• Policy and targets that impact 
practice / service 
3 PHD researcher • Genuine passion for topic / 
practice advancement 
• Improve IC to CCTs 
• Maintain good researcher-
participant relationship 
• Academic credibility- good data 
/ dissertation 
• Easy access to participants 
• Example: Uncertainty about 
value of interprofessional 
practice 
• Time – prioritise ‘actual job’  
• Facilitating within others’ jobs 
• Potential to affect collegial 
relationship 
• Ability to step back when shared 
emotional experiences 
• Lack of objectivity / keep separate -
Mason (2002) 
• Perceived as practice challenger 
• Need for staff support 
• Threats from gate-keepers 
• Impartiality 
• Assumptions about doctor’s lack of 
appreciation of nurse role 




Given these assumptions and competing role identities, Munhall (1989) explains a 
fusion resulting from the interpreter’s transaction with the world where one reality constitutes 
and constructs another. There may be more than one truth where epistemology was derived 
from interpretation of the participants’ experience, hence there is potential for argument about 
what the truth is. Where some participants’ views stood outside the common themes, these 
were considered deviant cases that challenged and enhanced the ‘true’ picture of the situation.  
5.2.3 Research design 
The Research design incorporated an instrumental local institution case where the subject is 
the interprofessional experience and the object is informed consent to CCTs. The case study 
was appropriate as it investigates according to Yin (2008) the real-life context within 
boundaries by using different sources of evidence.  
The boundary was set out from the outset as the single centre tertiary cancer centre in 
keeping with Silverman (2010). The triangulation of methods by using the research diary and 
different levels of professional interviews enabled ‘getting close to reality’; as described by 
Flyvbjerg (2001) thereby enhancing the research validity. The study neither seeks to change 
nor is it experimental as with a nomothetic generalisable approach used in the natural sciences. 
There was a cautious attempt to make generalisations, although the findings could well be 
perceived as typical to other research practice settings. Therefore, the findings may be in 
keeping with Flyvbjerg (2006) who vehemently defends the misunderstanding that case studies 




5.3 Approval for the study 
Approval was sought via the IRAS study application and subsequent Clinical Effectiveness 
Unit (CEU). Academic approval was gained from Royal Holloway University of London 
(RHUL).  
5.3.1 The approval process 
The applications requesting permission to undertake the study were sought. See below for the 
list of approvals received. No ethical concerns were raised and ethical considerations were 
included within the application. See Appendices C5.1- C5.4 for approvals.  
Approval 
IRAS Approval (Integrated Research Approval System) 
Clinical Effectiveness Unit 
RHUL Approval 
Self-certification of Ethical Content 
RHUL Ethics Approval Form  
 
5.3.2 Ethical considerations 
Ascertaining the participants’ experience of communication challenges involved in hard cancer 
patient consent decisions was considered in accordance with the ethical principles of 
Beauchamp and Childress (2001) and the ethical guidelines of the Belmont Report (1979).  
Beneficence 
Polit and Beck (2012) highlight that the guiding research principle ensures increased benefit 
over risk for participants. The study aimed to benefit the staff by allowing them to have a voice 
regarding the consent communication difficulties they experienced with CCT patients, 
potentially contributing to patient care and professional practice. In ascertaining potentially 
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sensitive information I was aware that the success of data collection partly relied on the 
collegial trust and rapport with staff. The researcher however was in a fortuitous position as an 
inside field expert, having ‘finer discernment’ and sensitivity (Mason, 2002). The researcher 
was aware of the possibility of a ‘pseudo therapeutic’ relationship developing which must not 
be exploited.  
Protection from harm (non-maleficence) 
The main consideration was that some data regarding professional communication could be 
emotive. The participants had access to an NHS counsellor and clinical supervision, which was 
made known to the staff in the Letter of invite (see Appendix C5.5) In keeping with Polit and 
Beck (2012) measures used to maintain confidentiality and protect misuse of information were 
undertaken. Each participant was given an ID preserving anonymity. The interviews were held 
at an agreed time in a private booked clinic room. The data storage and disposal was treated in 
accordance with the Data Protection Act (2018) and the RHUL Data Management Policy. A 
Consent Form was created to capture participants’ consent as well as demonstrating that there 
was agreement to the researcher communicating patient safety issues to the authorities (see 
Appendix C5.2). Participants did not fall under the vulnerable person group/s, thereby no 
additional strategies were required.  
Autonomy 
All participants were invited to participate voluntarily. After responding, participants were 
given the Participant Information Sheet (see Appendix C5.7). They were allowed up to two 
weeks to decide on participating and then signed the Consent Form voluntarily, which was 
locked in the data collection cabinet. The participants were required to consent to providing 
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demographic information and an interview and an optional short second interview (see 
Appendix C 5.6). Participants had the right to withdraw at any time.  
Justice 
Blaxter et al. (2010) recommend that the researcher observes responsibility for the data 
collection, analysis and dissemination. In the event that practice concerns were raised 
(knowingly or unknowingly), the participant would be informed as to the seriousness and a 
formal concern raised if needed. A decision would be made as to whether the study is more 
beneficial than harmful to the participant.  
5.4 The Sampling Strategy 
The overall intention was to select the experiences of representative professionals who could 
be accessed within the CCT trial practice area. Participants were purposefully sampled aiming 
to seek a good cross sectional interprofessional group of an intended 25 professionals. 26 
participants were selected (see Table C5.1) 
5.4.1 Sampling (purposeful sampling) 
The central goal of purposeful sampling (non-probability) sought out the professionals most 
involved with IC to CCTs. Blaxter et al. (2010, pp. 170) recommends selecting participant 
suitability by ‘handpicking supposedly typical’ as opposed to randomly picking cases. This 
ensures similarity, supporting the purpose of knowledge sought, as intended to represent the 
phenomenon identifying non-probability sampling as purposeful sampling. However, variation 
within the similarity was derived from snowball cases. The inclusion / exclusion criteria can 




Table C5.1 Table of Participants (P) - Demographics 
RN= Research Nurse  N= Registered Nurse (in Haemato-Oncology) 
P PN1 PN2 PN3 PN4 PN5 PN6 PN7 PN8 PN9 
MN 



















50-59 30-39 20-29 
Gender F F F F F F F F F M M F 
Job RN RN RN RN N N RN RN N RN RN/N N 
 
Con= Medical Consultant (CD = Consultant Doctor)   Prof= Professor of Medicine (Haem-Oncology) 
SpR= Specialist Registrar      F2 = Senior House Officer Doctor  
P PD1 PD2 PD3 PD4 PD5 PD6 PD7 PD8 PD9 PD10 
Age 30-39 30-39 30-39 20-29 30-39 60+ 40-49 30-39 30-39 30-39 
Gender F M F F M M F F M M 
Job Con SpR SpR F2 SpR Prof Con SpR Con SpR 
 
OPM = Outpatient manager    CM = Clinical manager 
BTM =Blood Transfusion Manager  Dip = Diploma 
P PM1 PM2 PM3 PM4 
Age 40-49 20-29 30-39 20-29 
Gender M F M F 







Table C5.2 Inclusion / Exclusion Criteria 
Inclusion criteria: (within the Clinical Academic Group (CAG) for Cancer Services) 
• Consultants 
• Specialist Registrars 
• Research Nurses 
• Specialist Nurses 
• Managers- clinical or non-clinical (from professional backgrounds). 
• English speaking nurses 
Exclusion criteria: 
• Non-English-speaking nurses 
• Pre-Registration students 
• Temporary/agency nursing staff/non-professionally qualified staff 
• Locum doctors 
 
The variation was derived from nurses and doctors depending on their role and 
seniority, and the experiences of clinical managers. Purposeful sampling was chosen over 
theoretical sampling as there is theory available on informed consent. Additional participants 
through snow-balling self-selected potentially assisted with data validation because suitable 
participants volunteered. 
Letters of invite were sent to potential participants, preceded by a short conversation to 
explain the study. This approach was thought to improve access. If an initial strong interest 
was apparent, the letter invite was sent with the Participant information sheet (Appendix C5.5) 
on the same day / next day via email or in a printed version. All potential participants were sent 
a reminder after 5-7 working days (flexible according to leave), and up to two weeks to sign 
the consent form. All potential participants were given the option to recommend a colleague. 
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Every effort was made to facilitate the interview. Participants were not pursued after a 
reminder, nor were they pursued if they declined.  
The researcher recruited, interviewed, transcribed and verified the content of each 
interview verbatim while incorporating the initial analytical process. The sample size was 
estimated, but was determined by the depth and quality of information achieved as indicated 
by Polit and Beck (2012). There was an attempt to validate the themes and form a temporal 
view over time. However, professionals’ time limitations permitted one interview, except for 
one candidate. 
5.4.2 Access 
Access was achieved by presenting the initial proposal and application to the medical and 
nursing leads in keeping with Blaxter et al. (2010) who recommends discussion with 
gatekeepers to outline the research purpose to them. Interim reports on the study progress were 
presented to the Clinical Effectiveness Unit ensuring transparency while maintaining access 
and support.  
5.5 Data collection methods  
The data collection methods used were mainly the semi-structured interviews and the reflective 
research diary. Policies and standard operating procedures were used as benchmarks that 
guided contemporary practice. A short demographic form (questionnaire) was completed to 
provide more role context. For instance, the dual clinical and managerial roles were highlighted 
and verification of consent training. Interestingly, the Good Clinical Practice (GCP) course, 
mandatory for all research staff was not always considered by participants and therefore was 
not ticked.  
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5.5.1 Semi-structured interviews 
Semi-structured interviews were the main tool chosen because they could provide an in-depth 
qualitative exploration of the participants’ experiences (Fielding and Thomas, 2008). 
Quantitative data collection tools would limit capturing experiences (Bryman, 2008). 
Exploration of the lived experience was possible as a result of skilled interviewing through 
probing responses and feelings unlike questionnaires (Bell, 2005). The interview style also 
enabled expression and tone of language (Bell, 2005) transcribed in bold to highlight its 
importance within the analysis.  
The semi-structure style allowed the participant to expand and reflect through guided 
questions enabling flexibility (Creswell, 2004; Mason, 2002). Seidman (2006) points out that 
the interview can flow and that periods of silence are beneficial. This time allows the 
participant to relay narratives, opinions and feelings, observed by van Manen (1990). The 
interview Schedule (see Appendix C5.9) comprised of a semi-structured / loosely guided style 
hinging on 6 main questions, supported by prompting phrases. The interview schedule was not 
piloted mainly because of clinicians’ time limitations. The researcher was aware of the 
possibility of leading questions due to own assumptions. However the questions were peer 
reviewed by the CEU and supervisor to allay the risk of this limitation happening. The use of 
open-ended questions, paraphrasing and summarising enabled the exploration, Sullivan (1998), 
allowing participants’ ‘thinking time’ and clarification which closed questions would not allow 
(Byrne, 2004). I refrained from strictly keeping to the interview order of questions to enable 
participants’ flow of expression. 
One-to-one interviews were decided over a focus group, for the potential to yield better 
data than previous research. Protection of participant confidentiality was observed via one-to-
one interviews (Holland et al., 2010). Within a focus group there was potential for some 
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participants to dominate others as advised by Holland et al. (2010). The researcher assumed 
that the medical profession or senior nurses could dominate the group. Coordinating a focus 
group with time constraints would prove very difficult.  
The scheduled time and privacy of interview location was facilitated. The interview 
was audio-taped over 45-60 minutes. The researcher felt that longer time would detract from 
concentration levels and increase participants’ inconvenience. A copy of the transcript was sent 
to each participant for verification (Appendix C5.12). Creswell (2007) highlights that this 
allows time for the participant to confirm or add to the data, enhancing the validity. Van Manen 
(1990) proposes that this process of data checking is essential to the depth of the information.  
5.5.2 Diary keeping and Reflexivity 
The researcher’s reflective diary was intended to assist with interpreting the meaning of the 
data, enabling reflexivity to occur. The reflective process described by Rolfe et al. (2001) was 
deployed to rigorously analyse my own practice and CCT practice. In keeping with 
interpretation of the meaning, the diary acted as an aide memoire where prompters were 
collected in keeping with Thomas (2011). Although the meaning was interpreted, the intention 
was not to change the content. The exercise of reflecting on the diary content was guided by 
Schon’s (1983) approach to practitioner research, however reflecting-in-action was difficult 
for the researcher due to the insider researcher limitations. The practitioner also held 
management responsibilities, therefore keeping the diary required discretion. The value of the 
reflective diary could only be fully realised later when the data were analysed as the reflection-
on-action. In keeping with experiential learning from reflection, judgement occurred to 
interpret the meaning which formulated the themes, (Dewey, 2010). The limitations of the 
insider researcher is explored in the conclusion chapter.  
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5.5.3 Documents used 
Silverman (2010) recommends analysis of documentary evidence relating to policies, green 
and white papers in exploring a phenomenon. The primary documents were derived from the 
local standard operating procedures (SOPs) for consent taking (see Appendix C5.10). Job 
descriptions were considered which indicated the practitioners’ responsibility within consent. 
The guidance provided by  the Nursing and Midwifery Council (2015) and the General Medical 
Council (2008) on consent taking were mainly used to determine the (sometimes vague) 
professional practice and duty. While policies ought to be considered ‘neutral’, Blaxter et al. 
(2010) point out that they can be a means of expressing power depending on context. Meeting 
minutes and letters were too sensitive to use, for which there was not ethical clearance. The 
National Institute for Health Research (NIHR), cancer care guidelines, governance and team 
management were considered for their impact on contemporary practice. The National Institute 
for Health Research (NIHR) targets and the National Patient Cancer Survey on Patient 
Experience (2018) have assisted in gaining study access and peer review due to a desire to 
improve CCT uptake. The guide to the researcher’s selection of documents policies was their 
ability to impact or challenge practice.  
5.6 Data Analysis 
The data analysis involved mainly inductive reasoning from the interview data (Boyatzis, 
1998), while the research diary accommodated the use of the conceptual framework and 
suppositions and the interpretative analysis of the participant experiences. Schutz (1973) 
describes this as using the clarity of the conceptual framework, followed by the participants’ 
subjective meaning; and then finding consistency between the concepts and the experiences. 
An example of this was forming linkage between codes that related to how trust was gained or 
lost to the overarching concept of trust. Furthermore, when considering ‘professionalism’, I 
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was guided by what people thought their roles were. Their interpretation of roles signified how 
different professions have emerged and advanced over time. The steps taken to analyse the data 
resembled the Colaizzi (1978) 7 steps (see Appendix C5.11), although used to assist the 
thematic analysis rather than just describing participants experiences.  
5.6.1 Data analysis steps 
The data were read through the conceptual lens by analysing the interviews as they were 
transcribed. Typing up the transcript (see Appendix C5.12) enabled familiarity with the content 
(Fielding and Thomas, 2008). This approach was not intended to test a hypothesis. 
Step 1 and 2 were undertaken simultaneously by reading the content at least twice, 
numbering the lines and pages. Within this process significant statements were highlighted 
(colour coded on paper) that pertained to the phenomenon. As recommended by Bryman (2008) 
a large margin was allowed within the transcript where reflective notes or annotations were 
inserted. These notes were cross-referenced with the reflective diary to ascertain parts of the 
consent process, the timing of consent conversations and who undertook them. Consistent with 
Thomas (2011), the researcher has kept the typed raw material and made notes on margins, a 
working copy and backed up copy ensuring validity of analysis. 
Step 3 and 4 involved grouping / categorising these statements into clusters of themes. 
A bank of codes was derived from statements and were categorised containing as Bryman 
(2008) describes familiarity or unfamiliarity in what was spoken about by participants, 
sometimes accounting for frequency of word used, suggesting a ‘discourse’. Further 
categorisation occurred by including statements into codes that pertained to each professional 
role. This bank of codes was entered into the NVIVO 10 IT management system to enable 
sorting categories, resembling a Code Manual. See Appendix C5.13 for how statements were 
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coded and categorised by formulating the meanings as interpreted through the conceptual lens. 
Often one statement could evidence more than one main theme and therefore these statements 
were entered into the code manual twice  taking the most impactful participant statement within 
the results.   
Steps 5 and 6 occurred continuously to link the meanings form the interviews as related 
to the phenomenon. The clusters of themes were reduced under the main themes and presented. 
The writing of the results was presented by firstly linking with the themes and explained as set 
against a background of the concepts. The analytical discussion incorporated previous research. 
The way the interpreted findings could impact practice and knowledge was alluded to, but 
brought together in the Chapter 9. 
Considering step 7 of Colaizzi’s process of analysis, participants were unable to 
validate the interpretation of their subjective experiences, although they were asked to verify 
the transcripts. The validation of the interpretation was undertaken by relaying to my supervisor 
how the participants’ experiences were interpreted, examples given above. The conceptual lens 
was a significant bedrock for the validation of interpreted experiences.  
5.7 The research validity 
When ascertaining the validity of this qualitative study the types of validity as devised by 
Lincoln and Guba (1985), and Rebar et al. (2008) in nursing are considered. Validity is 
ascertained by assessing credibility, dependability, confirmability and transferability of the 
study methods and findings. These considerations centred around the interviewing and 
researcher rapport with the participant as described by Cohen et al. (2007). Reliability refers 
more to quantitative research methods and is not discussed. 
 
 76 
Adequate data were collected using semi-structured interviews, and the research 
practitioners’ meaning was shown to be convincing due to the balanced meanings presented 
(for instance that doctors valued nursing practice). Robson’s (2002) strategies for off-setting 
threats to validity comprised the use of triangulation and highlighting negative cases (when 
two doctors sought consent from the family). First, data were collected via the interviews using 
person level triangulation where data from one level of person (research nurse) validated data 
from the next level (doctors) or highlighted incongruences or deviants. The research diary was 
used to understand the meaning of the experiences, accounting for the practitioner identities. 
Linkage of codes and themes to theories and concepts provided accuracy in answering the 
research questions. 
The prolonged researcher involvement was an advantage, demonstrating the 
dependability and trustworthiness based on the collegial rapport. However, there are limitations 
to the study replicability because of researcher subjectivity when interpreting the data. To 
counter-balance this, the data quality was ensured by rechecking the coding as peer reviewed 
by the CEU and supervisor as themes were identified. The data were kept as coded in auditable 
fashion. 
The research validity was confirmed and attained by an appropriate interview schedule, 
using valid questions to ascertain communication experiences of obtaining informed consent 
in CCT practice. Possible threats as an insider researcher for instance bias or researcher 
assumptions were documented. Member checking was achieved by sending the participants the 
transcripts to verify the content and an additional interview was offered. Assumptions / bias 
prior were accounted for. Volunteer participants from the snowballing effect assisted in 
accommodating for selection bias by purposeful sampling. However, snowballing may have 
brought about a ‘Hawthorne effect’, which Thomas (2011, pp.150) describes as productivity 
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increasing, evidenced by increased staff interest. To counter-balance the effects of the 
‘experimenter effects’ or respondent bias (participants saying what the researcher wanted to 
hear), a deliberate attempt was made to avoid sampling line managed staff. I was also aware of 
prioritising conclusions poignant for nursing practice due to my own background. 
Possibilities to allow for generalisation were considered under study transferability. 
The case study boundaries were well defined, thereby permitting transferability to a 
similar/broader practice setting. The data collected was in-depth and consistent with practice 
and previous literature. Practice implications and research possibilities are accounted for in the 
concluding chapter.  
5.8 Summary 
In this chapter the methodological approach, the ethical considerations and the data collection 
method and analysis have been presented and discussed. It has been argued to fully answer the 
research aim and the experiences sought, a qualitative methodological approach was 
undertaken. Data were collected from semi-structured interviews with 26 participants 
comprising doctors, cancer nurses and clinical managers. The research diary supported 
reflexivity and policies informing practice were considered. Data were examined by means of 
thematic analysis. The research validity was defended. Limitations of the insider researcher are 
discussed in Chapter 9. The data will be presented as results followed by an analytical 
discussion in the empirical chapters. The empirical chapters begin with an exploration of how 
responsibility was shaped / determined by time.  
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Chapter Six: Professional responsibility as determined / shaped by time 
_________________________________________________________ 
6.0 Introduction 
In this chapter, the supporting research question addressed is: How does the experience of 
interprofessional responsibility as determined / shaped by time influence obtaining informed 
consent to CCTs? This question supports the overarching question: What is the 
interprofessional experience of communication that impacts on obtaining informed consent to 
CCTs? The results of the study in relation to the associated themes and sub-themes are 
presented. Following on from these themes, there will be an analytical discussion, which will 
link the findings with the literature to support the discussion. The role of obtaining informed 
consent has traditionally been a medical responsibility. However, knowledge regarding the role 
of time and the timing of interprofessional involvement in the consent process is lacking. 
Therefore, a further aim of this chapter is to find out whether the traditional roles are 
challenged.  
The way professional responsibility was experienced within the time spent 
communicating with cancer trial patients when seeking consent was a major theme expressed 
by participants. The structure of the chapter comprises of two parts. First, there is a focus on 
the timing of professional responsibility for diagnosing and recommending the trial, which 
includes the patient assessment and the Multi-disciplinary (MDT) interprofessional 
involvement. Second, there is an exploration of how time is used differently by professionals 
to give information to patients. The exploration begins with the timing of exercising 




6.1 How timing impacts on diagnosing and recommending the trial 
The participants spoke frequently about the timing of exercising their responsibilities prior to 
the patient’s informed consent to the trial. Both professions felt that doctors held the 
responsibility for diagnosing and making an initial trial recommendation, although there was 
some disagreement about how the trial was presented. Additionally, many research nurses and 
managers felt that the timing of the patient’s assessment and nurses’ involvement in the MDT 
decision could challenge the initial trial recommendation, which could potentially impact 
informed consent.  
6.1.1 The importance of the initial trial offer 
The timing of the doctor’s involvement with the patient was important, signifying for them 
making a diagnosis and offering the ‘best option’ of treatment to the patient which was 
sometimes a trial over standard treatment. The importance of the timing doctors’ involvement 
was described below.  
RD8: “So first off, the diagnosis has to be confirmed and that’s before you even 
think about a clinical trial and then you liaise with part of the medical team and 
this includes the Clinical Nurse specialist (CNS) and the research nurses.” 
Another Registrar felt that the timing of his involvement had a definite impact on recruitment 
of patients to the trial. 
RD2: “Yes, I do because I am one of the people who see patients on the front-
line. All our patients need to be recruited by a consultant …but I see them first-




For doctors, the trial didn’t necessarily need to be offered by a consultant. However, research 
nurses said that consultants were responsible for confirming the diagnosis and offering a 
treatment option.  
RN11: “Ideally, I think the consultant should be the primary information-giver 
as to whether the trial offers them (patients) a best chance or …at least the same 
prognostic outcome as the standard treatment.” 
The general view of doctors making a diagnosis and trial offer is supported by Davis (1995) 
who asserted that the complexity of skills needed has been perceived as a medical and a 
hierarchical responsibility. Diagnosing and recommending in this CCT setting was 
acknowledged as mainly the consultant’s responsibility particularly because trial medicines are 
unlicensed. This is supported by Breier-Mackie (2001, p.5) who argued that doctors have ‘the 
knowledge, expertise and authority to recognise physiologically viable or futile treatment’. The 
timing of recognising treatment viability was particularly relevant for a cancer diagnosis which 
informed these doctors’ treatment judgements. 
The way some participants described how doctors initially offered the trial was felt to 
have an important impact on how patients perceived the trial, constituting the first impression 
for the patient. Doctors referred to ‘identifying’ a potential trial patient, or ‘suggesting’ a ‘good’ 
treatment option when ‘approaching’ a patient. Doctors frequently described presenting the 
trial using positive language to the patient as illustrated. 
CD1: “The first step is informing the patient of the potential options relating to 
the clinical trial and then having an informal discussion about what the trial is 
and why they would be suitable, why we think it is a good treatment option… 
as opposed to the standard treatment if there is one.” 
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This extract is one of many similar extracts which illustrates as Barton and Eggly (2009, p.301) 
have argued how doctors presented the trial in a positive way to the patients. However, these 
theorists argued that doctors use of positive statements, for example, ‘better outcome’ / ‘good 
option’ could be persuasive by presenting trials with a ‘positive valence’ (on a continuum from 
positive to negative). Mostly nurses and managers intimated that the initial medical approach 
could be persuasive, indicated in the language nurses used to describe how doctors offered the 
trial. 
CN5: “They (patients) might have been propositioned by the doctor about it. If 
doctors are able to, they will give them (patients) time to think about it and come 
back to decide and agree to it.” 
The use of ‘propositioning’, where ‘giving time’ seemed uncertain may suggest a persuasive 
urgency. In keeping with the possibility of persuasion, research nurses and managers explained 
the medical recommendation as ‘pushing’ for the trial or not giving enough time to the patient 
to decide as illustrated below.  
M3: “Definitely there is an element of really pushing. Doctors will try anything 
and let’s be honest x speciality is a very good example. Doctors say ‘I will keep 
on pushing and pushing until the last minute even giving as many drugs’, 
sometimes nurses say ‘Is this really fair on the patient? Have you discussed this 
with the patient and is that going to be causing more co-morbidities (additional 
conditions and complications) to the patient?’ So, I can see where they (doctors) 
are coming from because they want the best for the patient but sometimes it 
doesn’t come across as this.”  
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The nurse and manager’s perception of the doctors’ initial communication is interpreted as a 
divided view. On the one hand, they spoke about doctors ‘pushing for the trial’ or pressurising 
the patients regardless of more co-morbidities or complications. Yet, the manager did not seem 
to object to the doctors’ persuasive approach as he said that doctors ‘want the best for patients’. 
Similarly, theorists have noted that persuasion may exert pressure on patients which Brown et 
al. (2011) says may challenge the bioethical principle of respecting patient autonomy to achieve 
informed consent. Furthermore, Chwang (2016) argued that the way risk is ‘framed’ could 
exploit benefits for patients. However, physicians presenting risk judgments in a positive light 
was asserted by Brown and de Graaf (2013, p.1) as enabling patients to construct ‘positive 
future time’. Indeed, in the cancer setting the physicians' role was suggested as a ‘paternalistic 
recommender’ (often not giving an alternative option), thereby giving ‘unrealistic 
hopefulness’, and oncologists expressed optimism twice as much as pessimism in patient 
consultations (Brown et al., 2004, 2011; Robinson et al., 2008). However, Barton and Eggly 
(2009, pp.297) emphasised that ‘persuasion is licensed in treatment recommendations which 
sometimes included clinical trials’. Positive language may have had significance in obtaining 
informed consent, because in keeping with Jonson et al. (2015) positive prognostic information 
given by doctors can appeal to the generation of hope for cancer patients.  
It is unclear if the nurses voiced their concerns about this persuasive approach to the 
doctors or to the nursing managers. However, questioning the trial recommendation was 
perceived as central to the MDT decision-making. Interestingly, only one consultant who led 
the MDT expressed what appeared to be his dissatisfaction about ‘pushing’ for the trial in this 
extract. 
CD6: “And they (patients) might say: ‘do you really think this will make a 
difference?’ In your heart of hearts there may be a bias that you come to pushing 
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towards that or pushing towards what you feel might be better more 
conventional and some trials are just plain boring… I think sometimes they 
(doctors) are pushing. It means that nobody questions some of the MDT 
decisions saying, ‘is there an alternative?’” 
It may be significant that CD6 felt he could say that doctors were ‘pushing’ for the trial. Within 
his role as an MDT lead, he held the responsibility to encourage team involvement and he 
possibly had additional autonomy to voice concerns, unlike more junior colleagues who may 
not have the autonomy to ‘question’. The ‘pushing’ approach described was in keeping with 
Eigenmann (2015, p.1) who interpreted the MDT recommendation as sometimes aggressive, 
suggesting the MDT recommendation may not always have a positive effect and can be 
‘miserable’ for the patient. 
The responsibility for diagnosing and the way the trial was initially offered by doctors 
greatly impacted on the patient’s perception of the trial and subsequent consent, although there 
was interprofessional disagreement about their approach. Furthermore, the timing of the 
matching of the trial with the diagnosis was significant to enable the recommendation. 
6.1.2 The timing of the eligibility and suitability matching 
Some doctors and research nurses highlighted that the eligibility and suitability assessments 
have an impact on the timing of trial recommendation and subsequent consent. Many 
participants seemed to use these terms interchangeably providing lack of clarity about 
responsibilities as the Registrar describes below. 
RD5: “Often it is the clinicians who identify patients who are suitable 
for the clinical trial. Often these are clinicians who are not directly involved in 
the trial and they may refer to the Investigators who are running the trials and 
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see whether that person feels that the patient may be eligible for the trial…" 
This extract shows that patient’s diagnosis can alert doctors that the patient may be suitable for 
the trial and therefore refer the patient. However, it would be the specialist team who decides 
on the patient eligibility later. Another doctor referred to disease confirmation as ‘compatible’ 
with the trial recommendation. However, the timing of when they matched the patient 
diagnosis with the trial, or the trial with the patient’s suitability differed because other 
participants formed a distinction between eligibility and suitability as below.  
RD8: “A person can be eligible if they can tick the boxes, so the age requirement 
and the blood tests. But they might not be suitable if there are other personal 
situations ..or social or language even, they might not be entirely suitable.” 
Although the timing of eligibility is considered before suitability by RD8, the assessment 
distinction did concur with Sharkey et al. (2010, p.363) who highlighted eligibility as a ‘factor’ 
where patients fit the trial criteria based on mainly ‘disease factors’ and ‘medical history and 
age’, whereas ‘suitability’ referred to the patient’s ‘personal situation’, opposing RD5’s 
original view where ‘suitability’ was identified as the compatibility test referring to disease 
matching the trial suitability only. Importantly, CD5 confirmed that eligibility may not always 
be confirmed until after the recommendation. This is important because patients found 
unsuitable after the satisfactory eligibility (test results), could mean that such a 
recommendation may be devastating or misleading for patients who anticipate the trial offered. 
The uncertainty about the timing of the eligibility or suitability assessments is in line with 
Kidger et al. (2009) who found that most professionals preferred to seek patient suitability after 
the MDT treatment recommendation in the clinic consultation where time is spent with the 
patient. However, a minority of Kidger et al.’s respondents sought the patient’s suitability prior 
to making a recommendation in the clinic. The reason given in favour of assessing suitability 
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before clinic was to ascertain the patient’s social needs and preferences which the 
recommending consultant may not have knowledge about. The patient’s suitability was 
clarified by the senior consultant. 
CD6: “And also, the patients age if they can tolerate the treatment. The other 
thing is the social circumstances of the patient and if the family agree with the 
trial. If the family doesn’t want how can you reconcile the patient and family?” 
Nurses, including nursing managers seemed more aware of the need for patients’ suitability 
assessment prior to the trial offer as they felt it impacted on informed consent. For instance, 
N5 felt that patient motivation and understanding was part of the trial suitability assessment. 
“So, their (patients’) motivation…what is actually the most important thing is 
making sure that they are suitable and that they understand it. Initially they need 
to be sure that they can understand it so that they are suitable.” 
In a similar way, this research nurse felt that lack of patient compliance, possibly due to lack 
of understanding of the trial would make a patient unsuitable. 
RN10: “It is more important that it is right for the patient. They (the patient) 
were failing to turn up and it was a while before the medical team decided that 
they were not suitable even though it was kind of obvious that even if we did 
get them on to the trial, they were not going to be compliant.” 
In many cases it was the doctors in this study who made the decision about patient suitability 
without actually making this assessment, having already offered the trial to the patient. This 
appears in keeping with Wenger and Vespa (2010) who argued that doctors made decisions 
about the appropriateness of ‘patient factors’ that were compatible with the trial, not limited to 
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diagnostic matching. The timing of MDT challenges to recommendations on the basis of 
patient’s eligibility and suitability can impact on gaining or maintaining informed consent. 
6.1.2 Multidisciplinary team (MDT) professional involvement 
An overwhelming majority of participants spoke about the MDT as an opportunity for 
decision-making and agreeing treatment recommendations. Both professions spoke of medical 
dominance in the MDT meeting, where many research nurses felt their role lacked impact. 
However, many doctors spoke about how the nurses’ role was important in challenging the 
MDT recommendation. Managers spoke about the hierarchical constraints of the MDT, but 
rarely attended except for auditing of practice purposes.  
A minority of doctors affirmed that the MDT was medically dominated. However, 
while these doctors highlighted that nursing involvement was lacking, they did not always 
explain why nurse involvement was important.  
CD9: “I am not convinced that I know the role of the research nurse and there 
is the question of where the research nurse / staff fit in. The model that we run 
is that the patient doesn’t have any contact with the research nurse until they are 
quite far down the line, after they have already been given the information sheet. 
Then meeting the patient is essential to the screening [after consent] and getting 
them started. I’m not sure that we integrate the role enough here, to get research 
nurses involved early enough in the patient journey.” 
There was uncertainty about what benefits involving the research nurse earlier would bring 
leading up to informed consent. Most of the doctor’s references to MDT working were from 
CD6, the most senior consultant who had a managerial responsibility to encourage team 
attendance as mandated in policy (Improving Outcomes, 2016). CD6 recognised that nursing 
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involvement was beneficial in questioning doctors ‘pushing’ the trial, illustrated previously, 
and, that nurses were not as “active as they should be in the MDT”, which he said resulted from 
nurses and others not being “aware of it and therefore they don’t question it.” 
Despite doctors encouraging nurse involvement, nurses’ lack of trial awareness was in 
line with Ulrich et al. (2012) who linked nurses’ lack of involvement to their knowledge deficit. 
Interestingly CD6 did not mention if doctors questioned medical decisions. However, it was 
possible that the non-consultant doctors’ responsibilities may be unclear in the MDT. Sidhom 
et al. (2008) found that only 48% of UK doctors believed they were responsible and ‘liable’ 
for MDT decisions, if they attended. Failure to attend the MDT might account for why junior 
doctors may not question MDT meeting decisions afterwards, together with not knowing the 
patient’s suitability which could be reason for challenge. Both nurses and doctors in the current 
study highlighted that the nurses’ role (particularly the clinical nurse specialist role or CNS) 
was that of a ‘challenger’ who ‘should’ be involved in the patient suitability assessment within 
the MDT discussion.  
CD6: “Absolutely, we use them (CNSs) that way, as an advocate. They are very 
much part of the team and the decision-making, listen to them, ignore them at 
your peril because they are a very good radar that tells you … because they act 
as a conscience that if you are not thinking about things quite properly they are 
a reasonable conscience that reminds you, ‘do you really think they (patients) 
are actually going to cope with it?’ ”. 
This extract illustrates that CD6 viewed the CNS as a ‘conscience’ checker possibly 
necessitating rethinking the medical recommendation on the grounds of patient suitability, 
which he likened to an ‘advocacy’ role. Interestingly, RD8 initially was firm about the lack of 
nursing input, although intimated that the hierarchy of the MDT may affect CNSs’ involvement 
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depending on their seniority and individual ‘capability’. On further discussion and probing, 
RD8 described how the CNS or Research nurse is needed for decision-making with new 
patients because the CNS knows the patients’ background, as illustrated below. 
RD8: “No and it is the doctor will present and they will talk amongst themselves 
and come up with a treatment. I have to say depending on who it is and 
depending on the condition, because the CNSs are often the ones who have seen 
the patient and spent more time with the patient or know the background so 
actually although my initial gut thing was no, I have to say it depends on what 
the question is. If it is about a new patient and treatment trials, I think there is a 
question to the CNS or Research Nurse regarding what they think and if they 
(patients) should have it”.  
These extracts illustrated that the primary decision-makers regarding the trial were the doctors 
in the MDT meeting in line with Eigenmann (2015). However, the role of the nurse was 
acknowledged by some doctors in this study as a voicing the patient’s preference and 
contributing to supportive care discussions in the MDT, although this involvement did not 
always happen. The lack of nurse involvement is similar to Taylor et al. (2012, p.8) who 
observed that a lack of CNS or any nurse involvement explained ‘the lack of patient-based 
information’ in their study, although they emphasised that nurse involvement is expected since 
the National Institute for Clinical Excellence (NICE) guidelines (2004). In line with Lamb et 
al. (2011), the doctors’ view was that interprofessional and professional hierarchy exists in the 
MDT and contributes unequal contributions resulting in ‘poor consideration’ of suitability, 
social issues and preferences. The MDT literature has not referred to the nurse as a ‘challenger’.  
 
 89 
Research nurses were less emphatic than doctors about their advocacy role. They 
described their role only as a ‘challenger’ by questioning the eligibility and suitability 
assessment, after the MDT recommendation was decided. The timing was important.  
RN3: “The doctors will just know the exclusion and inclusion criteria. I have to 
make sure that before the consultant says ‘Oh we have a potential patient’. There 
are certain things that doctors might not know about the protocol, so I have to 
say to the consultant, ‘Oh I think this patient cannot go into the study because 
of …either one, two or three things’.”  
This research nurse implied that she has a role in the eligibility and suitability assessment by 
assuming this responsibility. The research nurses felt they would know ‘certain things’ about 
the patient that provided reason for them to challenge the trial recommendation, which 
according to this extract the doctors needed. It is intimated that nurses providing patient 
suitability details may not be perceived as a hierarchical challenge.  
A minority of research nurses expressed discontent regarding insufficient time given to 
patients to deliberate, even outside emergency situations because of the potential for patient 
lack of understanding of the trial. RN11 explained how research nurse involvement earlier in 
the consent process would benefit the patient. 
RN11: “The first time I see the patient after signing the consent it is to review 
the consent form and try to review their understanding of the trial to ensure that 
it has not been a rush job and if I thought that I needed to revise or refer back to 
the consultant to say that I thought that the patient needed a bit more time to 
properly understand. Sometimes in particular instances of emergency there is 
not that luxury of time to give them the PIS (Patient Information Sheet). After 
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they have had the information for a time then they usually come back to me. 
Typically, I have not met patients before consent.” 
Interestingly, this extract shows that the consent was undertaken before the research nurse met 
with the patient, thereby preventing an opportunity to review the patients’ understanding of the 
trial. In the reflective diary, it was noted that nurses were unable to contribute to the discussion 
leading up to the decision and expressed discontent about their lack of involvement. Another 
research nurse, RN10 expressed unhappiness about the trial consent being rushed, although 
there were sometimes medical reasons for this.  
RN10: “But the patient won’t know anything about it until they are seen in 
clinic. I think for patients sometimes it can be a bit rushed. I mean there may be 
clinical reasons for that and if it is important to start treatment quickly. They 
might be given a form to go away and read it for an hour and come back. I’m 
not very happy with that but it does happen from time to time.”  
The element of the recommendation being ‘rushed’ was poignant for nurses, but it appeared 
necessary sometimes depending on the clinical need or urgency, thereby allowing patients less 
time to deliberate. This finding is in keeping with Alby et al. (2017, pp.1) who found that high-
risk patients have less time to decide, although could be pressured to choose in the consultation 
where the treatment recommendation was presented as ‘mandatory’ because of the clinical 
urgency.  
The element of being ‘rushed’ was a concern for research nurses as they linked it to the 
patients’ lack of understanding of the trial information. RN10 said there was no opportunity 
because patients were considered for the trial before any nurse involvement. Furthermore, 
RN11 spoke of concerns voiced about ‘unsafe care’ if staff were ‘overstretched disadvantaging 
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patients’, resulting in ‘challenging’ by ‘feeding back concerns’, but said that staffing did not 
prevent the trial offer, if the patient has no other option. RN11 explained that there was a 
reluctance to voice a concern after the MDT decision because it may ‘not be heard or acted 
upon’ and challenging depended on the doctor-nurse relationship. The importance nurses 
placed on the timing of challenging the decision echoed the Kidger et al. (2009) study where it 
was found that nursing personnel were unable to take an active part in the case discussion due 
to the MDT hierarchy. Furthermore, Klimaszewski et al. (2008) identified the US advancing 
research nurses’ role in patient safety monitoring, due to their knowledge and skill. Some 
research nurses in the current study felt they could challenge the patient’s ineligibility or lack 
of suitability on the grounds of patient safety. However, there was general uncertainty among 
nurses whether they could challenge MDT decisions. This may resemble a lack of nursing 
confidence and autonomy needed to voice concerns (Spilsbury et al., 2008; Hyland, 2002). 
Many research nurses explained that nurse involvement in consent was team-specific 
and depended on their relationship with the medical team. For instance, RN4 explained that 
the nurse has to ‘gauge’ what the doctor wants of her role, but involved checking the documents 
were signed ‘in the right place’. Another research nurse, RN2 explained that in one sub-
specialty the MDT involved only the doctors, described as a doctor’s ‘huddle’ before the clinic 
commenced. She added that her role involved filling in the “missed out steps” in the process 
after the patient had consented. 
The notion of the research nurse role ‘fitting’ in with the doctor, or supporting the 
doctor did not constitute for them responsibility for informed consent. For the most part 
research nurses did not want to claim responsibility for the consent, except for mainly their 
supportive role to the doctor. In line with Lee et al. (2010) nurses checking consent 
documentation as described by RN4 was similar to a witness or adjudicator of the doctors’ role. 
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Furthermore, for many nurses, their ad-hoc involvement was in keeping with the traditional 
role of fulfilling the doctor’s wishes and instructions, likened to the nursing stereotypical 
‘handmaiden’ image (Fagin and Garelick, 2004; Roberts and Vasquez, 2004). 
The formal hierarchical structure of the MDT appeared to fall short of interprofessional 
involvement at the time of decision-making, except for the possibility of CNSs or research 
nurses’ ‘challenging’, encouraged by the doctors in some specialities, often after the consent 
was taken. The information-giving role was integral to supporting the trial recommendation.  
6.2 The Impact of time on information-giving 
Doctors and nurses described their overlapping role in providing information during their social 
encounters with patients. Both professional groups liberally referred to this role which may 
indicate that information-giving was perceived as an essential responsibility for both. Three 
main elements of information-giving as shaped by time are explored. First, there is an 
exploration of the problems associated with the time of signing the consent form. Second, the 
way professionals spent their time in the delivery of information to patients. Finally, how time-
constraints may impact on professionals’ responsibility when obtaining informed consent.  
6.2.1 Problems with the time of signing of consent form  
Most nurses and doctors placed huge importance on when consent was ‘taken from the patient’ 
and referred to it as the time of ‘signing of the consent form’ following a trial recommendation. 
This time signified when the patient’s understanding of the risks/benefits were assessed and 
confirmed. However, some participants spoke about problems associated with the time the 
consent form was signed, and questioned the quality of the consent. Nurses and junior doctors 
were emphatic that consent taking ‘should’ be undertaken by the Principal investigator or 
consultant, emphasising clear separation of role responsibilities.  
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RN2: “The only people in my team that consent are the consultants and no one 
apart from our two consultants can consent to our clinical trials.” 
Although the consenting was separated as the senior doctor’s responsibility, participants 
explained that this doctor may not know the patient. RN2 explained that the doctor who sees 
the patient in the clinic may neither have been present at the MDT, nor have met the patient 
before, but is required to follow the MDT recommendation, which some participants previously 
intimated as an aggressive recommendation. In line with Eigenmann (2015, p.1) not seeing the 
patient before an MDT decision was problematic because he says that ‘collective’ decision 
making in the MDT may be ‘biased towards recommending aggressive treatments’. 
Furthermore, CD6 felt that the MDT recommendation can involve ‘pushing’, but the physician 
who sees the patient directly may have a different bias in favour or against the trial if he knows 
the patient. RD10 alluded to the nursing role as an obvious contributor to enabling informed 
consent in situations where the doctor may not know the patient. 
RD10: “I think that the initial recruitment and consent should come from the 
clinician who sees them, and then the research nurse would take over because 
it is very difficult to consent a patient you don’t know.”  
General cancer nurses reported that the responsibility for information-giving needed to achieve 
informed consent lay only with the physician giving information at the time of the consent 
‘agreement’ with the patient. Some doctors, for instance RD8 said the timing of the 
information-giving supports the doctor ‘ultimately’ achieving consent at the time of signing of 
the consent form, although she alluded to consent as ‘everyone’s’ responsibility. 
RD8: “I think the doctor taking the consent and signing the form it is their 
ultimate responsibility. They are the ones who are going through the last check 
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but before that I think everyone is responsible for making sure that whatever 
they are telling the patient they understand it and retain it and the benefits and 
cons but obviously, the final signing of the consent form needs to make sure 
100% that there is understanding and there is consent.” 
While RD8 highlighted that it was the doctor’s responsibility as he took the consent, she also 
said that ‘everyone’ was responsible, but did not elaborate on those responsibilities. 
Interestingly, RD3 described that the signed form counts for ‘full’ patient awareness at the time 
when the doctor gives the information to enable a decision.  
RD3: “I think the patient is fully aware of his medical condition. He is fully 
aware of his treatment options and that the clinical trial is the best option for 
him. So, it’s just letting him know that he has the information to make his final 
decision.” 
From this extract, ‘full’ patient understanding was achievable at the time the patient signed the 
consent form. These registrars seemed to defend the validity of informed consent achieved by 
doctors, by claiming that patients had ‘full’ understanding at the time of consent, although it is 
uncertain if this understanding was checked. In fact, Bergenmar et al. (2011) asserted that rarely 
did investigators/physicians assess if the patient understood the information in consent 
discussions. Furthermore, by way of contrast to these registrar and nurses’ views, regardless of 
signed consent paperwork, its ‘usefulness’ has been previously recognised as ‘incomplete’ 
(Jordens et al., 2013, p.76; Shannon-Dorcy & Drevdahl, 2011). Similarly, O’Neill (2002, 
p.157) speculated that procedural practices enabling informed consent are merely informed 




It may be significant that for some registrars there may be more active checking of 
patient understanding as registrars were responsible for what they called ‘frontline’ immediate 
patient safety. The perspective that some doctors and cancer nurses assumed the consent was 
‘fully’ achievable at the time of signing the form is questioned by most participants who felt 
that valid consent was not possible at the time of signing the form, but that consent was an on-
going ‘process’ over time.  
6.2.2 Information giving as a process  
Most participants explained was that consent was an on-going ‘process’ of information-giving 
intended to allow patient understanding and ‘deliberation time’, which they connected with 
following the Good Clinical Practice (GCP) guidelines. For instance, CD6 emphasised that 
day-to-day encounters with patients provided opportunity for them to revisit information-
giving and confirm consent. Doctors admitted that giving detailed information in one encounter 
was ‘a lot to take in’ for the patient. 
CD9: “There is a culture of this in the institution, this would be first broached 
in a clinic consultation in broad terms. Usually with our patients there is 
sufficient time that we are able to drip feed the information.. and what their 
options are.” 
Doctors suggested that this slow delivery of information was ‘drip fed’ in more than one 
encounter which is similar to Pujol et al.’s (2016) speculation that slow construction of 
information provides the patient with more deliberation time. RD8 explained that consent was 
best taken place in more than ‘one sitting’, which allowed the patient to take away the written 
information, giving time to consider questions prior to the next ‘sitting’. There was agreement 
with Bergenmar et al. (2011) that giving the patient more time is likely to impact positively on 
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consent, although Bergenmar et al. (2011) linked giving more time to ‘easier’ patient decision-
making but did not specify that more time improves patent understanding. The significance of 
comparing to Bergenmar et al. (2011) is that for participants in the current study giving 
information over time was an important factor which did contribute to patient understanding. 
‘Frontline’ participants and managers spoke about professional responsibility for information-
giving as a process. Their concern related to potential patient safety problems because of a lack 
of handing over trial information from the research team to frontline staff which they said could 
negatively impact patient safety.  
JD4: “I am not saying that we should give detailed information but the general 
things like checking bloods tests. I was doing an on-call day and the research 
nurse asked me to chase the bloods. We didn’t know what to do. Then 
something may happen to that patient and I don’t know what to do.” 
M2 pointed out that if ‘frontline’ staff lack this trial knowledge “the patient can be put off the 
trial”, potentially causing withdrawal of consent. One research nurse highlighted that lack of 
trial “familiarity” among ‘frontline’ staff can cause lack of “ownership”, or lack of 
responsibility. Many research and cancer nurses who administered the trial spoke about the 
research nurse’s role as upholding patient safety throughout as illustrated. 
RN11: “I don’t think informed consent ever ends particularly if it is a complex 
trial. They (patients) probably haven’t been able to fully understand the trial. 
You need to revisit things. While a patient has said yes and signed the consent 
perhaps you might liaise about well are there any potential safety issues. And 
any time you are treating them you should re-confirm that they wish to continue 
on the trial. I see informed consent while they are on the treatment up until the 
publication of the trial.” 
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The responsibility for information-giving over time by re-iterating information between 
professionals at the frontline was deemed a factor in maintaining patient understanding and 
safety. Giving information over time was described as undertaken in an ad-hoc way as the 
process of consent unfolded because ‘qualitative time’ is likened to “irregular self-determined 
temporal patterns” (Hassard, 2001, p.136). The ‘frontline’ medical and nursing role of trial 
safety monitoring is supported by Klimaszewski et al. (2008) who acknowledged that the 
research nurse’s responsibility for trial consent has developed in this way. Furthermore, the 
time allowed in the delivery of information is developed in the next section. 
6.2.3 The way professionals spent time with patients  
Many doctors and nurses spoke about how they spent time providing trial information to 
patients. Doctors and nurse managers recognised how the nurses’ relationship with patients 
contributed to ‘valid’ informed consent. Doctors explained the potential constraints with ‘clinic 
time’, which some described as likely to have a strong impact on difficulties they experienced 
obtaining ‘valid’ informed consent. Many participants referred to nurses spending more time 
with patients. The majority medical view was that nurses are best placed and knowledgeable 
about the ‘logistical information’ of the trial and can explain the information in detail which 
was not possible for the doctors to relay in the clinic because of lack of time.  
RD10: “It would be really difficult for doctors, because they (research nurses) 
are experts in the trial. They (research nurses) are experts and they have a lot 
more time to sit down with the patient. They are prompting everyone to make 
sure that they are sticking to the trial.” 
Both doctors and research nurses referred to nurses’ beneficial informal approach with patients. 
RD5 referred to nurses improving patient understanding by “taking time and space” to explain 
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terminology, particularly in relation to the complexity of randomisation. Furthermore, research 
nurses were described by doctors as checking the information after the clinic appointment or 
answering questions.  
CD7: “That is (the research nurse’s role) to reiterate and to go through the 
information again because it is a lot of information to take in and sometimes the 
patient will ask the nurse questions that they won’t ask the doctor. They 
(patients) may just have small questions that they may not feel are appropriate 
to ask the doctor and it gives them another opportunity to raise any questions.”  
Nurses were described as re-iterating the information doctors had given and answering ‘small 
questions’, yet these small questions could require more detail and more time. The reference 
to answering ‘small questions’ may have devalued the role of nurses. It is interesting that CD7 
separated the type of questions by saying certain questions were ‘inappropriate’ to ask the 
doctor. This suggests that the nurse had a different skill set or merely more time to answer such 
‘small questions’. The consultant’s perception could be that patients do not want to waste the 
senior doctor’s time. Research nurses said that patients felt reassured because they spent more 
time with patients re-iterating the information to support the medical recommendation. 
However, many research nurses said that they are often not involved although they wanted to 
be present before the consent to enable patient understanding.  
The research nursing view of the clinic appointment was described by RN3 as an 
opportunity to provide an overview of the trial ‘in simple terms’, which could be interpreted as 
not complicated. Giving information ‘in simple terms’ is interesting because one might expect 
the physician’s explanation to be scientifically more complicated. The overview may well be 
scientifically complicated although portrayed simply, but was described as leaving gaps in the 
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technical detail, although it appeared to refer to the day-to-day practical details as described 
below.  
RN3: “The physician obviously, I wouldn’t say is going into the detail of the 
consent, they kind of explain in simple terms and then the research nurse will 
go into all the technical bits, whether they need to come every day, but they 
(doctors) are just there to tell the patient about the study and then take the 
consent.” 
The doctor’s simple overview seemed to set the tone for the initial informed consent. Giving 
information in understandable terms however was qualified by both professions and nursing 
managers as giving more detail to include the ‘the technical bits’ and the ‘minutia’ and the 
‘intricacies’ of the trial which they said falls outside the clinic appointment and sometimes 
referred as taking the form of a ‘chat’. Many research nurses referred to ‘going through’ the 
information with patients in a detailed way outside of the doctor’s clinic appointment as 
described. 
RN4: “So, he (Consultant) would normally say here is the PIS (Patient 
Information sheet) and the research nurse will go next door and go through the 
trial in more detail with you. Obviously, we (research nurses) will go through 
the drugs and he gives them the option of both treatments and I go through the 
intricacies of the trial. He wouldn’t go through the in-depth details of the bloods 
and so on.”  
Doctors communicating simply may mean the brevity of the overview given the clinic 
appointment which may undermine the quality of communication. Brown et al. (2004) advised 
medical communication courses that focuses on ‘quality’ of information exchange. Research 
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nurses appeared to give more time to patients, providing more detail, seen as enabling the 
patients’ understanding of the trial information that the doctor presented. It is possible that 
professionals may have encountered more communication problems with the diverse cancer 
trial patient group, where prognostic information is often referred to in doctors’ consent 
discussions about trials, although participants did not refer to percentage information delivery 
problems. It is known that that cancer patients needed sense to be made of numerical prognostic 
information which they struggled to understand in the medical appointment, although they 
didn’t say that nurses were responsible for making sense of this information according to 
Thorne et al. (2007 cited in Johnson et al. 2015 ).  
 A minority of doctors spoke about gaps in what they could feasibly deliver due to their 
time-constraints. They emphasised how nurses spend their time by responding to patient’s 
needs which they said was an ‘essential’ requirement for informed consent. Where physicians 
acknowledged time-constraints they highlighted how research nurses spent their time with 
patients differently.  
RD2: “We tend to be so absorbed into the care of our own patients that we do 
miss a lot of the information aspect of the trial. I think the research nurses are 
the only ones who can deliver that, informed consent and following that is not 
just the piece of paper. To be honest if it wasn’t for them I don’t see that the 
service could run. Clinicians don’t have time. We don’t have the time. Really 
informed consent needs much more details than 10-15 minutes in the clinic so 
I believe that the nurses do have flexibility in terms of time to meet the patient 
either before or after or during the clinic to make sure that that word informed 
consent is truly happening. To deliver informed consent as per clinical trials 
research nurses are an integral part of the team.” 
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This extract shows how the lack of time available in the clinic appointment meant that doctors 
missed information, and the way that RD2 felt the ‘service could run’ was for nurses to see 
patients outside of the clinic appointment to enable ‘truly informed consent’. The clinic time 
constraints in the CCT setting is in keeping with MacBride-Stewart (2013, p.564) who 
described that in general practice doctors’ work is, as she terms it, ‘colonised’ by time where 
she explained ‘medical time’ is structured by management scheduling, portrayed as ‘clock 
time’ in minutes. The way nurses experienced their time with patients fell outside of clinic time 
which for them became an on-going process of patient encounters. In line with Davis (1994) 
this ‘process time’ was cyclical / rhythmical and importantly he described this social 
construction of time as ‘relationship governed time’ as opposed to time that was governed by 
a ‘clinic slot’. It seemed that the missing information that the doctor was unable to give due to 
time constraints has been fulfilled as an essential part of the research nurses’ time spent with 
patients. RD2 placed importance on consent as not just a “piece of paper” by emphasising the 
word ‘informed’. In keeping with MacBride-Stewart (2013, p.1), these doctors lacked 
sufficient time, ensuring ‘informed’ consent (traditionally a medical responsibility) became 
‘re-distributed’ to the CCT nurse. 
Another consultant described how nurses enabled “good consent” by developing a 
meaningful relationship with the patient. In this extract ‘good’ consent is likened to “informed 
consent” by contrasting it with “uninformed consent”.  
CD6: “They (nurses) are an essential part of it. I can give overview of an 
exciting new treatment, but I may not be as aware of how much time and effort 
and everything else the patient might have to go through. If they are explained 
at the beginning then their informed consent is really good informed consent, as 
opposed to uninformed informed consent, which is so much the minutia and it’s 
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the minutia that often gets the patients and upsets them not the big picture. So, 
I think it is an essential part. So, it is as an information-giver, coordinator, and 
also a friend of the patients by which I mean the patients like to know whom do 
I deal with and they want to know who the team is and want to know that you 
are part of my team or I am part of your team. They need to know that if they 
talk to me I will talk to you and keep everybody informed so making them feel 
comfortable.” 
In this extract although coordination was needed it was the ‘extra time’ effort to develop the 
‘reliable’ relationship of ‘friendship’ that nurses experienced with patients that brought about 
this ‘good consent’. CD6 implied that the nursing relationship makes it easier and more 
comfortable for patients, enabling them to talk to nurses and feel sufficiently reassured. 
Interestingly research nurses did not refer to their relationship with patients as a ‘friendship’, 
unlike Dowling (2008, p. 5) who observed that friendship was a key theme which nurses felt 
permitted intimacy with cancer patients. She attributed the creation of a friendship to ‘self-
disclosure of information’ and the creation of a ‘homely atmosphere’. The ‘homely 
atmosphere’ is not too dissimilar to the team togetherness portrayed by CD6. Importantly this 
friendship, as Campbell (1989, p.50) explained resembled ‘skilled companionship’, and 
develops with a ‘time-phased’ approach to intimacy, as found by Dowling (2008). Strazdins et 
al. (2016, p. 21) identified that time is required for ‘building strong and supportive 
relationships’. Although most research nurses acknowledged their time with patients as an 
informal approach, they did not directly attribute ‘good’ or ‘truly’ informed consent to this 
approach. However, nurses related the building of their relationship with patients to the 
creation of trust.  
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Only nursing managers spoke about how nurses made a significant impact on gaining 
informed consent because of how nurses spent time with patients. The crucial element M1 
spoke about was that nurses are “more people-based”, by taking the time to give detailed 
information that the “patient can understand” enabling ‘valid informed consent’ by making the 
patient feel comfortable enough to ask questions. The nurse managers were responsible for 
ensuring a good patient experience, therefore they had interest in nurses developing a good 
relationship with patients.  
Doctors recognised that unstructured ‘process’ time is needed for research nurses and 
‘frontline’ professionals to give detailed information to enable patient understanding and 
maintain patient safety. However, most nurses, except nurse managers did not connect the 
process of time as a defining element of ‘valid’ informed consent. A minority of doctors and 
managers emphasised that clinic time constraints have brought about the need for valuable time 
constructed as a process by nurses which they felt enabled ‘valid’ informed consent.   
6.4 Summary  
This chapter has answered the research question that asked how does the experience of 
professional responsibility as shaped / determined by time influence obtaining informed 
consent to CCTs? The experience of professional responsibilities in contemporary 
interprofessional CCT practice has been explored to ascertain if the traditional standpoint was 
challenged. The majority of participants confirmed that the consultants made judgements and 
undertook the responsibility to diagnose and make trial recommendations. However, there was 
disagreement and discontent about their sole responsibility in coming to a recommendation. 
The positive, even persuasive language used by doctors to present the trial was a source of 
discontent for all participant groups.  
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The MDT meeting was identified as a forum when professionals exercised their 
responsibility regarding trial treatment decisions, although was described as dominated by the 
medical profession, deterring nurse involvement. A minority of doctors recognised the need 
for nursing involvement to give a view on patient suitability assessment for the trial, although 
it was often unclear what suitability or eligibility meant to professionals. The timing of making 
a patient suitability and eligibility assessment was of concern for the research nurses because 
they felt they wanted to challenge the trial recommendation prior to the patient consenting. A 
minority of doctors acknowledged the possible advocacy role of the CNS relayed as 
“challenging”. Research nurses acknowledged their role as a ‘challenger’, although nurses 
lacked autonomy in decision-making and mostly did not challenge the traditional standpoint. 
However, some doctors and research nurses could be seen as challenging the traditional 
standpoint when they did question decisions and seemed to welcome the nurse as a ‘challenger’ 
of decisions. It was not clear if research nurses felt the role of a ‘challenger’ resembled that of 
an advocate.  
Both professions placed huge importance on the time needed to fulfil their 
responsibility for information-giving where arguably roles did overlap. Some registrars seemed 
to defend the ‘completeness’ of the consent form. Nurses and doctors described how they spent 
their time with patients differently; whether as ‘clinic time’ or as a ‘process’. The reason why 
‘frontline’ professionals felt consent was incomplete at the time of signing the form was that 
information-giving as a process maintained patient safety. Doctors explained that giving 
information slowly was necessary for cancer trial patients, although they gave a brief overview 
of the information in ‘clinic time’ and relied on nurses to re-iterate information informally over 
time. Some senior doctors and managers described the way nurses spent time with patients as 
essential to obtaining ‘valid’ and ‘good’ informed consent because of the nurses’ relationship 
with patients over time. These doctors delegated or expected that the once traditional medical 
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role of achieving consent in the CCT setting is now best supported by nurses. However, nurses 
emphasised that consent was the doctor’s responsibility. 
This chapter has shown how interprofessional responsibility as shaped by time can 
enable ‘valid’ and ‘good’ informed consent to CCTs. Professional roles have been made 
somewhat more explicit thus challenging the traditional standpoint of informed consent as 
solely a medical responsibility. The way professionals experienced their role has another 




Chapter Seven: Trust 
___________________________________________________________________ 
7.0 Introduction 
The focus of this chapter is the interprofessional experience of trust. The supporting question 
addressed is: How does gaining trust enable informed consent and how is interprofessional 
trust associated with the patients’ best interest in the CCT setting? This question supports the 
overarching question: What is the interprofessional experience of communication that impacts 
on obtaining informed consent to CCTs? Trust was a common theme that mainly nurses and 
doctors spoke about, including how they associated acting in the patients’ best interest with the 
creation and erosion of trust. The positive language used to recommend the trial in Chapter Six 
may have initiated a trusting relationship and created a patient expectation of hope regarding 
the trial outcome. However, it is likely that patient trust is needed to span the informed consent 
process.  
The structure of this chapter is divided into 3 parts. First, it will be established how 
participants gained relational trust enabling informed consent to CCTs. Second, there is an 
exploration of how team transition impacts on trust maintenance, and finally, an exploration of 
how interprofessional perceptions of the patient’s best interest could affect trust. It is hoped 
that presenting these thematic findings will provide an enhanced understanding of how trust 
impacts on enabling informed consent to CCTs. The exploration begins with how professionals 
gained relational trust. 
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7.1 The creation of relational trust 
This thematic finding refers to how both professions experienced the ways emotional and 
competence-based trust was built up or gained through their interactions with patients. 
Professionals explained the impact of maintaining the initial trust gained on consent and the 
patient experience. Professional communication and competence was experienced in relation 
to building up trust, off-setting distrust and preventing the erosion of trust.  
7.1.1 How emotional trust was gained 
Registrars explained that showing support of the trial offer as part of their initial interaction 
with the patient gave them an opportunity to establish the patients’ ‘willingness’ to accept the 
referral to the trial team at the tertiary centre. The initial interaction with the patient was 
explained as starting the informed consent ‘process’ as Registrar Doctor 2 (RD2) explained:  
“I see patients on the ‘frontline’ and am one of the first people who encounter 
the patients… I can have an impact on the number of recruits and to start the 
process off…If the trial drug is an advantage over the standard treatment or if 
the patient has failed multiple lines of treatments, we (doctors) look for 
experimental therapy.” 
Another Registrar Doctor (RD5) used this initial interaction with the patient to develop a 
rapport with the patient that enabled the referral for the trial by first establishing the patient’s 
‘willingness’ to participate in the trial.  
RD5: “Often referring clinicians who are not directly involved in the trial may 
refer to the Investigators who are running the trials and have the preliminary 
discussion to see if the patient is willing to participate in the trial.” 
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The role of the Clinical Nurse Specialist (CNS) who worked outside the trial team was 
acknowledged by many doctors as gaining trust because of their close emotional relationship 
with patients that preceded referral for the trial as Consultant Doctor 9 (CD9) explains: 
“There is a situation there where the patient transfers from someone (known 
CNS) they trust.”  
The importance of the ‘initial trust’ interaction is supported by Hurd et al. (2017, p. 175) who 
asserted that the referral to the trial team confirmed this initial, which they called, ‘ex-ante’ 
trust between teams. Therefore, the referral between teams for the trial appeared to have two 
functions. It gave clinicians whom the patient already trusted an opportunity to point out the 
advantage of the trial and gained the patients’ willingness to accept the trial offer allowing 
them to refer the patient to the trial team.  
For referred patients and for those who were already attending the tertiary trial centre, 
the trial was ‘broached’ initially by the consultant in the clinic. Many doctors spoke about the 
time available for them to gain informed consent, but a minority attributed the time they spent 
with patients as contributing directly to trust creation. There were two ways that repeated 
interactions over time with patients were important for these doctors in gaining patient trust. 
First, Consultant Doctor 9 (CD9) said that in an emergency situation it was difficult to ‘build 
up trust’, whereas in non-emergency situations there is an opportunity to ‘drip feed’ 
information and to include the relatives, which enabled building up trust. In addition, CD9 
intimated the possibility of less trust in emergency situations because consent was difficult by 
saying: 
“In my area...of lymphoma and myeloma…we can build up the trust with 
patients so that we can drip feed them information and meet with their relations, 
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in contrast with the doctors who treat acute leukaemia, where the patient may 
be coming in the middle of the night, acutely unwell and need immediate 
treatment. So, in terms of recruiting people the process of informed consent is 
difficult in those (emergency) situations.” 
The second instance for doctors where repeated interactions and time were highlighted as trust 
gaining factors was also in the Haemato-oncology sub-speciality as Consultant Doctor 6 (CD6) 
described below.  
“They have (other cancer sub-specialists) more numbers whereas we tend to 
have fewer patients but a greater intensity of work because they (other cancers) 
are quite complicated and quite often they are quite ill and certainly have things 
that are life changing, so I think we have more trust because we have more time 
because of more interaction with the patients.” 
CD6 suggested the possibility of gaining ‘more trust’ in Haemato-Oncology when contrasted 
with ‘other areas’ within oncology where there is less time due to illness complications. 
Gaining trust from positive interactions lends support from Calnan and Rowe (2008) who 
found that patients’ trust was conditional and was earned by positive experiences with 
professionals, although they said that ‘familiarity’ over time with the clinician did not make a 
difference to diabetic patients’ trust. However, Jackson et al., (2004) found that trust developed 
over time through doctors’ positive experiences with cardiac patients on the basis of doctors 
drawing from evidence-based recommendations. In this study, the repeated encounters 
positively contributed to building the relationship, where ‘more interaction’ gained ‘more trust’ 
with Haemato-oncology trial patients, although it was not clear if these doctors based creating 
trust from an emotional interaction. 
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The comment about gaining ‘more trust’ suggested that trust could be increased over 
repeated interactions with patients. The possibility of gaining more or less trust has similarities 
to research by Zinn (2008, p. 439) who argued that trust was a ‘measureable experience’ in the 
risk management field. Of relevance, Zinn asserted that ‘increased trust’ is needed when there 
is ‘less knowledge’ and ‘less time’, akin to ‘contemporary decision-making’. Contemporary 
decision-making could relate to cancer emergency decision-making situations where clinicians 
in the current study said there was less time to build relational trust because there was less time 
to ‘drip feed information’ to patients about the trial, which implied that gaining trust depended 
on time and a rational information-giving component. Clinicians’ descriptions of decreased 
availability of trust in emergencies was different to the need for more trust was in emergencies 
according to Zinn (2008). The possibility of sufficient trust, although it is implied as less by 
this clinician in an emergency may be explained by Simmel (1950 cited in Mollering, 2001, p. 
407)  who points out that ‘unaccountable faith’ is needed to support uncertainty (the uncertainty 
of the emergency decision). The reason given by Brown et al. (2015) for patients accepting the 
uncertainty of cancer treatment decisions was that patients ‘bracket out’ the uncertainty. 
However, doctors did imply that more trust was needed in cancer trial decisions which 
presented uncertainty because their repeated interactions increased ‘more trust’, implying that 
CCT patients may require more interactions with them to create trust, which didn’t completely 
rely on information-giving. It appeared that the rational component of information-giving 
relied on the repeated professional encounters with patients to gain trust, which lends support 
from Keynes (1936 cited in Zinn, 2008) who pointed out that trust doesn’t solely rely on 
rationality.  
Within the trial team nurses and doctors gave examples about how positive interactions 
over time were important for the creation of emotional trust with patients. For instance, 
Research Nurse 4 (RN4) explained how she built up trust with patients. 
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“It is about getting someone’s trust. You are starting to build that relationship 
with somebody it is the stepping stones and building blocks and explaining it 
all to them. It is motivating to be able to explain in a way that they understand.”  
RN4 felt that the relationship built via ‘stepping stones’ enabled getting someone’s trust’. She 
referred to the trial as a ‘good’ option, possibly reinforcing the patient’s positive trial 
expectation which demonstrated positive evaluation by affirming the trial benefit. The creation 
of patient expectation because of providing a positive evaluation is in line with Nekolaickhuk 
et al., (1999) who asserted that both practitioners and patients felt that professionals who 
provided a positive evaluation also created the expectation of hope. Nurses in particular 
connected responding to patient expectation through their emotional interactions.  
Emotional closeness was mostly discussed in terms of how verbal communication 
gained cancer trial patient’s trust. Nurse communication was described as gaining trust by 
building supportive emotional relationships (even ‘friendship’) with CCT patients. Nurse 
Practitioner 9 (NP9) explained how gaining emotional trust impacted on achieving informed 
consent by describing trust gaining qualities below. 
“A lot of reassurance about the treatment and there are medications to 
counteract the side-effects. It’s more like reassurance that these patients 
need…Yes, the trust comes with this as well. And I think for patients knowing 
that you are on the other end of the line… also to offer counselling to the patient 
and to give information.”  
NP9 explained that responding to the patients’ emotional need for reassurance and reliability 
was part of creating patient trust. These findings lend support from theorists, Sabo (2001) and  
Simpson (2004) who argued that reliability and repeated emotional reassurance gained non-
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rational trust because the trust was based on patient’s dependence and hope. It is possible that 
reassuring patients helped to sustain patients’ hope at the same time as gaining emotional trust. 
Similarly, Weidan et al., (2016) found that emotional support was a predictor of ‘more’ hope, 
which they said further increased trust. Of significance, NP9 took consent for procedures and 
therefore had first-hand experience of the value of reliability and reassurance in gaining 
patients’ emotional trust.  
Emotional relationship building was also derived from the body language of the 
professional. CD6 emphasised the importance of the professional’s body language below in 
interpersonal encounters with patients form different religious groups.  
“They haven’t got all of the skills, they judge body language and other forms of 
non-verbal communication. You need to deal with these people (from different 
religions) differently because they have different customs and habits and 
therefore you respect the fact that you might not shake hands of some people. 
Women (from different religions) don’t want to do that.”  
Respect seemed to constitute regard or thoughtfulness for religious practices, which may have 
appealed to emotional-based trust. Many participants also spoke of ‘sitting down’ with patients, 
which they felt was of relational benefit in gaining emotional trust during a patient consultation 
because they said it made patients feel ‘comfortable’. Additionally, gaining trust through 
respectful body language is supported by Wynne (1996a,b cited in Zinn, 2008) who explained 
that lay people judged body language as a means of evaluating a decision-maker’s 
trustworthiness.  
The interactions described were poignant examples of how gaining relational trust 
impacted informed consent by positive affirmation of the trial, repeated encounters with 
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patients and by respectful body language particularly during professional interactions with 
patients from other religions. More interaction seemed to enable ‘more trust’ with cancer 
patients, although gaining more trust was difficult in emergency cancer decisions, although 
implied as needed. Professional competency was experienced as a trust gaining quality which 
is explored next in relation to enabling informed consent.  
7.1.2 Competency-based trust 
Professional competence was rarely referred to directly by participants. However, participants 
referred to ways in which rationally based trust was gained and not eroded depending on their 
particular profession. Doctors based competence on the knowledge the professional showed 
the patient which they said prevented patients’ ‘mistrust’. On the other hand, nurses based 
competence on nurses showing confidence and skills to patients, which they said gained trust.  
A majority of participants referred to the patient or public perception of patients used 
as ‘guinea pigs’ in clinical trials. In response to this perception, showing knowledge 
competence was described by doctors as a means of them not losing patients’ trust. Many 
doctors linked ‘patient suspicion’, ‘resistance’ and ‘mistrust’ with minority ethnic groups as 
Registrar Doctor 5 illustrated.  
RD5: “You have a big demographic (ethnic minority patient group) who are 
intrinsically suspicious of the medical profession, and it is not uncommon here 
for you to feel that the patients think you are trying to trick them.” 
The way doctors created competency based trust was by communicating their trial knowledge 
to patients as a means of protecting them, thereby dispelling mistrust. Registrar Doctor 10 
(RD10) illustrated how honest and clear communication with patients dispelled mistrust and 
the possibility of cancer patients’ ‘guinea pig’ perception as follows:  
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“I think to be very clear and honest. People need to trust you. I think it is 
important to inform the patient and take away any worries that they might have 
about entering into a clinical trial. In my experience cancer patients who are 
introduced to a clinical trial they may think that they are guinea pigs, so they 
need to feel protected. We need to show them that we have evidence that it 
might be better at least not worse and explain that their safety is first for them.” 
The use of ‘evidence’ suggested a defence of the clinical trial which relied on honesty and 
knowledge clarity by emphasising the benefits over potential harm of the trial. The use of the 
word ‘protected’ was revealing because it implied CCT patients’ vulnerability to which RD10 
responded by saying that patients need to ‘feel protected’ while on the trial. The sentiment of 
protecting patients was connected to ‘frontline’ doctors and nurses who spoke repeatedly about 
their concern for patient safety on the trial and was not limited to protecting patients from 
ethnic minority groups. Communicating honestly to gain trust is similar to previous research 
on Oncologists’ communication where communicating honestly maintained patient hope and 
expectation (Mendrick et al., 2011). 
A consultant doctor emphasised that dispelling the patient’s ‘guinea pig’ perception 
also required communicating ‘non-biased’ information, and that competence trust was created 
by providing the patient with the correct knowledge.  
CD6: “There is a perception that trial means I am a guinea pig and the patients 
need to trust their physician, needs to be able to have medical trust and to trust 
what you are saying about the trial is correct and we need to impart an informed 
non-biased approach that tells them what the trials are about in words that they 
can understand.”  
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The correctness of information was described as a trust gaining factor because patients could 
understand the information. CD6 implied that presenting the trial in a ‘non-biased’ way 
enhanced trust by emphasising patients ‘needing to trust’ the physicians’ information. CD6’s 
explanation of ‘non-biased’ information and correctness could allay the fear of the patients’ 
‘guinea pig’ perception. Allaying fear is supported by Quinn (2002, p. 5) who highlighted that 
‘fear’ is often associated with the ‘guinea pig’ perception because patients feared being 
‘experimented on’. Additionally, giving corrective information may have had the function of 
allaying patient fears in accordance with Kenny et al. (1999).  
Nurses were less concerned with gaining competence trust by dispelling the ‘guinea 
pig’ perception, but instead nurses felt confidence and skill showed their professional 
competence. The administration of trial treatment ‘at the frontline’ was described as requiring 
the ‘clinical confidence’ of both the research staff and cancer ward nurses. Research Nurse 
(RN1) explained that lack of ‘skill’ and ‘confidence’ may mean the patient ‘won’t get it’, 
meaning won’t understand the trial. However, the lack of patient understanding may not mean 
lack of sufficient ‘active’ trust needed for consent to occur, as ‘passive trust’ can still bring 
about informed consent. NP9 linked the importance of confidence with trust gaining behaviour 
to gaining cooperation from the start with the patient as the following extract demonstrates. 
“Yes, from the start, if they (patients) trust you they will cooperate with you. If 
you are the one giving the information you should present yourself as you know 
what you are saying… if you are not sure what you are talking about obviously 
patients won’t trust you.” 
The finding of displaying professional confidence as a trust gaining factor is supported by 
Gambetta (1988 cited in Mollering, 2001) who associated the notion of cooperation with 
‘trustful’ behaviour, demonstrating a functional outcome of trust. Furthermore, the patient’s 
 
 116 
cooperation chimes with the ‘active’ trust action as explained by Giddens (1984) that 
demonstrated informed consent.  
Doctors were concerned more about maintaining trust already gained and dispelling 
mistrust by using their knowledge clarity and honesty to protect patients. Many nurses at the 
frontline felt that competence based trust was derived from clinical competence and 
confidence. Overall, it appeared that rational or competence based trust did rely on an 
emotional element to support it because showing correct ‘non-biased’ trial knowledge and 
clinical confidence had the potential to allay the patients’ fear of the guinea pig perception. 
Perspectives as to whether trust is achievable and possible to maintain with minority ethnic 
groups and lower socio-economic groups is explored in the next theme. 
7.2 The difficulties with trust in specific patient groups 
There were mixed views about whether language barriers associated with what participants 
called ‘ethnic minority groups’ impacted on gaining or eroding patients’ trust. Mostly research 
nurses found language and family pressures were a barrier to gaining informed consent in 
minority ethnic groups. The reason given was that research nurses explained difficulties in 
building a relationship solely with the patient, which caused them to question if the consent 
was obtained from the individual patient. RN2 said that language barriers caused lack of patient 
understanding. Even though the patient had already consented by the time she met them, these 
barriers caused practical logistical trial problems for research nurses. RN3 questioned the 
validity of the consent in minority ethnic groups and potentially related the problems directly 
to lack of family trust in the following extract. 
RN4: “Yeah, they (patients from ethnic minority groups) come with a lot of 
people and sometimes there is a lot of heavy family pressure which does impact. 
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Maybe they (the family) don’t trust in what we are doing or I’m not quite sure 
what those reasons are, but sometimes we have patients who have not consented 
or otherwise maybe have consented when you feel they were not very keen but 
the children were very keen and you are thinking well, ‘are they (patients) 100% 
aware of what is involved?’, but so sometimes you don’t know what goes on 
there, so sometimes you sense that.” 
It appeared that the family influence or scepticism impacted on gaining trust as well as ethnic 
families lacking trust in the trial which could change the patient’s willingness to consent. The 
‘heavy family pressure’ RN4 described seemed to primarily put pressure on the patient to 
make a decision in accordance with the families’ wishes. Certainly, professionals found it 
difficult to know what the individual patients’ wishes were, potentially causing barriers to 
gaining trial consent. This finding supports previous research which found that scepticism was 
a source of ‘distrust’ in racial and ethnic minority groups and was attributed to previous 
historical ‘fear of mistreatment in clinical research’ (Durant et al., 2014 p.1100). 
In contrast to the experiences of research nurses, a minority of doctors felt language 
and cultural family influences were not necessarily seen as a barrier to trust creation, 
irrespective of the families’ religious background. This minority of doctors implied that trust 
could be maintained because these individuals trusted doctors unconditionally. Another 
example of how trust was maintained was by appropriately respecting and supporting patients 
through consistent accurately translated information. However, JD4 explained the possibility 
of a barrier or decline in the already available trust as can be seen in the extract below. 
“They (minority ethnic groups) trust the doctors. They don’t think that the 
doctors don’t know what to do here. They think whatever we are doing we know 




JD4 implied that ethnic minority groups already have available unconditional trust in what the 
doctor is doing. However, below she implied a potential for trust erosion due to 
‘miscommunication’ as a result of the poor interpreter services.  
“The way they translate it is different from what you say because they don’t 
have medical knowledge... The wife told me that the interpreter is translating 
something else she was asking about the type of chemotherapy before and after 
the transplant and is really confusing. Dangerous, yes. And so, you are having 
someone giving you confusing information and you don’t know what is 
happening to you (the patient) and then they (the patients) are not going to go 
for that trial.” 
The discrepancy in translation described could dissuade patients from consenting by 
undermining the initial unconditional trust. Also, it was necessary for the frontline doctor to 
recognise the disparity of information translated, otherwise the patient could consent to the 
wrong treatment, which was described as ‘dangerous’. Similarly, M4 reported “lots of 
problems” with interpreters or absence of booking them which affects trial patients as the 
following extract illustrates:  
“We have lots of problems with interpreters. I am sure that this affects the 
patients coming in for trials... They will be booked interpreters and they won’t 
come. If patients are new patients being referred from the GP, they have to book 
the interpreter and that doesn’t happen. Some patients don’t even get seen and 
they have to go home because there is nobody to interpret for them.” 
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Interestingly the manager pointed out that it was the referring GP’s responsibility to book the 
interpreter for their patient to support language differences which further emphasises the 
importance of maintaining the initial trust gained for the referral to take place successfully. 
Additionally, while ‘written communication in the patient’s own language’ was described as 
essential to gaining consent, the patient’s ability to read was only a possibility as illustrated 
below. 
RN10: “You can try and get information sheets produced in Bengali for 
instance. Just because the patient speaks Bengali doesn’t mean that they can 
actually read Bengali. I think consent is an issue yes…”  
In the absence of an interpreter there was a failure to gain initial trust or maintain it because 
reliable communication was limited. The significance of the interpreter and correct translation 
in this case study was supported by Gul et al. (2010) and Rubin et al. (2014) who highlighted 
the importance of the initial contact with minority ethnic groups. The translation problems 
interfered with gaining trust which lends support from Durant et al. (2014, p. 1101) who 
highlighted that translators could pose a barrier to obtaining informed consent. 
CD6’s view contrasted mainly with the research nurses above because he explained 
that different cultural practices did not negatively impact on consent to clinical trials. The 
reason he explained was that the professional needs to build the relationship of respect with 
the patients, not excluding the family within the consent as below.  
CD6: “The culture of these people is that they are really ill and they want 
something to happen to get them better; I don’t find that a cultural problem at 
all. I may be biased. You need to deal with these people (EMG) differently 
because they have different customs and habits and therefore you respect.” 
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Interestingly, the consultant said because of his experience working with minority groups his 
view could be a ‘biased’, because he explained that he had experience of previously living 
abroad in a Muslim community and therefore was familiar with ways to build a trusting 
relationship in this community. Regardless of what he calls his ‘biased’ view, this perspective 
was likely to be significant because there was a large minority ethnic patient population served 
in this case study. Dealing with ethnic minority group ‘patients differently’ supports previous 
literature which found the need for ‘culturally sensitive’ approaches (Rubin, 2014). Building 
a relationship with minority ethnic group families is further explored in Chapter 8.  
CD6 explained that cancer patients start off with trust in the doctor’s expertise and 
knowledge and are supportive to the doctor because of this trust. CD6 explained how a 
patient’s unconditional trust can be eroded by failing to communicate with them in a language 
they understand and by making assumptions about their lack of education. He refers to patients 
from deprived socio-economic groups. 
“Actually, they (from deprived socio-economic areas) are an easy bunch of 
patients to treat because actually if they trust you they would almost have their 
head cut off for you if they thought that was going to make them feel better 
cause you are the doctor and you are good and you know what you are about 
and they are very supportive to you but you need to earn that support... People 
who treat them as fools because they may not have necessarily have the same 
P’s and Q’s are idiots because they are not stupid. So, they always bring up the 
question of education. Actually, they are very intelligent. It is actually being 
able to communicate in the right language, the right way.” 
It appeared that unconditional trust could be eroded where an effort is not made to re-enforce 
the already available trust. ‘Earning’ it was described as relying on this tailored 
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communication. Showing professionalism by individual patient respect regardless of the 
patient’s education was important for maintaining trust. This is supported by Calnan and Rowe 
(2008) who asserted that relational trust is built by interpersonal interaction where they say 
professional’s personality and professionalism is integral.  
Many participants were concerned with either alleviating mistrust or maintaining trust 
because of the language barriers and family influences associated with minority ethnic groups. 
Research nurses felt that these families posed challenges to gaining and maintaining trust 
because they questioned the validity of the individual patient’s consent. There was a possibility 
of cancer patients’ unconditional trust. However, this could be eroded by inappropriate 
professional behaviours that demonstrated lack of support for cultural issues or socio-economic 
status according to a minority of doctors. The notion of trust as an on-going process where 
initial trust (whether already available or earned) needing to be re-visited and maintained is 
explored in the next sub-theme.  
7.3 The difficulties with maintaining trust across teams 
Many doctors referred to the possibility of a change or a loss of patients’ initial trust they had 
gained which they felt could put the patient at risk of harm because of not starting treatment 
while transitioning teams. Nurses explained the potential for trust decline due to care 
fragmentation. Managers were concerned about the lack of trial knowledge among non-
research staff which they felt could contribute to a poor patient experience while on the trial. 
Such an experience could create patients’ unhappiness and frustration potentially leading to 
patient ambivalence about the trial. The potential for trust erosion due to increased risk to the 
patient is first explored. 
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7.3.1 Increased risk affecting initial trust gained 
The potential for increased risk to the patient’s safety as a result of referral delays to the trial 
team was emphasised by doctors. For instance, one Registrar felt it necessary to offer a 
‘safeguarding’ appointment, to off-set the possibility of this risk.  
RD5: “I think the most important thing as a regular doctor.. is to keep an eye on 
that patient so I usually give them a safeguarding appointment within a few 
weeks of the appointment if they haven’t been seen by the clinical trials team 
or slipped up. Then they have an opportunity to come back and re-discuss 
conventional treatment and see me. I have started patients on conventional 
treatment at their request because that patient has become upset or unhappy with 
the duration of time that they are waiting for tests or to begin some kind of 
treatment.” 
The use of the term ‘safeguarding’, although a policy term, captured the vulnerability of the 
patient because of the risk that RD5 felt the patient was exposed to while transferring between 
teams. The Registrar perceived the patient as still reliant on him (as the referrer), to which he 
responded by providing a ‘safeguarding’ appointment. RD5 said that the patient could become 
‘unhappy’, which suggested a change to the initial emotional trust necessary for referral for the 
clinical trial. The finding that the patient’s sufficient trust for referral could be altered was in 
line with previous research which speculated that the already established trust needed to be 
‘honoured’ by maintaining the patients’ expectation of the trial offered (Barbalet, 2009), and 
by professional behaviour that responded to the patients’ expectation of hope (Simpson, 2004).  
Team transition was felt mostly by doctors to contribute to the erosion of patient trust 
because doctors had established the initial trust necessary for the referral to the trial team. 
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Delayed treatment is explored for its impact on trust under the best interests’ theme. ‘Frontline’ 
professionals seemed more aware of the reasons for care fragmentation, and how fragmentation 
altered the patient rapport because of their patient safety concerns.  
7.3.2 How fragmentation of care potentially erodes trust 
Many participants spoke about how fragmentation of care across teams could alter the rapport 
with the patient. The damage to the relationship was attributed to professionals working in 
separation akin to ‘silo working’, and where discrepancies regarding ‘ownership’ of the care 
of the patient was described in Chapter Six. CD6 referred to care being ‘slightly divorced’ once 
the patient has been referred to the trial team. The use of ‘divorce’ implied a severing of the 
emotional, interpreted as possibly loss of the trusting relationship because of the change of 
team directly looking after the patient. CD9 explained how this fragmentation affected the 
patients’ trust as below: 
“The patient transfers from someone they trust to someone they don’t know and 
then when they are finished their treatment they go back to the care of the 
original person…so it’s a bit fragmented.” 
Doctors explained how there can be confusion because care could be separated between the 
research and the non-research teams. In addition, when the patient had finished the trial drug 
and was returned to the non-research team (although still on trial follow up), RN4 indicated 
there may be a ‘reluctance to accept the patient back’ into the standard team. One reason for 
care fragmentation could be that (as identified in Chapter Six), there were often disagreements 
about who was responsible for the trial patient. Additionally, Junior doctors (for instance, RD3) 
linked ‘frontline’ staff with avoiding trial patients, but highlighted the importance of ‘frontline’ 
staff for detecting problems.  
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RD3: “The main (‘frontline’) staff feel that they shouldn’t touch the research 
patient but they are always around if something happens so mostly they are 
mostly like this and if they need to call someone else they will.” 
Research nurses explained that the main reason given for the detachment of frontline staff from 
care was that nurses were scared because of lack of clinical trial knowledge of an unlicensed 
drug, as described by RN2 below. 
“I think whenever you say trial or unlicensed drug while we (research nurses) 
have better training, we have the protocol and more information than they (ward 
nurses) are given and yes it is scary and whilst you are doing your chemo 
training ..you don’t come across trial drugs and how things are different to 
standard treatments.” 
Research nurses concurred with doctors who said that CNS nurses detached from the care of 
the research patients. RN10 explained how this ‘hands off approach’ negatively impacted on 
the patient.  
RN10: “Things that normally a CNS would do I end up doing because they 
basically say, ‘well that’s your patient’ which may not be great for the patient.”  
The detachment occurred from the patient previously known to them with whom trust had been 
established, before patients were referred for the trial. N5 said that if nurses are not 
‘comfortable’ with the trial, ‘it could put people (patients) off’, which was interpreted as a 
potential for patient ambivalence regarding continuing the trial. As previously highlighted, 
body language can also impact on trust where the ‘hands off’ approach may have fuelled the 
lack of trust. The resulting patient discontent described below by RN3 as patient ‘frustration’ 
had the potential to ‘put barriers’ to patients continuing the trial. 
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“If the nurses in the day-care are not treating as per protocol that might delay 
patients you know. On a visit to the day unit patients might get frustrated. And 
think “why am I on this study? Because the other patients came and they were 
seen before me.” 
Managers were concerned about how fragmentation of care affected the patient 
experience. Mainly managers attributed this to lack trial knowledge among non-research staff. 
M1 said that there was a lack of ‘actual explanation’ about the trial to the ‘frontline’ staff which 
caused further fragmentation of care. Another manager, M4 pointed said that ‘a good patient 
experience’ was created by patients’ day-to-day experience of professional competencies, 
which they said required staff knowledge of the trials. As these nursing managers were 
responsible for continuous workflow (ward nurses administering trail treatments) in the clinical 
area, fragmentation of care was of relevance to them.  
The fragmentation and poor patient experience was intimated by research nurses and 
managers as negatively impacting on the patient’s willingness to stay on the trial, although it 
is not explicitly stated that poor experience caused trust erosion. Some doctors felt that the 
(although subject to change) original relational trust created good interpersonal encounters. In 
accordance with Robbins (2016, p. 16) ‘social trust influences relational trust’, although they 
described in the business economics sector. The comparison to this previous research is useful 
because Robbins explains that ‘social trust’ was derived from ‘general cooperativeness and 
helpfulness’ in the everyday experience with individuals that ‘fosters high levels’ of relational 
trust where ‘trustworthiness’ and brings about the ‘function of trust’. It is possible that an 
interruption to the patients’ positive day-to-day experience because of the fragmentation and 
team transition had the potential to erode or fail to maintain trust. Furthermore, lending support 
from Hurd et al. (2017), there was potential for patient ambivalence or mixed feelings as 
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described by doctors and nurses who referred to patients’ unhappiness and frustration due to 
transition delays and fragmentation. There was also a potential for the loss of trust because of 
differences in how professionals perceived the patients’ best interest as the next theme 
explores.  
7.4 How best interest differences affected trust 
Many research nurses and consultant doctors explained how professionals had different views 
about the patients’ best interest which in some cases opposed the trial offer as the ‘best option’. 
Both professions referred to doctors making treatment recommendations that were in the 
patients’ best interest. Although the nursing impact on the patients’ best interest was in line 
with Beauchamp and Childress’ (2001) by advocating for the patients’ quality-of-life 
perspective, research nurses were concerned that differing best interest perspectives could 
affect their ability to build ‘trustworthiness’ with the patients. Managers appeared significantly 
less concerned with best interests and infrequently referred to it, as they had little patient 
contact and therefore were unaware of the patients’ treatment preferences. The areas that will 
be explored are, medical advocacy and the presumption of patients’ trust; the impact of 
differences in professional beliefs about the uncertainty of trial design on building trust, and 
how targets could influence the trust relationship. First, there is an exploration of how medical 
advocacy and decision-making could have interfered with the patient’s trust. 
7.4.1 The relationship between advocacy and the assumption of trust 
Doctors frequently intimated that patients trusted them, often unconditionally to decide on 
treatments according to the patients’ best interest. Consultant doctor, CD1 explained that the 
doctor’s advocacy role was fulfilled by offering ‘the best option for the patients even if that 
was a trial’, as previously quoted. Doctors may have assumed that patients trust in the doctor 
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to decide on the best treatment for them. Medical advocacy may impact on the patients’ consent 
to the trial, where patients expect the doctor to advocate by deciding in their best interest. The 
meaning of advocacy for CD1 seemed merely ‘giving balanced information’ and on that basis 
making a trial recommendation. This meaning contrasted with Beauchamp and Childress’ 
(2001) definition of advocacy as a surrogate decision-maker on behalf of someone else, or as 
legally defending a person’s rights, according to Spence (2011). However, the use of advocacy 
to bring about the patients’ decision could be interpreted as a ‘paternalistic-style’ of doctoring 
where doctors lead by deciding the best recommendation which could influence patients’ 
consent, although doctors fulfilled their assumption of patients’ trust.  
CD6 was probed as to whether the patient had a choice if the MDT best interest decision 
was already made. There was some uncertainty about whether the consultant’s choice and the 
patient’s choice amounted to the same thing as shown in this extract. 
I: “Yet, informed consent is too about patient choice, isn’t it? As opposed to 
best interests is slightly different than patient choice. How would you 
understand that?” 
CD6: “I disagree with that. The answer is the best interest of the patient in as 
much as not the medical team looking after them. Why want things that are 
more demanding and more difficult to deliver? If they are not offered then it is 
not informed consent. I think you have to / should be looking at alternatives. I 
think you should try. I agree, it is a difficult thin line that you are treading 
between what’s patient’s choice and what’s consultant / physician choice.” 
This ‘thin line’ between best interest decision-making and patient choice could be difficult if 
the patient decided against the doctor’s trial decision. Where the doctor made the best interest 
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decision for the patient, the patients’ choice could be subdued, thereby resembling ‘ascent’ to 
the clinical trial, as opposed to patients showing ‘active trust’ by consenting to the trial. 
However, where the patient assented to the trial because of the doctor’s decision to offer trial 
treatment, the assent shows the patient’s trust, albeit in line with ‘passive’ trust (Giddens, 
1984).  
Doctors described themselves as best interest decision-makers or advocates possibly 
based on the presumption of the patient trusting in them to decide the ‘best option’. Nurses 
were not perceived as making best interest decisions, except for knowing the patients’ quality-
of-life preferences as was previously highlighted in Chapter Six as their expected role in the 
MDT. It appeared that because doctors held the power needed for patients to trust them to 
make a best interest decision, the impact of the nurses’ role on the patients’ best interest was 
important in gaining trust, but not explicitly explained. However, both doctors and nurses 
spoke about how conflicting best interest views and beliefs might affect patients’ trust.  
7.4.2 How ‘beliefs’ and views about trial uncertainty impacted trust 
Mostly doctors spoke about their difficulties in gaining patient trust due to their differing views 
about the clinical uncertainty that the cancer clinical trial presented, aligning with increased 
uncertainty and risk potential because of efforts to advance medicine (Fox, 1980; Bauman, 
1991; Adamson, 1997). Managers explained that patients’ trust could be also difficult to 
maintain after the patient had consented to the trial due to nurses’ beliefs regarding the trial. 
Research nurses to a lesser extent expressed difficulties with maintaining trust after patients 
had consented. This was because they felt their relationship with the patient declined if they 
didn’t view the trial favourably and if patients’ lacked understanding of the trial, as explored 
in Chapter Eight.  
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The clinical uncertainty presented by the trial caused some doctors to hold conflicting 
views and beliefs or even ‘bias’ regarding the trial best interest decision. In particular differing 
perspectives about trial design and randomised controlled trials were problematic for building 
patients’ trust. Although RCTs were considered ‘the gold standard’ by doctors, in some cases, 
the RCT decision conflicted with the doctor’s perception of the patients’ best interest. Some 
doctors (for instance CD6) felt randomisation or trial design further increased the uncertainty 
of the trial outcome which impacted on their belief in the trial, especially if the trial did not 
meet patient’s suitability for the trial offered. CD6 felt gaining trust partly relied on the 
physician giving a non-biased approach. 
CD6: “Patients need to trust their physician and to trust what you are saying 
about the trial is correct and we need to impart an informed non-biased approach 
too… In your heart of hearts there may be a bias pushing towards that or pushing 
towards what you feel might be better, …sometimes trials are not offered 
because people (nurses and doctors in the MDT) say, ‘oh a trial is tough and I 
don’t believe in the design’. There is a bias for or there can be a bias against it, 
the overall package, the decision at the bottom of the report would be what is in 
the best interest of the patient not what the doctor said or thinks so other people 
within that set up can question that…” 
It seemed that there was an internal conflict experienced by the physician because he felt that 
an un-biased view of the trial was necessary to gain patients’ trust, yet he explained that the 
physician may be biased for or against the trial which can sometimes run contrary to the MDT 
best interest decision. His view questions if a physician’s unbiased view was possible. CD6’s 
best interest preference or view was based on what the physician believed was ‘best’ for that 
individual because of the physician’s knowledge of and relationship with that patient. This 
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finding is partly in line with Calnan and Rowe (2008) who asserted that professionals are 
obligated to act in the patient’s best interest to fulfil the patient expectation. As the patients 
were described as needing to trust in the doctor’s view, if the doctor didn’t believe in the trial 
design, then it is possible that the patient won’t believe in the trial. This extract illustrates that 
as Featherstone and Donovan (2002) have argued, patients trust in the clinician was a key factor 
that extended to patients’ trust in the trial. Trust in the clinician is likely to extend to trust in 
the clinician’s beliefs indicated from what the clinician is saying about the trial to the patient. 
The way the trial was presented by doctors was described previously as influencing the 
patients’ decision by some participants. Therefore, as Jenkins and Fallowfield (2000) asserted 
the physician’s ‘enthusiasm’ could influence the cancer patient participating in the trial. The 
professional’s belief or hope in the trial possibly then directly affected the patients’ hope and 
trust in the trial.  
Many professions expressed the difficulties they encountered with gaining or sustaining 
trust due to patients viewing randomised controlled trials (RCTs) ‘with suspicion’ and 
‘mistrust’ in line with Featherstone and Donovan (2002). Doctors spoke previously about their 
communication struggles with patients because of patients’ mistrust about the trial (ethnic 
minority groups), but also because of the uncertainty randomisation posed as relayed by RD5: 
“You have a big demographic who are intrinsically suspicious of the medical 
profession.”  
Doctors explained that the uncertainty of randomisation (RCTs) and trial design affected their 
communication with the patient. The following extract illustrated the difficulties doctors 
experienced when communicating with patients about taking part in RCTs in the general cancer 
patient population.  
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CD9: “I think a big part is the uncertainty. Quite often people (patients) want us 
to put them on the trial arm that is best, but the whole point is we don’t know 
what is best. It is important that that patient understands that there is uncertainty 
and the arm that they are randomised to may not help them and that is quite a 
difficult concept for them to understand. It is a risk that those who get the 
standard treatment arm (after randomisation) may drop off and lose their 
motivation because they are aware that they are not getting the exciting drug.” 
CD9 explained the importance of the patient understanding the uncertainty of randomisation, 
but alluded to the doctor-patient relationship difficulties because of patients’ failing to 
understand the ‘concept’. In line with previous research by Featherstone and Donovan (2002), 
the difficulties doctors faced posed by randomisation had the potential to dissuade patients 
from participating in trials due to distrust, lack of motivation and patients’ unacceptance of 
randomisation to the standard treatment arm. The communication difficulties experienced by 
clinicians and patients because of clinical uncertainty was in line with previous theorists 
(Davis,1960; Adamson, 1997) who argued the difficulties doctors faced when communicating 
uncertain prognoses.  
Furthermore, RD5 said that patients’ ‘unhappiness comes from the uncertainty’, which 
he said caused doctors to commence standard treatment.  
RD5: “It can very easily drag on, recruiting small cohorts and then closing again 
and all the uncertainty for the clinician about will I be able to recruit that patient 
or will they come to any harm in the meantime... I have started patients on 
conventional treatment at their request because that patient has become upset or 
unhappy with waiting to commence treatment (trial). And “oh, we are expecting 
this trial to be open”, which is unethical to talk to them about that trial. But, in 
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the absence of any other option or decent option I think many doctors do that. I 
do find that uncomfortable.”  
RD5 had ethical concerns about talking to a patient about a trial that may not come to fruition. 
Such concerns could impede the physician’s ability to build patient trust as the expectation of 
the trial offer was uncertain, causing the doctor to commence standard treatment instead of the 
trial, which has similarities with physicians’ biased view against the trial as explained by CD6. 
Where standard treatment was commenced instead of the trial due to the physician’s belief or 
bias against the trial, there was a deviation from the MDT best interest decision. Although 
deviations from MDT best interest decisions have been found (Wood et al., 2007; Blazeby et 
al., 2005), physician bias was not mentioned previously as a reason for the deviation.  
To a lesser extent, research nurses also experienced difficulties building trusting 
relationships with patients’ due to RCT uncertainty where RN3 found that patients ‘would 
rather be safe’ by having the standard treatment. Similarly, RN10 spoke about professional 
struggles to assess patient understanding of ‘the process of randomisation’ and if patients ‘were 
happy with it (the trial)’, having consented; interpreted as a difficulty with maintaining 
emotional trust where the outcome was uncertain.  
Nursing managers expressed how nurses’ beliefs could affect everyday practice 
because of their attitudes to the trial, which in turn could affect the patient’s trust in the trial. 
M1 described how professionals were motivated by their ‘belief in the trial’. This manager held 
the view that professionals must themselves believe in the trial to gain willingness from the 
patient. Another manager, M3 explained how nurse’s personal beliefs may influence’ nurses’ 
‘judgement’ about the trial because the nurse may have lacked knowledge and may ‘not know 
the boundaries’ of emotional involvement and could be influenced by the patients’ views. 
Managers worried that nurses’ views could affect maintaining the on-going trusting 
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relationship where those administering the treatment don’t believe in the trial as a best option, 
yet managers explained that ‘they are unable to challenge it’. It was interpreted that where 
differences of professional beliefs occurred, patient experience could be affected by 
professional attitudes. This is in keeping with Hurd et al. (2017) who pointed that the 
maintenance of trust is affected by the presence or absence of team shared goals and values.  
The increased clinical uncertainty was seen as posing relationship difficulties for 
doctors gaining patients’ trust. Although lack of doctors’ bias was described as needed to gain 
patient trust by fulfilling the patients’ best interest expectation, trial design and randomisation 
uncertainty was shown to bias or change doctors’ beliefs in the trial, thereby commencing non-
trail treatment. Research nurses struggled with assessing patient understanding and happiness 
with the randomisation decision after patients consented and worried about relationship 
decline. Managers worried that differing nurses’ beliefs could affect the patients’ experience 
on the trial. Additionally, participants reported that external pressures affected their practice 
and impacted on patient trust as explored in the next theme.  
7.4.2 External pressure impacting on patient trust 
Research nurses were acutely aware of recruitment targets (the quantity of patient participants) 
set by the study centre and the National Institute for Health Research (NIHR). They spoke 
about how pressure to recruit challenged their patients’ best interest perspective and could 
negatively affect their care priorities and relationship building with patients.  
RN11 described that ‘trustworthiness’ could be undermined if research nurses 
pressured patients (badgered them) to recruit to the trial, especially given the fact that many 
patients mistrusted science in some religions. It is interesting that RN11 felt that such mistrust 
could be alleviated by the nurse’s leadership in showing trustworthiness as illustrated.  
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“Obviously, there are no hard and fast rules and there are people who mistrust 
science in all religions. But there are concentrations of mistrust in the 
communities that we serve… I honestly think that the best thing that you can do 
is to lead by example if you will that you are trustworthy then you are 
trustworthy. I don’t think that you can ‘badger them’. You just have to take the 
time to prove to them that you have their best interest at heart and to build a 
trusting relationship with them.”  
RN11 says that building a trusting relationship needed to be ‘balanced with patients’ best 
interest’. It seemed that spending the time to build the trusting relationship was a way of 
demonstrating acting in the patients’ best interest, while spending less time with patients to 
build a trusting relationship was implied as pressuring patients to enter the trial. Similarly, RN7 
intimated below that working to a target could subordinate what the research nurse felt was 
best for the patient: 
“The recruitment target- they (the study centre or NIHR) want to finish (finish 
recruiting) ten people, 20 people. I know for sure that every healthcare 
professional wants to help treat patients and that’s why we are all doing this. 
That is another factor other than the target. Influenced by the study centre, you 
have to meet the targets. My first and foremost objective is to help the patient… 
probably targets come secondary cause I always feel sorry when they progress 
and get off the trial.”    
While RN7 implied that it is healthcare professionals’ priority to treat patients, her description 
of ‘having to meet targets’ implied pressure on the research nurse to recruit patients to the trial, 
as an imposed priority. The pressure on professionals to recruit patients is in keeping with 
Evetts (2011) who speculated that professionalism is ‘imposed from above’ and is defined by 
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effectiveness and target achievement which has become integral to practice. While pressure to 
recruit was a concern, for RN7 the target was secondary to helping patients, which may have 
had the potential to conflict with the MDT decision. Another research nurse, RN10 highlighted 
that the pressure to recruit should not ethically contravene patient care, for instance if the 
patient lacked understanding of the trial.  
RN10: “Ethically, we have to be convinced that the patients do understand the 
information and are able to make an informed decision and are able to 
understand randomisation…and that the whole process of the trial is not 
detrimental to them anyway.”  
A minority of participants spoke about how financial pressure and pressure to benefit the 
medical portfolio could affect patient recruitment to the trial, although these pressures were not 
associated directly with eroding patient trust. One Registrar doctor, RD10 linked the more 
patients recruited to career gain, as illustrated in this quote. 
“I would like to get as many patients in the trial as possible because I know then 
that you get answers quicker. But also, I am very competitive so I always want 
to be number one in the inclusion (of patients into a trial), because I know I 
want to be in charge and be on top and if wherever possible.” 
Financial and medical career pressures were a concern for RN11 which caused discontent 
because of lack of the research nurse’s control which was explained as ‘frustrating’ to work 
with. The medical career gain due to doctors’ active trial involvement was described as causing 
pressure to recruit patients which RN11 explained nurses had no control over.   
“Other benefits to the consultant would be it is effectively cost neutral 
for the hospital. It is good for them in their professional career to have active 
 
 136 
involvement in CCTs and to have their name attached to a published piece of 
research… funding is based on recruitment so there is a great deal of pressure 
to recruit patients. That pressure is generally put on the research team. It is a 
frustrating system where the people who identify the patients are the consultants 
because we wind up getting a lot of pressure over something we don’t have 
much control over.” 
The language was emphatic repeating ‘pressure’ to recruit patients with particular career and 
financial benefits for the doctor and the hospital, while there was no account of career benefit 
for the nurse. Unlike Ellis (2015) who raised concerns about research integrity because of the 
pressure placed on medical staff to publish papers, the ‘pressure’ in this extract seemed 
associated with nurses’ professional dissatisfaction and ‘frustration’. There was concern that 
this pressure could impact negatively on the nurses’ relationship with patients and nursing 
morale because nurses had no ‘control over it’. In line with Spence (2012, p.57) the financial 
and recruitment targets were described as commonly prioritised or imposed, but ‘at the expense 
of the relational quality between care-givers and receivers’.  
Research nurses emphasised the pressure on them to recruit which was not always in 
agreement with their perception of the patients’ best interest. Research nurses encountered 
professional difficulties in building a trustworthy relationship with patients. The reason they 
explained was that their care priorities were sometimes challenged due to imposed targets, 
sometimes potentially compromising their relationship with patients. Doctors didn’t speak 
about pressure on them to recruit, while increased recruitment was pointed out by a Registrar 
doctor as potential for career gain. It was interpreted that trust was at stake where the team 
were not in agreement about what was in the best of the patient. The negative impact on 
building trust due to differing views of care priorities is in line with Robbins (2016) and Hurd 
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et al. (2017), who asserted that ‘pushing’ towards the trial resulting from differing beliefs 
impacted on trust.  
7.5 Summary 
In this chapter, the research questions relating to how gaining trust can enable informed consent 
to cancer clinical trials has been answered. It has been argued that the maintenance of trust is 
as important as the initial trust gained or already available. The findings have given insight into 
how differing professional perceptions about patients’ best interest could interfere with 
professional practice, thereby impacting on trust creation or erosion.  
Doctors and research nurses illustrated how relational trust was created by building up 
emotional and competency-based trust with patients. Doctors found it particularly important to 
create sufficient initial trust because gaining initial trust enabled doctors to refer patients for 
the trial, which signified for them the commencement of the informed consent process. Many 
participants felt that positive and supportive affirmation of the initial trial offer not only created 
a trust expectation, but also an emotional expectation of hope for cancer patients.  
Doctors emphasised that ‘more interaction’ gained ‘more trust’ with patients, however 
they did not associate more patient encounters with the creation of emotional trust. Within 
emergency situations for instance in Haemato-oncology there was less opportunity for gaining 
‘more trust’. Research and senior cancer nurses described how they built emotional trust with 
patients through the creation of positive caring experiences, reliability and by reassuring 
patients; the latter may have sustained patients’ hope. Both doctors and research nurses 
explained how appropriate body language was found to support building emotional trust and 
maintained unconditional patient trust through respectful professional behaviour. They felt that 
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by showing respect for the customs of the ethnic minority patient population and treating them 
‘differently’, they maintained the essential trust needed for consent.  
Research and senior cancer nurses explained that clinical and professional confidence 
and skill were trust-gaining behavioural qualities of frontline professionals. For them, 
professional competence enabled patient cooperation and trial participation which they felt 
showed that patients trusted them. Nurses felt that informed consent was achieved by patients 
‘actively’ showing they trusted them. Many doctors on the other hand felt that showing 
knowledge competency was an important factor that dispelled the patient’s initial mistrust and 
suspicion about the trial. They explained that showing knowledge competency meant giving 
non-biased, honest information, which they felt showed they protected the patient. It appeared 
that cognitive or competence based trust was supported by an emotional element which allayed 
patients’ ‘guinea pig’ fears by ensuring patients felt protected. 
There were mixed views as to the impact of language and culture on trust creation where 
the majority participant view was that sufficient trust was difficult to achieve in the ethnic 
minority groups. Many research nurses struggled to build a consensual trusting relationship 
with the patient because they described that in some religious cultures the family scepticism 
influenced the patients’ trial decision. Research nurses found the planning of trial logistics 
difficult because of their indirect communication with the patient, which caused nurses to 
question the individual patient’s consent. Only a minority of doctors felt that ethnic diversity 
did not pose any problem for patients’ consent, because they felt that many patients regardless 
of their ethnic background trusted doctors unconditionally. However, these doctors felt it was 
necessary to support patients’ unconditional trust by appropriate language translation and by 
not making assumptions about education depending on a patient’s socio-economic status. 
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Doctors and managers explained how interpreter service difficulties could erode a patient’s 
initial or gained trust by incorrect or lack of translation.  
Many doctors were concerned that referral and fragmentation between teams could 
potentially damage patient trust which they had gained or which was already available. A 
minority of doctors spoke about patient safety concerns due to care fragmentation which could 
subsequently cause the commencement of standard treatment in preference to trial treatment. 
The transition delays were found to affect the rapport with patients, potentially causing 
patients’ unhappiness and unwillingness to participate in the trial as patients’ initial 
expectations were not being met, thereby potentially eroding trust. Managers were particularly 
concerned that lack of ‘frontline’ professional knowledge and helpfulness could directly 
impact on the patient experience or could cause barriers to patients having the trial because of 
a decline in the relationship with professionals.  
It has been shown that doctors were particularly concerned with acting in the patients’ 
best interest, which they felt patients expected or trusted them to do. There was uncertainty 
that doctors’ best interest decisions interfered with patient choice because the doctor’s choice 
could differ from the patient’s choice in some cases. A minority of participants felt that the 
professional’s belief and ‘bias’ could differ from the MDT trial best interest decision. Doctors 
felt that communicating in an unbiased way was needed to gain patients’ trust. However, it 
was found that consultants could also be ‘biased’ against the MDT trial decision if they didn’t 
have belief in the trial or felt it was not right for the patient, resulting in a deviation from the 
MDT trial decision. However, the MDT decision to offer the trial was intended as a best 
interest decision, therefore ‘bias’ against it could interfere with patient trust in the trial as a 
best interest decision. Nursing managers worried that nurses’ beliefs could impact on the 
patients’ experience of the trial.  
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External ‘target’ pressures from the NIHR and the ‘push’ to benefit the medical 
research portfolio resulted in research nurses feeling pressured by managers to recruit patients 
to the trial, which they explained could interfere with maintaining ‘trustworthiness’. The reason 
was that some research nurses felt their care priorities were different to the trial best interest 
decision. As a result, some research nurses were found to struggle with building a relationship 
of trust with patients while balancing best interest, which they felt ‘frustrated’ about, and had 
no ‘control’ over. Furthermore, there was the potential for a negative impact of targets on 
building trust because nurses’ care values were different to the trial best interest decision. 
Overall, it was found that trust, gained by professionals’ relational interactions with 
patients was needed to enable and maintain informed consent to CCTs. The ways in which 
patient trust was maintained and not eroded were outlined. Additionally, it has therefore been 
argued that differing professional beliefs about patients’ best interest can affect the doctor and 
research nurse’s trusting relationship with the patient. Even where trust was gained, some 
professionals were unsure about the validity of patients’ informed consent. The next chapter 
focuses on facilitating patients’ autonomy within ‘valid’ informed consent. 
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Chapter Eight: Facilitating Patient Autonomy 
___________________________________________________________________ 
8.0 Introduction  
The focus of this chapter is how professionals experience facilitating patients’ autonomy when 
obtaining informed consent to cancer clinical trials (CCTs). The supporting research question 
addressed is: How does the professional experience of facilitating patients’ autonomy provide 
insight into the ‘validity’ of informed consent to CCTs? The prevalent theme participants spoke 
about was their efforts and difficulties with facilitating the patient’s individual autonomy to 
provide valid consent to a cancer trial treatment offer. The challenges professionals 
experienced while facilitating patient autonomy will be explored in relation to two interlinked 
sub-themes. First, the difficulties they experienced when facilitating patients’ autonomy in the 
ethnic minority patient group is explored, and, secondly, how cancer as an illness impacted on 
patients’ ability to provide ‘valid’ informed consent to the clinical trial.  
This chapter begins with an exploration of professional perceptions about how patients’ 
lack of trial knowledge affected the ‘validity’ of informed consent. Secondly, assumptions 
made by doctors and nurses about the patient’s individual ability to provide valid informed 
consent; and in some cases, their concerns about the family involvement in obtaining informed 
consent.  
8.1 Perceptions about patient knowledge 
Doctors and research nurses spoke at length about patients’ lack of trial knowledge and 
subsequently questioned the ‘validity’ of patients’ consent. They perceived that a certain 
amount of trial knowledge is necessary for the patient to make an autonomous informed 
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consent decision. Professionals spoke about struggles to facilitate autonomy within the ethnic 
minority patient group mainly. While cancer as an illness was perceived as affecting the 
patient’s retention of information, professionals did not always perceive this lack of knowledge 
as necessarily a limiting factor to facilitating informed consent, although some doubted the 
validity of consent they obtained.  
8.1.1 Knowledge defects among ethnic minority groups 
The majority of doctors and research nurses spoke about the possibility of language difficulties 
impeding patients’ autonomous decision-making in the ethnic minority patient group 
pertaining to non-English speaking patients. Interestingly, managers were concerned about the 
validity of the consent because of the difficulties with the translation service provided in the 
hospital for which they held responsibility. The main barrier language difficulties presented 
was the difficulty for professionals to communicate the trial knowledge needed, and the 
subsequent perceived lack of patient understanding of trial information. RD2 not only spoke 
of language itself as a problem but also spoke of the difficulties in facilitating the language 
barrier when obtaining informed consent. 
RD2: “Course it does and there are different ethnicities and the language barrier 
can be an issue and ..when there is a significant language barrier it does reduce 
the chances of this patient being recruited to a CCT. Because having to cross 
that barrier and facilitate the communication every time won’t be a viable option 
so that’s from a research point of view.”  
It was intimated by RD2 that the language barrier may not be feasible to cross every time to 
obtain informed consent. A consultant doctor (CD9) linked language difficulties and socio-
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economic problems to increased patient vulnerability, highlighting the organisational 
difficulties in surmounting the problem.  
CD9: “Yes massively, there is a real danger that there is a group of patients that 
get a raw deal.. so the most vulnerable in our population are the lower socio 
economic group where a number of patients do not have English as their first 
language and up to 60 per cent in English and are not even literate in their own 
language so there are huge barriers in accessing health care, then late diagnosis 
and advanced disease and then when they present they may not have the support 
network to help them through treatment and they are less likely to be enrolled 
into a CCT because of the barriers in terms of providing consent that we think 
is adequate. In order to change that would require huge investment of man 
power – there are massive problems it is a heterogeneous problem for example 
by having just Bengali advocates because there are huge numbers of people who 
speak Bengali, Polish, Korean and Russian and all sorts of other languages. It’s 
not solvable.” 
These extracts illustrate as Shrank et al. (2016) found that among cultural factors, above all 
language barriers were deemed to have the most effect on the quality of communication. It 
was intimated by CD9 that the consent that was achieved could lack validity because consent 
may not be ‘adequate’, as a result of these communication difficulties. Doctor participants 
showed their willingness to ‘cross the barrier’ and considered ‘investment in manpower’ to 
facilitate what they called ‘vulnerable’ patients with language difficulties. The majority of 
doctors seemed to associate the lack of being able to facilitate non-English speaking patients’ 
informed consent with institutional deficiencies and staff shortage problems they felt needed 
to be addressed to solve the language barrier issues. Previous theorists associated 
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professionals’ restricting trial entry as ‘gate keeping’ due to cultural, language and socio-
economic barriers in the United States (Ford et al., 2007). Hussain-Gamble and Leese (2006) 
in a UK study found that staff ‘stereotypical assumptions’ about non-English-speaking 
patients caused professionals (nurses and doctors) to judge the patient’s ability to consent or 
participate in the trial. Although doctors in the current study said that the translation facilities 
and staff shortages were considered a major problem for the facilitation language consent 
barriers, they seemed to endeavour to surmount these obstacles to facilitate patients’ autonomy 
to consent. While doctors were keen to facilitate informed consent, they expressed discomfort 
about the validity of the consent they could achieve when patient understanding was lacking 
as indicated in the following extract.  
CD9: “I can speak for myself. It is a difficult situation and makes me feel 
uncomfortable. On the one hand, you don’t want to expose somebody to a CCT 
that you feel they don’t understand or be able to provide valid informed consent 
but at the same time you don’t want to deny them access to potentially the best 
treatment for them and this creates a bit of a conundrum and I’m still not exactly 
sure how to resolve that.” 
In this extract, CD9 expressed a dilemma regarding precluding trial entry on the grounds of 
invalid consent. In keeping with Howerton et al. (2007), doctors in the current study felt 
uncomfortable about consent although they accepted the patient’s consent even if there were 
communication difficulties. Another doctor, RD8 said that “99% of patients’ are on a particular 
trial ‘even if English isn’t their first language’, interpreted as part of the course. It appeared for 
RD8 language was less of a barrier to informed consent. It is possible that some doctors were 
more comfortable with lesser patient understanding than others to fulfil valid informed consent 
or merely obtain consent.  
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Research nurses seemed more concerned about the validity of the consent because they 
encountered practical problems associated with the patient’s lack of knowledge understanding, 
which led to them to question patients’ consent. In the following extract RN3 expressed doubt 
over the patient’s consent because of the associated difficulties in trial planning with non-
English speaking patients.  
RN3: “Yes, Barriers could be language. The majority of the patients don’t speak 
particularly good English or that English isn’t their first language so there are 
barriers for example if they are going into the study their bloods need to be 3 
days old. If they were being treated on a standard treatment their bloods don’t 
matter. To be honest it is a sham because the patient doesn’t speak English and 
you think maybe if they had they would probably make their own decision.” 
This extract illustrated the difficulties of patient compliance needed to meet with the trial 
regulations (‘the 3 day old bloods’), where RN3 found facilitating a standard treatment would 
be less difficult for non-English-speaking patients. The use of the slang word ‘sham’ gives the 
impression that the consent was perceived as ‘false’ or the validity of consent was 
questionable because the patient lacked the knowledge needed. Another research nurse, RN1 
felt that consent for some patients “can happen without patients knowing everything”. It was 
intimated by these nurses that individual patient understanding was linked with the validity of 
consent because patient understanding enabled the patient’s autonomy to choose to enter the 
trial. In keeping with Van der Biessen et al. (2017), research nurses implied that the more 
information the patient understands and retains, the more valid the consent will be on the basis 
of improved patient autonomy (‘making their own decision’). By way of contrast, Chwang 
(2016) disagrees that the validity does not rely on patient knowledge alone, but is based on 
the patient’s ‘moral power’ which is perceived as the freedom to consent, thereby making it 
 
 146 
valid, regardless of the knowledge understood. Further exploration of facilitating autonomy 
within the ethnic minority group may demonstrate ‘moral power’ or freedom to make a 
decision within a social context. 
Research nurses and junior doctors found that the translation service was either 
inadequate or that the translation was not always correct, previously highlighted as affecting 
patients’ trust. However, managers were particularly concerned that inadequate translation 
impeded professionals’ ability to achieve ‘valid’ consent. Managers explained that the 
translator issues were further complicated by family members translating the information, 
which they appeared to discourage as this extract illustrated. 
M3: “I am going to be honest with what we have found is that there will be 
interpreters in the family and if the interpreter is not around and how is this 
interpreted? We don’t know how much is truly translated. Their interpretation 
might be completely different and that has a big impact on informed consent.” 
Although attempts were made to facilitate non-English speaking patients by requesting 
information in their own language, the problem faced was that the said patients were also 
illiterate. Patient illiteracy was not only described by research nurses as a reason to preclude 
informed consent but also precluded the running of the trials where it was not possible to 
complete quality-of-life questionnaires.  
RN10: “I think the assumption was made that she could read the language and 
I don’t think anyone went through the information sheet with her and translated 
it. Also, quality-of-life questionnaires was an issue.” 
The majority view was that language difficulties within the ethnic minority group was 
the main barrier to the achievement of valid autonomous informed consent because it 
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precluded professional communication of knowledge and patient understanding. While some 
doctors and many research nurses felt that informed consent was achievable irrespective of 
the quality of the consent, many felt that such consent could be invalid. The majority attributed 
possible invalidity of consent to lack of patient knowledge and lack institutional services 
needed to support language or communication problems. Patient insufficiency of knowledge 
was not limited to language. Cancer as an illness posed different knowledge barriers also 
causing professionals to question the validity of consent. 
8.1.2 The impact of illness on the validity of consent 
Many doctors and research nurses spoke about how cancer patients struggled to understand 
trial information, in particular trial design. Doctors not only spoke about their difficulties in 
gaining trust to RCTs because of patients’ suspicion and lack of understanding and the trial 
uncertainty; they also questioned the cancer patients’ autonomous ability to decide because of 
patients’ lack of trial knowledge. Research nurses spoke about the impact of cancer and poor 
prognosis on the validity of patients’ consent, particularly in relation to phase 1 clinical trial 
consent. Many research nurses perceived that a ‘desperate’ patient situation and cancer 
patients’ reluctance to decide caused them to question patient autonomous decision making.  
8.1.2 The ‘desperate’ patient 
Although, many doctors seemed more concerned about the cancer patient’s initial trust, some 
questioned the patient’s lack of sufficient knowledge to enable valid informed consent. For 
instance, CD9 consultant doubted if valid consent was achievable because of cancer patients’ 
insufficient scientific knowledge as this extract illustrated. 
CD9: “And also about what is true informed consent, whether it is actually 
possible for patients to really (emphasised) make an informed decision when 
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they haven’t got a professional medical background, especially when the 
science which we are dealing with is becoming much more complicated.”  
CD9 placed doubt over any possibility of gaining what he calls ‘true’ consent which could be 
interpreted as ‘valid’ consent, due to the differences between patient and physician 
knowledge. On this basis, in keeping with Jansen (2014), it seemed unlikely to achieve valid 
consent, because CD9 associated knowledge and understanding as a key element of informed 
consent.  
A majority of research nurses spoke about the difficulties with facilitating consent with 
cancer patients embarking on phase 1 clinical trials. For instance, RN7 explained below that 
patients could make hasty consent decisions possibly questioning the validity of consent 
because of what she referred to as the ‘desperate’ patient situation or because there were no 
other options.   
RN7: “Usually what I have noticed, not saying in general and just applies with 
our trial, patients are desperate and want to be on the trial as soon as possible. 
They are lung (patients).” 
RN3 found particular differences between early and late disease stage patients, where in the 
later stages (more advanced disease) patients were prepared to try anything which could mean 
that patients were desperate.  
RN3: “ I kind of feel when patients are in their late stages they just want 
anything to get better and of course they want quality-of-life as well, but they 
just want that. Unlike the patients who first get diagnosed in early stages they 
feel like they have more choices in terms of treatment.”  
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When research nurses were probed about differences in patient consent decisions they felt that 
there was a consent issue with early phase trials. They explained that patients’ ‘desperation’ 
caused ‘an issue’ for valid consent because the trial was not ‘going to be of any benefit’ and 
was the only ‘option’. RN8 below gave an account of how the patient misinterpreted the phase 
1 trial purpose and questioned the consent decision on the basis of patients’ incorrect 
understanding.  
RN8: “Their (patients) train of thought is: “what is the worst that can happen?” 
Because they are there and the illness is going to kill them at the end of the day 
so, “what is the difference in having the trial?” And (they say) “how long am I 
going to be on this trial or how long is it going on for?” Maybe they probably 
would make the same decision and at the time they understood it, but that 
changes because even though you have been told your disease has gotten 
smaller and that’s good but that doesn’t mean forever. People suddenly think: 
“it is going to get smaller and smaller and go away but it has gotten smaller but 
it is not going away.” 
This extract shows that in keeping with Dolly et al. (2016), research nurses found that patients’ 
understanding over-estimated the response possibly caused by patients’ ‘desperation’ or 
clinging to unrealistic hope. RN8 found this problematic for valid consent because it seemed 
that the initial understanding was questionable because later the research nurse needed to 
repeat the trial purpose. Furthermore, in keeping with van der Biessen et al. (2017); nurses 
described the ‘desperate’ patient as possibly ‘ignoring’ the information given at the time of 
consent, further questioning consent validity. While research nurses spoke of consent 
difficulties due to no other treatment option, interestingly most of them didn’t link lack patient 
‘desperation’ to lack of patient ‘voluntariness’ or freedom to decide directly. However, in 
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keeping with van Kleffins et al. (2004), where there was often not another option, it did 
influence the patient’s ability to provide valid consent.  
Research nurses were generally more concerned than doctors with trying to facilitate 
consent because of their perceived lack of consent validity which they associated with cancer 
patients’ distorted understanding or patients’ unrealistic trial outcome estimation. This was 
particularly problematic in phase 1 studies for advanced stage cancer patients whom they felt 
were ‘desperate’, causing them to question the patients’ ability to consent. Although most 
participants did not link lack of understanding or lack of choice with voluntariness, a minority 
of research nurses spoke about how patients opted to give up their freedom of choice or 
‘voluntariness’.  
8.1.3 ‘Relinquished’ autonomy 
Most participants spoke at length about the doctor deciding on the trial recommendation if 
doctors felt it was the ‘best’ option for the patient, even if there was no other option offered. 
Although the doctor decided, the majority view was that patients would then consent to what 
the doctor felt was best for patients. However, in many cases it seemed that the patient assented 
to the trial, which for some professionals meant that patients gave up their autonomy. There 
were few instances described where patients did not agree to the trial and sought a second 
opinion. It was not perceived that the doctor deciding on what was best for the patient interfered 
with patient voluntariness, except for the instances of perceived ‘pushing’ for the trial 
previously explored which in keeping with Gilson (2003) could have interfered with 
‘voluntariness’. Although only a deviant case, one research nurse described the patient’s wish 
for the professional to make the consent decision for them or on their behalf. 
RN3: “I think from my experience I have noticed that you know those patients 
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who are academically aware, or those patients who ask you; “Nurse what would 
you do if it was you?”, and if a patient comes and they don’t speak English or 
have poor English sometimes you find you make decisions on their behalf.” 
The research nurse pointed out that patients who lacked the knowledge or language skills 
seemed to give up their ability to consent by either asking or preferring the professional to 
decide; interestingly, in this case the nurse to do so. Although the research nurse was aware 
of the lack of perceived patient autonomy to consent, it seemed acceptable for the purpose of 
gaining a version of consent. In keeping with previous studies, because patients were 
overwhelmed with information, they wanted professionals to decide or particularly doctors to 
‘direct’ them, thereby assenting to the trial, termed as ‘relinquishing’ autonomy (Mc Kinstry, 
2000; Sinding et al., 2010). Furthermore, while Madsen et al. (2007) pointed out that where 
the patient had only one option they felt patients’ freedom was limited and many patients 
experienced the ‘loneliness’ of autonomy; and therefore, wanted professionals to decide with 
them. Conversely, Mendrick et al. (2010) argues that patients felt autonomous even if they 
saw no choice, and felt ‘ownership’ of the decision if they asked doctors to decide because 
they interpreted the doctor’s ‘paternalistic’ approach as a recommendation.  
It appeared common practice that professionals accepted assent (agreeing with the 
doctors’ decision or advice) as patients’ consent. However, for some nurses this assent 
appeared to support the patient’s lack of knowledge or ability to decide. It was interesting that 
patients in some cases also wanted nurses to decide for them. In keeping with O’Neill (2002) 
in some instances, ‘fully informed’ consent is not achievable, which may place doubt over 
facilitating autonomy and ‘voluntariness’ as advised by Beauchamp and Childress (2001) 
bioethical principle of respecting autonomy. It could be that assent to CCTs in the cancer and 
ethnic population is accepted as a form of informed consent. However, there were some 
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instances where professionals could impede informed consent by making assumptions about 
the patient’s autonomy based on the factors particularly associated with the ethnic minority 
patient population. 
8.2 Professional assumptions made about patient autonomy 
Despite many participants referring to potential barriers to informed consent in the ethnic 
minority population and patients from the local lower socio-economic group, only a small 
minority of doctors and one research nurse spoke about how professionals could make 
assumptions about the patient’s ability to consent. These limited accounts may represent a 
much higher assumption than the ratio of professionals who spoke about them. Possible 
professional assumptions made were because of the patient’s culture, perceived intelligence 
and level of education. The assumptions made caused some doctors and nurses to 
underestimate the patient’s ability to consent or the patient’s autonomy. Some participants 
described assumptions as having a direct effect on facilitating autonomy, where there could be 
a ‘steering’ away from the trial or at a minimum these patients were described as being ‘treated 
differently’.  
8.2.1 How professional assumptions affected facilitating autonomy 
Some doctors referred to assumptions that were made about the patient’s ability to decide 
depending on their patients’ socio-economic and educational status as illustrated in this extract.  
CD6: “People (doctors and nurses) who treat them as fools because they may 
not have necessarily have the same P’s and Q’s are idiots because they run rings 
around them because they are not stupid. They always bring up the question of 
education being part of things actually there are quite and very intelligent.” 
 
 153 
CD6 expressed his disapproval of those who question intelligence on the grounds of education 
by referring to such professionals as ‘idiots’. It is possible that such an assumption may be 
frequent because he refers to professionals ‘always’ bringing up the question of education. 
While he doesn’t elaborate on the possibility of professionals excluding such patients from 
the trial offer, it is interpreted that this could be a possibility. A Registrar elaborated on what 
the impact of the assumption might be, where judgements are made about the patient’s 
autonomous ability. There is a possibility of trial exclusion on the grounds of presumed lack 
of patient engagement and compliance as illustrated in the following extract.  
RD8: “People (doctors) assume that if you have a certain level of education and 
language you might be more keen to go onto trials. Compliance and 
engagement, they (doctors and nurses) might think is a problem because no-one 
has looked into it but you should treat everyone the same obviously but I don’t 
know if that is always the case just sub-consciously and people (doctors) make 
judgements about people depending on language and what they wear. I think 
everybody is going to be different, every doctor is different, any person out there 
will always have/ no matter how people deny it/ will have always preconceived 
views and it will depend on how that affects what they do, but in terms of going 
back to trials and ethnic groups I can’t see necessarily that they (patients) would 
be more resistant to taking part in CCTs. I think the problem lies on the doctor’s 
side where we don’t put people off and to make sure there is an extra level and 
to make we go through things with the patient and they are fully on board.” 
In this extract, a ‘judgement’ was described on the basis of patients’ ethnicity, education or 
even clothing as to whether the patient will engage with the trial. Interestingly, RD8 said that 
doctors can make this judgment ‘sub-consciously’, or even if they are conscious of it, they 
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could ‘deny’ it. Where there is a pre-judgment made about the patient’s ability to decide about 
a trial offered to them, there could be professional lack of respect for autonomy. In keeping 
with Howerton et al. (2007) and Bell and Balneaves (2015), bias or assumptions position 
health care professionals as ‘gatekeepers’, potentially precluding trial entry of such patients. 
Similar to the sub-conscious bias described by RD8, Hussain-Gamble and Leese (2006) found 
that patients can be ‘cherry picked’ for the trial, or certain groups can be treated with ‘passive 
exclusion’, which they say can be institutional.  
Within this contemporary London setting, the demographic details of the participants 
interviewed was not sought. However, the researcher is aware that both these doctors are 
familiar with ethnically diverse patients whether from their own family background or in a 
previous workplace. It seemed that these doctors had an appreciation for facilitating ethnic 
and diverse patient autonomy in the contemporary setting because they highlighted 
professional presumptions about autonomy and the need for more diversity among the staff as 
this extract illustrates. 
RD8: “I would have been more alert to it when other people might not be. It 
helps if you have gone through it and leads to an understanding. It might lead 
to people being more aware of different cultures I suppose and cultural 
sensitivities and increased awareness.”  
These doctors appeared to have an understanding of the value of different approaches to 
patient autonomy which is in keeping with Barvosa (2007) who described how doctors seemed 
to display appreciation for diversity in the contemporary setting due to what Barvosa calls a 
‘hybrid experience’, which factors in different cultural approaches. Furthermore, RD8 
explained how a more culturally mixed and sensitive workforce would be ‘aware’ of cultural 
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needs in line with Hussain-Gamble and Leese (2006), thus, providing improved facilitation of 
such patients’ autonomy.  
Assumptions made about the patient’s ability to consent was not generally described 
as a concern for nurses, although research nurses found that language and ethnicity were cause 
for questioning of the patient’s consent. However, one research nurse (RN10) spoke about 
professional assumptions about a patient with a possible learning disability (although the 
patient was assumed as having capacity initially) causing a ‘steering away’ from a clinical 
trial as illustrated.  
RN10: “I had a case recently where a patient was given trial information and it 
was obvious that they didn’t necessarily have learning difficulties (LD) but they 
didn’t understand the process very well. I was kind of encouraged to steer them 
away from consenting and when I spoke to them initially they said they did want 
to consent to the trial but then after talking to them a bit more they didn’t kind 
of understand the whole randomisation issue and weren’t very happy with that 
and another issue was it would have delayed them starting treatment if they had 
gone on the trial and they did decide not to go on. But yes, I was encouraged to 
steer them away.” 
This situation was difficult for the research nurse due to denying the possible LD patient 
access to the trial based an assumption about the patients’ autonomy to decide. Secondly, 
taking away the initial LD patients’ consent, possibly damaged the patient’s expectation of 
the trial. However, RN10 described how such patients struggled with the concept of 
randomisation, and therefore it was intimated that deterring them from a trial that could be 
justified. In keeping with Tobias (1998), deterring patients from the trial could be justified 
because he recognises that rigid positions about obtaining informed consent ignore the 
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realities and difficulties of gaining consent and calls for a ‘more directive’, even paternalistic 
approach, which arguably could be perceived too much a shift away from facilitating 
autonomy. Furthermore, Jansen and Wall (2016) condone what they call ‘soft paternalism’ in 
similar cases to RN10’s case where a patient’s therapeutic misconception and lack of 
understanding is cause for a doctor to decide against the trial. The reason they give is to 
‘safeguard’ the patient and limit the risk of harm.  
It is interesting that only a minority of participants spoke about assumptions 
professionals made about patients’ autonomous ability to consent given that this case study is 
set in a culturally diverse, socio-economically challenged location. Of those who did speak 
about these assumptions, they explained that the impact on practice was that patients are 
potentially treated differently and could be precluded from trial entry. Precluding trial entry 
on the basis of presumed lack of the patient’s individual autonomy was also significant for 
another reason. Many professionals described their difficulties in facilitating informed consent 
because of how the families of ethnic minority group patients influenced ‘individual’ patient 
autonomy. 
8.3 Individual versus relational patient autonomy 
There were mixed experiences described by participants about how they perceived the ethnic 
family involvement in the patient’s consent. Many research nurses and managers felt that the 
family involvement was a barrier to achieving informed consent from the individual patient. A 
minority of doctors spoke positively about the family involvement in the patient’s consent 
decision. In this sub-theme, the way professionals perceived the influence of the family on the 
patient’s autonomy and the subsequent impact on how professionals facilitated informed 
consent is explored.  
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8.3.1 The family influence on ‘individual’ autonomy 
Participants spoke about the influence of the ethnic minority family on achieving patient 
consent. A minority of doctors spoke positively about the family influence. Many research 
nurses and nursing managers spoke about challenges in relation to achieving what they called 
the patient’s ‘own’ consent, as opposed to the family decision or consent to the trial, as 
illustrated in this extract. 
RN4: “I know that sometimes we have sensed that there is a lot of family 
influence to not come onto it (the trial) and vice versa and sometimes it is hard 
to gauge how much family pressures are going on. Or you might think they 
think, ‘oh yes brilliant’, and then they go away and next day the son rings up or 
family rings up and says, “no we are not doing it”, and you think how much 
family pressure has gone on..”  
RN4 questioned the family influence which she perceived as ‘pressure’ on the patient to make 
a consent decision because she struggled to know what ‘goes on’ within the family. In this 
instance, the ‘son rings up’ and decided to decline the trial that the patient had previously 
appeared positive about. As a result of what RN4 considered the family pressurising by the 
son deciding it appeared that the patient’s ‘individual’ autonomy was questioned. In line with 
Ho (2008), it could be that the patient’s lack of autonomy was presumed, who highlighted 
professionals presuming patient involuntariness due to family involvement in decision 
making. Similarly, RN10 said that achieving autonomous consent was a concern because ‘the 
family make the decision’. Previously, RN3 explained that there was no communication 
directly with the patient, and that the consent was a ‘sham’ or false as a result. M3’s concern 
was because of ‘children translating’ for patients and voicing the decision. In keeping with 
Bell and Balneaves (2015) and Hussain-Gamble and Leese, (2006) research nurses 
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particularly felt that family influences questioned ‘individual’ autonomy and were perceived 
as a barrier to patient consent in this CCT setting. 
Although the research nurses pointed out their concerns about not achieving consent 
from the individual patient there does not seem to be any resolve offered for this discontent, 
except in the case of RN3, who says: 
“Whenever we speak about these trials they always have a choice so I just have 
to respect their relatives wishes and hopefully that was their (the patient’s) wish 
and just wish them the best really.” 
There was an exception made here for the family involvement in the hope that the family 
wishes reflected the wishes of the patient. It is possible that RN3 appealed to accepting a 
relational version of autonomy where the patient is positioned within the family social context. 
In line with Kihlbom (2008) accepting consent according to Beauchamp and Childress (2001) 
appeals to the positive belief that the patient’s preferences are intentionally expressed (by the 
family), and that there is patient understanding and control of outside influences, which 
determines ‘individual’ autonomy needed for consent. Many research nurses knowingly 
undertook the pressures and influences of family as the day-to-day accepted version of 
facilitating consent, even though they felt uncomfortable with the ethnic family influence. 
Additionally, some nurses alluded to adhering to the policy for gaining consent from the 
individual patient, where ‘the subject’s’ consent is sought or else that of an ‘impartial witness’ 
or ‘legal representative’ if language is a problem as opposed to the family being used for the 
purpose of gaining consent. For the most part, research nurses questioned ‘individual’ 
autonomy and generally did not appear to consider relational autonomy within the context of 
the family as a contributing factor to patient autonomy. 
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Of the minority of doctors who spoke about the ethnic family influence on consent, it 
was felt that the family played an important positive influence on the patient’s autonomy. RD8 
previously spoke with disapproval about ethnic minorities being ‘treated differently’ 
generally, but feels strongly that the family are an important part of the consent as he explained 
below.  
RD8: “I don’t think that has ever posed a problem for them (patients) in clinical 
trials because they have been part of clinical trials because the family members 
explained it to them. Just that the demographics are that a lot of children should 
have been born and brought up here and are able to explain things in a way that 
the parents can understand.”  
Interestingly, RD8 incorporates the family, even the children into trial discussions and finds 
it helpful for gaining consent. The notion of engaging the family was implied as beneficial 
and was not seen to contravene policy or patient autonomy, but places the patient as part of a 
family relational structure needed to achieve consent to the trial. Similarly, CD6 endorsed 
particularly the ethnic family in the decision about the trial consent as illustrated below:  
“Having relatives and people around with them can be quite helpful on 
occasions because I think trials should be a family decision sometimes rather 
than just an individual and the individual goes back to the family and talks to 
them and they say don’t let them do that when they really don’t. They are as 
uninformed as most other people in the general public whereas if they are all 
there and they understand then you have support of and from the home when 
the patient is feeling tough and not too good they stick with it because the 
relatives are all there and they are all part of the treatment team so I think 
involving the family when you can is important and that is especially with the 
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more ethnically diverse patients more important and we don’t do enough of it.” 
This extract illustrates in keeping with Knobf (2007) the importance of ‘relationship building’ 
by involving the family presence who provided social support they for the patient’s trial entry 
and continuing on the trial when things are ‘tough’. There was no doubt placed over the 
patient’s autonomy here even where the family made the decision together. Similarly, 
Corrigan (2003) found that informed consent can be reduced to ‘individual’ autonomy which 
ignores the cultural dimension she feels is necessary, and a patient who acts within the family 
commitment according to Mc Kenzie (2008) is autonomous. CD6 expressed disapproval of 
not involving the family as accepted common practice as he referred to professionals not doing 
enough of it, implying a change in the way professionals facilitate autonomy within the family 
context.  
For the most part, research nurses and managers found that the family involvement in 
patients’ consent was a barrier to the patient’s individual consent and caused them to question 
the patient’s autonomy. A minority of doctors valued the family presence and involvement 
and believed it necessary to achieve patient consent within the relational context of the family.  
8.4 Summary 
This chapter has answered the research question that asked how professionals experienced 
facilitating patient autonomy when consenting in a diverse CCT setting. It has been argued that 
questioning the validity of consent is an important problem within the context of two patient 
groups: namely the cancer trial patients and the ethnic minority patient group. It was found that 
the majority of participants experienced certain patient knowledge and understanding defects 
which posed a challenging problem for them when facilitating autonomy needed to fulfil 
informed consent requirements, questioning the validity of consent they achieved.  
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Some doctors felt that language barriers were an insurmountable problem, but they 
were reluctant to use this as a reason to preclude trial entry. Doctors attributed the ‘massive’ 
language problem to the organisation’s translation service and staff shortages. They found the 
possibility of invalid consent a dilemma for patient inclusion in clinical trials, while other 
doctors varied in what patient understanding they were prepared to accept as consent, 
acknowledging the asymmetry of information with the physician and the patient. 
Research nurses encountered language difficulties affecting the logistical planning and 
subsequent patient compliance. In some cases nurses felt that the consent was invalid or false. 
Nurses intimated that the more knowledge that was understood by patients, the more valid was 
their consent. Managers were mostly concerned about the validity of consent because of 
deficiencies in the translation service or the involvement of the family. 
The other reason why knowledge deficiency caused difficulty with facilitating ill 
patients’ autonomy was because research nurses found that they demonstrated lack of 
understanding of trial design and in phase 1 studies misunderstood the trial purpose, thereby 
overestimating the response. While they managed a ‘desperate’ situation by going over the 
consent and trial purpose, nurses did not indicate that the patient’s ‘voluntariness to decide was 
threatened as a result. Research nurses found that patients who lacked understanding often 
wanted doctors to decide. It was described as common practice for the doctor to present the 
best option, to which the patient consented or sometimes it seemed patients assented to the 
trial, or even gave up their autonomy to decide. Interestingly, despite the diverse cultural and 
socio-economic patient population served, only a minority of doctor participants gave accounts 
of assumptions that professionals made regarding such patients’ ability to consent. There were 
instances when assumptions made were justified to protect the patient, presenting a dilemma 
for the facilitation of the patient’s autonomy.  
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The question about facilitating ‘individual’ patient autonomy was of concern for many 
research nurses and managers who found family involvement a barrier or even falsified the 
patient’s consent, questioning voluntariness, as there was no direct communication with the 
patient. Research nurses were aware of following the policy requirements for consent and 
ideally sought direct patient preferences. While research nurses felt uncomfortable about their 
views on family involvement, they incorporated the family in their daily practice and 
endeavoured not to let it preclude a version of consent. A minority of doctors spoke about the 
inclusion of family as an essential aspect when seeking consent in cultural situations; off-
setting the risk of patient attrition later. They did not feel that family inclusion posed a threat 
to the patient’s autonomy, but reconciled facilitating autonomy by suggesting the need for more 
culturally mixed staff and a culturally family sensitive approach. None of the participants 
suggested more training to equip them to facilitate the difficulties they encountered due to 
family cultural practices, although it was intimated. 
This chapter has shown that although professionals experienced difficulties with 
facilitating patient autonomy in a diverse CCT patient setting a variation of consent or assent 
was often accepted. The following Conclusion Chapter will draw together and summarise the 
key themes. The study limitations will be highlighted and how the findings have advanced the 




Chapter Nine: Conclusion and Recommendations 
___________________________________________________________________ 
9.0 The study summary 
In this study, the interprofessional experiences of communication involved in obtaining 
informed consent to cancer clinical trials (CCTs) was explored. In the role of nurse practitioner 
researcher and manager, my regard for valid diverse cancer patient consent has been a guiding 
principle. Identifying the need for a triangulated interprofessional voice has personally inspired 
this study, which is aimed at advancing CCT interprofessional practice and making a 
contribution to the literature. The problematic communication resulting in poor accrual to 
CCTs has provided an impetus for undertaking this study in a single tertiary London CCT 
centre.  
The research design entailed a phenomenological approach within a case study setting, 
comprising of 26 semi-structured interviews with mixed professionals and the upkeep of a 
reflective diary to enable reflexivity. The conceptual framework was built upon the main 
concepts and assumptions within the overarching research question which guided the literature 
review and data collection. Supporting research questions were focused on ascertaining the 
interprofessional experiences of responsibility, as shaped by time, trust and facilitating patient 
autonomy. The experiences have been presented and discussed with the use of the literature. 
In this chapter the main findings are summarised and the contribution to the literature is 
highlighted. The strengths and limitations of the study are outlined. It will be demonstrated 
how the researchers’ (my) interaction with the findings has been able to answer the overarching 
research question. As a result of the findings, recommendations will be provided which can 
either contribute to implications for practice or form a basis for future research.  
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9.1 Responsibility as shaped by time 
The timing of the doctors’ role is affirmed as important because of confirming the diagnosis 
and making the initial offer of the trial to the patient in keeping with Friedson (2001) and Davis 
(1995). There was interprofessional discontent or internal professional conflict regarding the 
positive (even persuasive) language used by doctors to offer the trial, which many referred to 
as ‘pushing for the trial’. Initially some managers and nurses and a senior doctor seemed in 
support of nurses challenging this ‘pushing’ for the trial’. Yet they acknowledged that the trial 
was often ‘the best option’ and ‘doctors wanted the best for patients’. The research practitioner 
empathised with the moral difficulty these opposing views had for nurses mainly. Regardless 
of this difficulty, it is intimated that the language used by doctors could have a positive effect 
on patients’ consenting to the trial. This could mean that obtaining informed consent to CCTs 
relied on presenting the trial in a positive, even persuasive way potentially created hope. The 
use of positive language in support of the trial chimes with previous theorists (Barton and 
Eggly, 2009; Brown et al., 2015), although conversely could be perceived as ‘framing’ the trial 
according to Chwang et al. (2016). 
Although participants presented a divided view regarding the timing of eligibility 
(medical / diagnostic factors) and suitability (social factors), most were in agreement that 
assessments spanned a process across professional boundaries. Research nurses and managers 
were more concerned about whether patients were suitable and gave reasons for patients’ poor 
suitability pertaining to day-to-day difficulties patients experienced on trials. The MDT 
decision-making forum was dominated by the doctors as found previously (Lamb et al., 2011; 
Eigenmann et al., 2015). However, some doctors encouraged the nurses’ role as a ‘challenge’ 
or patient advocate or even as a ‘conscience’ checker. It is deduced that direct challenges to 
medical recommendations were welcomed in contemporary CCT decision-making. Doctors 
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and managers linked nurses challenging decisions to nurse acting as patient advocates. Most 
research nurses were cautious about challenging decisions, but did contribute to the suitability 
assessment of the patient. However, they were often not involved in patient assessment prior 
to the trial recommendation or the actual consent which contrasts with Kidger et al. (2008) who 
deem suitability assessment essential prior to the trial recommendation. Although Davis et al. 
(2002) considered the importance of the nurse advocates, they did not specify as that of a 
‘challenger’ of the recommendation. Nurses’ autonomy could mean the ability to challenge, 
although, some research nurses described their role as dependent on the support of the medical 
profession, akin to the doctors’ ‘handmaiden’; or similar to the adjudicator roles respectively 
(Roberts and Vasquez, 2004; Lee et al., 2009).  
Some nurses and registrar doctors described the signing of the form as a time for doctors 
to confirm that informed consent has been ‘fully’ achieved. This contrasts to Bergenmar et al. 
(2008)  who recounted studies where doctors rarely did check if information was understood. 
Nurse participants questioned the quality or ‘usefulness’ of the consent paperwork validity in-
line with the literature (Jordens et al., 2013, p.76; Shannon-Dorcy & Drevdahl, 2011; Corrigan, 
2003; O’Neill, 2002). However, nurses did not want responsibility for the consent and often 
referred to the doctors’ responsibility in accordance with policy guidelines. Junior doctors and 
nurses at the ‘frontline’ felt that the ‘process’ of information-giving was on-going derived from 
ad-hoc social encounters with patients, which they said maintained patient safety and enabled 
informed consent by gaining better patient understanding. There was agreement with 
Bergenmar et al. (2011) that giving the patient more time is likely to impact positively on 
consent, although the reason was not necessarily because patients in their study had better 
understanding or trial knowledge.  
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Information-giving over time was likened to a social encounter, like ‘chatting with the 
patient’ particularly for nurses, which could be likened to Hassard (2001) who refers to such 
time as ‘qualitative’. Both professions felt such quality time enabled patient understanding of 
that information. Doctors reported time-constraints in the clinic setting, as identified by Jenkins 
(2010) and others. The constraints described in clinic time (‘10-15 minutes’) in the cancer trial 
setting is in keeping with MacBride-Stewart (2013, p.564) although described in general 
practice. Lack of doctors’ clinic time caused nurses to ‘fill in the gaps’ that the doctors could 
not attend to. Some doctors referred to these nursing tasks (information-giving and checking) 
as essential to ‘good’ informed consent. Importantly, the nursing time seemed to equate to as 
what Davis (1994) referred to as ‘relationship time’ as opposed to the ‘clinic slot’ controlled 
doctors’ time. When doctors lacked sufficient time, ensuring ‘informed’ consent (traditionally 
a medical responsibility) became ‘re-distributed’ to the research nurse, potentially changing 
practice. The unstructured social process by which nurses gave information was referred to as 
a ‘friendship’ with the patient as developed over time. This supportive relationship resembles 
the time-phased’ approach to intimacy, as found by Dowling (2008) and Strazdins et al. (2016). 
The unfortunate finding was that many nurses did not equate the nurses’ role or relationship as 
a defining component in obtaining ‘valid’ informed consent.  
9.2 Trust 
It has been argued that the maintenance of trust within informed consent is as important as the 
initial trust gained or already available. Doctors were more concerned with maintaining the 
‘initial trust’ that they had gained. While Calnan and Rowe (2008) found that patient trust was 
conditional and was earned by positive experiences with professionals; by way of contrast to 
the CCT setting they found that ‘familiarity’ over time with the clinician did not make a 
difference to diabetic patients’ trust. For professionals in this study, the repeated encounters 
 
 167 
over time with cancer patients engendering familiarity was trust-forming, in keeping with 
Jackson et al., (2004). Repeated patient encounters with patients gained ‘more trust’, except 
for the difficulty described in gaining ‘more trust’ in emergency situations. While Zinn (2008) 
asserts that when there is ‘less knowledge’ and ‘less time’, akin to ‘contemporary decision-
making’, ‘increased trust’ is needed. The descriptions of decreased availability of trust in 
emergencies was different to the need for more trust in emergencies according to Zinn (2008). 
However, these clinicians did not mention that a ‘leap of faith’ (Giddens, 1984) was needed by 
patients. It could be that physicians lacked comprehension of how emergency trust came about 
for patients, although they felt they achieved it.  
Nurses explained the possibility of reinforcing the patient’s positive trial expectation 
when the trial was presented as a ‘good’ option, in-line with Nekolaickhuk et al., (1999) who 
associated a positive evaluation with creating an expectation of hope. Nurses also seemed to 
associate gaining trust with reassuring patients, potentially sustaining the patients’ hope, 
appealing to the patients’ emotional trust in a non-rational way in keeping with Sabo (2001) 
and Simpson (2004). Similarly, Calnan and Rowe (2008) found that patients’ trust was earned 
by the quality of care they experienced from nurses, although they found that reassurance was 
attributed to the information patients received. The body language of the professional, for 
instance nurses’ ‘sitting down’ with the patient and observing religious customs was described 
as ‘making patients feel comfortable’, demonstrating respect. It is uncertain if these practices 
were trust-forming, although they did strengthen the professional-patient relationship.  
Some doctors felt that ethnic patients had unconditional trust, while others felt that these 
patients were suspicious. Many doctors dispelled the possibility of ‘mistrust’ or loss of trust 
and the ‘guinea pig’ myth. They showed their competence by communicating trial knowledge 
to patients honestly, in an un-biased way as a means of protecting patients and allaying fear. 
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Nurses felt their clinical confidence and competence ‘at the frontline’ showed competence 
when caring for patients. Nurses also associated gaining trust with gaining the cooperation of 
patients, in keeping with Gambetta (1988 cited in Mollering, 2001) who associated cooperation 
with ‘trustful’ behaviour as an ‘active’ component of trust Giddens (1984). Managers gave 
accounts of how professional interactions with patients affected the patient experience. It 
appeared that rational or competence based trust did rely on an emotional element. 
There were mixed views about whether ethnic minority group factors associated with 
language issues impacted on gaining or eroding patients’ trust. Mostly research nurses found 
language and family pressures were a barrier to gaining informed consent for minority groups. 
The reason given was that research nurses explained difficulties in building a relationship 
solely with the patient, questioning the validity of the consent and potentially related the 
problems directly to lack of family trust aligning with Durant (2014) who found that distrust 
was associated with ethnic groups. For a minority of doctors, it was implied that patients from 
minority groups trusted them unconditionally, but that trust could be eroded by poor translation 
of the information in keeping with previous researchers (Gul et al., 2010; Rubin et al., 2014; 
Durant et al., 2014). One consultant and a registrar welcomed the ethnic family involvement 
in decision-making. These doctors described trust as ‘earned’ for diverse patients, by 
tailormade communication and treating them ‘differently’, showing respect, without which the 
gained trust could be eroded. Dealing with these patients ‘differently’ aligned with the need for 
‘culturally sensitive’ approaches (Rubin, 2014). 
As noted in the research diary and interviews, the positive rapport needed to gain the 
initial trust or maintain it could change due to care fragmentation between teams. Maintaining 
the initial trust resembled honouring the patients’ expectation of the trial offered (Barbalet, 
2009), and by professional behaviour that responded to the patients’ expectation of hope, in 
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keeping with Simpson (2004). ‘Frontline’ professionals in this study highlighted that lack of 
ownership of the patient and even ‘avoidance’ of trial patients caused fragmentation of patient 
care, although this was often because the general team or the CNSs lacked trial knowledge and 
were fearful of an unlicensed drug. The ‘hands off’ approach to patient care was interpreted as 
ambivalence which was found to erode trust, in-line with previous research by Hurd et al. 
(2017). It was interpreted that what mattered to patients was the day-to-day rapport with staff 
that was built up through positive social encounters had the potential to change, in-line Robbins 
(2016), although in the business sector. Managers were concerned that patient experience 
would wane due to care fragmentation.  
There were differing views about what constituted the patients’ best interests. Doctors 
felt that they fulfilled the patients’ trust in them by offering the trial in the patients’ best interest. 
It was uncertain whether the doctors’ decision-making and the patients’ choice amounted to 
the same thing. It was interpreted that when a patient ‘choose’ the trial that the doctor had 
already decided on, it more resembled assent, in-line with the ‘passive trust’ referred to by 
Giddens (1984). Nurses were concerned that the trial recommendation could affect their ability 
to build a trustworthy relationship in instances where they questioned the quality-of-life of the 
patient, although nurses came across as having lesser importance in gaining trust on the basis 
of best interest decision-making.   
The uncertainty of the trial outcome impacted doctors’ trust creation. One consultant 
explained that having an unbiased approach to the trial may not be possible, as doctors were 
relied upon to act in the patients’ best interest, echoing Calnan and Rowe (2008), thereby 
questioning the collective MDT decision-making if it differed to the individual doctors’ view. 
The doctors’ view had the potential to influence the patients’ consent, in-line with Jenkins and 
Fallowfield (2000). As was expressed many times previously (Fallowfield, 2000; Davis, 1960; 
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and Adamson, 1997), RCTs posed communication difficulties for physicians. Another doctor 
believed that the patient relationship would be negatively affected when patients became 
unhappy waiting for the trial to commence or a cohort to open. This delay caused doctors to 
commence a non-trial treatment constituting a deviation from the MDT best interest decision. 
Although deviations from MDT best interest decisions have been found, (Wood et al., 2007; 
Blazeby et al., 2005), physician bias was not mentioned previously as a reason for the deviation, 
which contributes to the literature enabling an improved understanding of MDT deviations. 
The nurse-patient trust relationship was affected due to trial uncertainty and randomisation. 
Although managers were not clinical, they were concerned if the nurses’ views about the trial 
differed because it may influence the nurses’ ‘judgement’ about the trial. Managers felt the 
maintenance of the on-going trusting relationship could be eroded where those administering 
the treatment don’t believe in the trial as a best option, yet interestingly managers asserted that 
‘they (nurses) are unable to challenge it’. 
External targets from above were repeatedly reported as causing pressure for the 
participants because of the drive to recruit patients to trials, impacting on practice. Nurses felt 
this pressure could undermine their trustworthiness and that recruitment needed to be balanced 
with the patients’ best interest. Nurses were explicit in their views; and felt that this pressure 
could ethically contravene patient care if patients lacked understanding, subordinating their 
view of the patients’ best interests, while their primary objective was to help patients. Financial 
pressure and career gain was another pressure that nurses felt impacted on doctors’ clinical trial 
practice and was difficult to work with as it was implied as affecting patient relationships, 
possibly interpreted as an expense of the relational quality between care-givers and receivers’ 
(Spence, 2012). The influence of targets chimes with professionalism that is ‘imposed from 
above’ which has become integral to practice (Evetts, 2011).  
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9.3 Facilitating patient autonomy 
Doctors and research nurses spoke at length about patients’ lack of trial knowledge and 
subsequently questioned the ‘validity’ of patients’ consent. Professionals spoke about struggles 
to facilitate autonomy within minority groups mainly. While cancer as an illness was perceived 
as affecting the patient’s retention of information, illness did not preclude consent necessarily 
although some participants questioned the validity of consent due to the patient’s knowledge 
deficit.  
Language was relayed by many professionals as problematic, although it was the 
translator difficulties (institutional services) that caused the problem, because the consent taken 
might not be ‘adequate’. Some doctors questioned cancer patients’ autonomous ability to 
decide because of patients’ lack of trial knowledge and questioned if this was ‘true’ consent. 
However, doctors were emphatic that they did not use this issue as a means of not considering 
foreign language speaking patients; unlike the ‘cherry picking’ described in the Hussain- 
Gamble and Leese (2006) study. Some doctors in this study surmounted the problem even if it 
meant that the consent validity was lacking but did say that this caused a dilemma to preclude 
trial entry on this basis. Not all doctors felt this was a dilemma, interpreted as them accepting 
lesser patient understanding as consent. Nurses experienced the lack of validity as a result of 
patients’ lack of compliance and lack of information retention, in keeping with van der Biessen 
et al. (2017). Another complicating factor in gaining consent from minority groups was family 
translation which the manager disapproved of (in accordance with local consent policy).  
Research nurses spoke about the validity of patients’ consent, particularly in relation to 
phase 1 clinical trial consent, referring to patient desperation and patients not wanting to decide 
for themselves, thereby giving up their autonomy. Nurses also experienced how patients over-
estimated the trial benefit and not retaining the information akin to van der Biessen et al. 
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(2017), together with patients often feeling it was their only option; thereby influencing their 
consent as found with van Kleffins et al.(2004). Rarely did a patient seek a second opinion. It 
was not perceived that the doctor deciding on what was best for the patient interfered with 
patient voluntariness, except for the instances of perceived ‘pushing’. It was a nurse who 
relayed a patient seeking them to decide on the trial. Previous theorists reported that patients 
wanted professionals to decide, but did not necessarily say nurses (Sinding et al., 2010; Madsen 
et al., 2007), all of which placed doubt on the facilitating true patient autonomy in the cancer 
setting even with the best facilitation.  
Possible professional assumptions made were because of the patient’s culture, 
perceived intelligence and level of education. The assumptions made caused some doctors and 
nurses to underestimate the patient’s ability to consent or the patient’s autonomy. The senior 
consultant vehemently disapproved of this type of patient judgment on the basis of patient 
ethnicity and socio-economic status. While it was intimated that judgement did take place, it 
was not explicitly spoken about. Although a research nurse spoke about judgement as a 
possibility with a patient who had learning disabilities where the patients consent was revoked 
by doctors. The patient’s clear inability to understand could be interpreted as ‘soft paternalism’ 
indicated as justified in certain trial situations (Jansen and Wall, 2016).   
There was a possibility of precluding patient autonomy on the grounds of family 
influences, although doctors often welcomed families in the decision-making process together 
with their means of social support, in-line with Knobf (2007) and Corrigan (2003) who 
applauded relational autonomy as a means of facilitating informed consent. It was the nurses 
and managers who felt uncomfortable about what they felt was family pressure on patients 
which research nurses believed failed to meet individual autonomy requirements and were 
perceived as a barrier to patient consent specific to the CCT setting, in keeping with theorists, 
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(Bell and Balneaves 2015; Hussain-Gamble and Leese, 2006). Interestingly, none of the 
participants explicitly suggested more training to assist them with these family and cultural 
issues.  
9.4 Strengths and Limitations of the research 
The methodological strengths and limitations were considered in relation to the 
phenomenological approach within the case-study setting where the insider researcher 
interpreted the experiences of the participants.  
The case study 
For the most part the phenomenological approach within a case study setting provided good 
access to the interprofessional group involved in obtaining patient consent situated within the 
boundaries of the Cancer Academic Group (CCT real-life practice setting). In-line with Polit 
and Beck (2012), the case enabled insight into how participants behaved and clarified concepts 
and was enlightening of other relationships, for instance how doctors welcomed the research 
nurses challenging their decisions.  
However, in this case study two main limitations were identified that pertained to the 
research methods used and the generalisability of the study. Yin (2008) advocates using 
different sources of evidence, but this study mainly derived evidence from the interviews with 
participants and the reflective diary to interpret these experiences from different level 
professionals. On reflection, the use of observation as a data collection tool could have 
provided more rigor enabling more insight into the professional-patient interactions as it would 
have provided first-hand information, as opposed to professionals relaying how they 
experienced it. Yet, early on in the planning, I decided against observation, which could be 
seen as a limitation as observational data may have enhanced the generalisability. The reason 
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I decided against observation of a potentially contentious patient interaction was that it could 
prove difficult and may interfere with patient care and translators services were already 
struggled. Although there was an attempt to seek a pattern as case studies can do over time 
(Polit and Beck, 2012), I was only able to obtain one second interview due to the time 
constraints of the clinical staff.  
Case study and phenomenological generalisability 
Initially, the Integrated Research Application System (IRAS) did not gleam that the study 
would provide generalisable findings. To overcome this challenge to generalisability, it was 
recommended that the study ought to go through clinical effectiveness, which in turn approved 
the study commencement along with the RHUL approval with no ethical concerns. My 
supervisor recognised the knowledge sought could contribute to clinical practice and the 
sociology of informed consent, and I have illustrated how the case study could formulate a 
theory for practice.  
However, the generalisability of the case study could be difficult to defend because the 
findings reflected a particular situation or culture / way of working within this centre. For 
instance, one consultant explained that they did not involve the research team until much later 
and after the patient had consented. This way of working even differed from one cancer sub-
speciality to another, never mention the potential for different ways of working in another  CCT 
centre, plus as one research nurse explained the nurse seemed to align her practice with the 
residing physician. These examples show the difficulty in making generalisations on the basis 
of human interactions and unpredictability. Moreover, the thrust of the research was to voice 
clinical practice and advance it which held meaning for me as a practitioner and researcher. I 
wanted to understand how each professional group viewed their own role and how they 
interacted with each other within the social context of the case study. One way to look at it is 
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that as Thomas (2011) explains, abduction is possible which he explained as deriving 
conclusions from day-to-day generalisations as opposed to induction described as conclusions 
from specific generalisations. The case study none-the-less sought the practice experience 
informing the practical knowledge. ‘It is in practice that phronesis (as Aristotle found) is 
developed and in practice that it comes into play’ (Thomas, 2011, p. 214). The themes held 
specific meaning within the diverse CCT setting but could be generalisable in a similar cancer 
diverse setting, or within the general trial setting. 
The limitations of phenomenology 
From the outset, I felt that seeking the ‘lived-experience’ in the natural practice case study 
setting where the researcher was also a practitioner would make sense of the consent practices. 
However, I was mostly reliant on what the participants said when essentially it could be 
perceived as their interpretation of events and not the reality as ethnography would more likely 
reveal.  
There was a deliberate decision to undertake interpretive phenomenology. This choice 
accounted for suppositions, assumptions, knowledge and experiences within the research 
(reflective) diary by exercising reflexivity in keeping with Heidegger (1889-1976) who 
emphasises that we cannot stand outside our understanding. Although descriptive 
phenomenology developed by Husserl (1859-1938) may limit the meaning of the data because 
it brackets the practitioner’s interpretation and reflection, its use could have provided more 
objectivity of the data and would have been less of an emotional conflict for the insider research 
practitioner as discussed below. However, having considered the researcher’s role as a 
practitioner (research nurse) and a manager it was very difficult to bracket out the knowledge 
and personal beliefs as is required in a solely reductive approach (Streubert and Carpenter, 
2011), which is the essential difference with interpreting experiences.  
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The limitations of differing role identities 
The familiarity I had with the group whom I interviewed made objectivity difficult as my 
differing role identities were at loggerheads as outlined in the research methods chapter. The 
roles were the research nurse’s role  (clinical duty), the manager’s role and the researcher’s 
role, although my clinical duty to the patients took priority.  
To enable reflexivity, I had initially intended to use the diary to assist me with a 
complete cycle of reflection thereby interpreting each theme identified, as advised by van 
Manen (1997). I quickly realised that complete sense could not be made of these experiences 
in real time because reflexivity carried on for the entire study including the write up, and 
reflection-on-action (Schon, 1987) was more appropriate and fruitful. Secondly, there were 
differences between what Argyris and Schon (1995) termed the espoused theory (world view 
of behaviour as guided by values and beliefs) and theory-in-practice (behaviours driven by 
values and beliefs in reality) for both myself and my participants. Suffice to say that there were 
boundaries because of my practitioner researcher role that limited my actions although my 
beliefs of what ought to be as a nurse or manager sometimes differed.  
The nurse / clinical role 
As an experienced cancer nurse my underlying assumption that doctors may not recognise the 
value of nurses in obtaining informed consent was uppermost and therefore I did not expect 
professions to challenge the traditional standpoint. I had seen how hard it is for nurses to 
challenge medical decision-making to ensure that the patient was given a voice and sufficient 
time to consent to high risk cancer treatments. I had lived the moral dilemma of caring for 
vulnerable patients, wanting to protect them, when faced with treatment decisions that I felt 
they may not be suitable for, posing a challenge to the patients’ best interest. I questioned how 
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managers could improve practice or if it mattered to them. These experiences possibly over-
elevated my empathy towards nurses because of the struggles they faced.  
Furthermore, my suppositions as derived from experiences with patients were a strength 
because they caused me to have a valid viewpoint based on contemporary practice. I believed 
that obtaining informed consent in reality cannot rely on patient autonomy to fulfil the ethical 
principles of consent in the instance of many diverse cancer patients. I felt that the policy did 
not appropriately reflect practice for this patient group and could be misinterpreted. I had lived 
the journey with patients in gaining their trust, which I felt was more meaningful in gaining 
consent validity than autonomous consent.  
The manager’s role 
The research practitioner’s role as a manager proved initially desirable in making the research 
application locally because of the possibly of bringing patient benefit and revenue capture for 
the Department due to increased uptake of patient consent. However, the study was intended 
to highlight consent issues through the experiences of professions as opposed to any promise 
of improved recruitment or financial gain. Another strength in my managers’ role was that I 
perceived that staff would communicate issues to me. For instance, many nurses spoke of 
patients being ‘pushed’ into the trial, or not getting enough time, or their challenges not being 
heard, but I was bound by confidentiality not to disclose unless a concern was raised.  
The researcher role 
One of my main strengths was the degree of collegial trust that the participants had in me as a 
clinician to begin with and as a fellow colleague whom they confided in. As an insider 
researcher, I was most flexible in the planning of interviews and moving them at short notice 
while factoring into the researcher’s own job at the same time. The usefulness of the diary and 
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reflection only really came into its own when the thematic analysis of the interviews was taking 
place because of the annotations inserted in the margins indicating direct interpretations of the 
contextual reality experienced by the researcher as a practitioner. For example, when nurses 
expressed unhappiness about the persuasive language used and how they could not challenge 
decisions on the grounds of patient unsuitability, I was able to confirm my own assumptions 
by these recurrences, thereby also validating the themes.  
One of the limitations of the study was that the research was time dependent on the 
clinical professionals’ availability which had a particular impact on the recruitment of medical 
participants, although a sufficient number were very willing to participate. It took me by 
surprise that doctors were interested in taking part regardless of their lesser time availability as 
they were essential to the findings. 
Insider researcher sampling bias by purposefully selecting participants who would 
provide experiences that answered my questions in a way that met with my assumptions is 
defended. The snowballing effect counterbalanced this from occurring, together with the 
practice of research ethics, for example, member checking of the data and frequent reviews by 
my supervisor. Furthermore, I firmly held back my views, and only encouraged in the form of 
probing. My experience of counselling training was most beneficial in this regard. I was aware 
of the possibility that interviewees might communicate practice that misaligned with policies. 
Furthermore, the interview could be and was used as a means of venting their concerns which 
the purpose of the research was not intended to resolve. Within the ethical considerations I 
have shown ways to best manage this constraint by deliberately not interviewing line managed 
staff and by offering an impartial staff support facility. 
Another limitation of the study was that no clinical nurse specialists were interviewed 
although their input to MDT decision-making was spoken about at length by doctors. It is 
 
 179 
uncertain why CNSs did not participate, although they may have not perceived themselves as 
part of the research team but their practice outside of the research team could cause 
fragmentation of care. 
9.5 Implications for practice and future research 
This study has added value to the CCT practice of obtaining informed consent by challenging 
traditional practice. The study emphasises that informed consent is an interprofessional 
practice. Within this section, recommendations will be provided for incorporating this 
interprofessional view into CCT practice, as well as for future research. These 
recommendations will be aligned to the main findings of the study, thereby addressing the 
original research purpose and questions. 
9.5.1 Multi-disciplinary decision-making 
It appears particularly from the accounts of senior doctors and nurse managers that there was 
a definite responsibility for Research or CNS nurses to be involved or ‘challenge’ MDT patient 
decisions, thereby challenging what often is purely medical decision-making. This is a change 
in culture for the interprofessional team, in terms of how they involve themselves or are 
accepted by other professionals. Senior doctors had experienced the relational value of nurses 
with patients due to their (doctors’) lack of clinic time.  The reason why nurses were valued 
was due to their relationships with patients which positioned them well to express the patient 
preferences and provide a more accurate patient suitability assessment which avoided 
‘pushing’ an unsuitable patient to consent to the trial recommendation. Upcoming doctors 
focused mainly on the interprofessional contribution to patient safety as opposed to nurses’ 
value within decision-making. However, in practice nurses struggled to voice challenges to the 
MDT decisions due to their fear of not being heard or due to their lack of CCT knowledge. It 
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is questionable how much support managers could or did give to the nurses who felt this way. 
It could be possible for managers’ to improve the support of nursing involvement in the earlier 
suitability assessment and within the MDT, which I found myself more responsible for 
encouraging in my managerial role, thereby potentially enhancing or challenging medical 
decisions. While the Improving Outcomes (2011) mandated multi-disciplinary involvement in 
MDT decision-making, still the interprofessional presence is lacking. As physician bias (based 
on individual patient suitability assessment) could be a reason for MDT decision changes, so 
too can the interprofessional suitability assessment be reason for MDT challenge as well as 
eliciting suitable trial patients.  
9.5.1.1 Recommendation for MDT practice 
• The standard operating procedure  (Sop) for MDT practice should be made available to 
the MDT members, showing the alignment with Improving Outcomes (2011). Within 
the Sop; it is suggested that a directive is issued/revised by clinical managers to allocate 
nursing time for the mandatory involvement of CNSs and Research nurses in the MDT 
decision-making.  
• The mandatory interprofessional involvement should be supported by clinical managers 
(alternating their attendance with other clinical leads) wherein their visibly 
demonstrates support by their contribution to MDT decision-making, essentially 
‘walking the walk’. 
•  Research and CNS nurses or other professionals ought to be encouraged to present 
patient cases (and patient preferences if known) wherein they will have an opportunity 
to highlight patient suitability for the suggested trial.  
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• For patients who are presented as possible candidates for a trial, nursing suitability 
assessment should be undertaken first before the patient consent discussion, especially 
before the time of signing of the consent form.  
• Interprofessional MDT attendance should be monitored by role checking to meet the 
percentage requirement and for auditing target attendance purposes.  
9.5.2 The consent discussion with patients 
It  was identified that often research nurses were not involved in patient care until after patients 
had signed a consent to the CCT, which both they and many consultants felt was not soon 
enough in the process of informed consent. The main reason why nurses seeing the patient 
earlier in the process was important was that nurses were depicted as essential to the process 
of information-giving whether at the time of or after consent by clarifying and checking if the 
information given was understood. This role (responsibility) of information-giving was not 
only considered part of the nurses’ role, but was considered by senior doctors and managers as 
essential to ‘good’ informed consent. Yet, nurses themselves did not feel they were responsible 
for obtaining consent, but were upset if they were excluded from their information-
giving/checking role.  
9.5.2.1 Recommendation for obtaining consent  
• Managers ensure that patients are seen by nursing staff prior to or within their consent 
to CCT discussion as part of the Sop for undertaking consent. Their role should be 
defined as an information-giver and an information-checker who are encouraged to 
highlight lack of patient understanding or misinterpretation of the trial. 
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• Ensuring this interprofessional inclusion should encourage and emphasise the nurses’ 
role as a patient advocate highlighting their responsibility for ‘Prioritising People’ in 
accordance with the NMC Code of practice (2008).  
9.5.2.2 Research recommendation for interprofessional practice 
• A qualitative study ascertaining the quality of  patient consent that accounts for earlier 
nurse involvement. This would be both a patient and staff facing study. The aims of the 
study could be fourfold;  to find out whether patients understood the purpose of the 
trial, whether nurses felt patient preferences were included in the trial decision, whether 
the uptake of CCTs has increased, and whether the attrition from the CCTs has 
decreased. 
Both these practice recommendations should address how the undertaking of interprofessional 
responsibility as shaped by time can be enhanced. Nurses challenging or contributing to 
decision-making together with providing and conveying essential suitability checking 
information could be perceived as a challenge to the traditional medical standpoint of 
responsibility for informed consent in CCTs. Most nurses felt that they did not hold the 
responsibility for consent. It is likely that the success of these recommendations may rely on 
or bring about a cultural change as a result of how nurses exercise their professional confidence, 
identity and acknowledged role.  
9.5.3 Trust underlies obtaining informed consent 
To enable informed consent to CCTs, the theory for gaining consent was clearly shown as an 
interprofessional combination of doctors gaining of the ‘initial’ patients’ trust, and the nurses / 
frontline staffs’ maintenance of that trust. Both appeared to hold equal value. Competency 
based trust relied on relational trust. These findings are impactful for CCT practice and 
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necessary to communicate to the professions. At each junction the availability or possibility of 
trust could be unattainable or eroded because of communicative practices for example 
disrespect, targets, mismanagement of trial uncertainty or team transition. The NCPES seeks 
to find out if patients have confidence and trust in doctors and ward nurses by asking only two 
questions, but does not seek to find out how trust is gained or eroded. 
9.5.3.1 Recommendation for trust 
• Managers (nurse leaders) should ensure that during the handover of patient care staff 
are required to name an appropriate professional to whom the care is referred. The 
reason for the handover of care is explained while reassuring the patient that they will 
not break contact but the research nominated professional is more knowledgeable about 
the trial or the nurse specialist for their on-going care.  
• The National Care Patient Survey (generated by NHS England and NHS Improvement) 
could ask more questions about how trust can be gained, maintained or eroded. This 
would allow for these answers to be responded to as part of the already in existence 
local patient experience action plan. 
• Further trust related recommendations are found under the education sub-heading. 
9.5.3.2 Research recommendation for trust  
An ethnographic study may be a suitable research approach to ascertain the availability and 
decline of patient trust. The aim of this study would be to ascertain the behavioural traits of 
CCT patients by the observation of trustful behaviour and to ascertain how these traits can be 
mapped to patients’ willingness to provide informed consent to CCTs. Running alongside the 
patient observation could be observation of the associated interprofessional behaviour/s that 
correspond such patient trustful behaviour. 
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9.5.4 Consent Policy 
The policy for consent taking is focused on actualising individual patient autonomy. In many 
instances it was difficult to achieve complete patient autonomy due to lack of patient 
willingness to make decisions or their mis-understanding of the trial purpose for example in 
‘desperate’ phase 1 trial scenarios. Also, individual autonomy may not be always achievable 
for patients from diverse groups who are non-English speaking or who are illiterate. Nurses 
and managers expressed discontent or discouraged respectively a practice that involves the 
family members in making consent decisions. A minority of physicians appeared to challenge 
the ‘rigidity’ of consent policy by emphasising the need to directly involve the family of ethnic 
minority groups in informed consent, thereby formulating a need for policy allowances in these 
instances.  
9.5.4.1 Recommendation for consent policy 
• The roll out of the policy should be clearer by adding a concluding sentence that does 
allow for the inclusion of the family in the consent decision to accompany the impartial 
witness (translator). 
• The pitfalls in the way the policy is interpreted should be included within the GCP 
training or local training on consent taking, for example to make clear that the family 
involvement can support and be involved in the family consent decision. 
• The provision of institutional improvements to support language barriers by ensuring 
that translators are more readily available at the time of information delivery and 
consent taking when the family member is present. 
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9.5.5  Consent training  and education 
Although generic consent taking courses are taken online as part of Good Clinical Practice, 
there is a need to enhance professional communication skills or prepare staff for the needs of 
the diverse CCT patient group. An education session could be delivered locally to address the 
following items. 
• The correct interpretation of the newly revised Sop for consent taking by demonstrating 
examples of poor interpretation. This could be delivered using role-play scenarios.  
• Highlighting of the 4 ethical domains to be met within the consent discussions with 
patients in accordance with Brown et al. (2004).  
• Training that incorporates a revision of the difficulties with patient understanding of 
different clinical trial phases by giving examples.  
• The use of an anonymised patient case study to demonstrate the suitability and 
eligibility criteria. 
• Training (to include ward staff) that includes information about how to respect patients 
generally and cultural practices specific to particular ethnic groups engendering trust 
for example appropriate body language. 
• More readily available trial information for ward staff allaying misinterpretations and 
fear of clinical trials. 
• Communication training via role-play scenarios led by an education facilitator 
requiring informal peer review of role-played professional-patient interaction/s.  
• Further interprofessional research is encouraged within the Department and that IRAS 
welcomes qualitative research studies.   
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Adopting these managerial recommendations may be challenging due to additional 
work for clinical managers and the reluctance to make cultural changes. However, the first step 
is to set these recommendations out to the clinical effectiveness team and research gatekeepers 
who have been and can provide practical support to clinical managers and professionals aiming 
to improve CCT practice by assisting with putting interventions, audit or study proposals in 
place.  It is intended that the findings of this study will be communicated via a series of papers 
in relevant journals for example, Clinical Trials or The Sociology of Health & Medicine. This 
will facilitate the adoption of the findings in this study for consent practice improvements, 
advanced practice or Masters courses in the future. Such publications would also support 
qualitative research attaining greater recognition within the Integrated Research Application 
System. 
9.6 Conclusion 
The way contemporary informed consent in the CCT setting is obtained has challenged the 
medical standpoint, and elevated the need for interprofessional responsibility. The boundaries 
between the medical and nursing profession in relation to obtaining and maintaining informed 
consent to CCTs are defined for their contribution, although roles do overlap. This research 
has shown the importance of promoting professional values, respecting interprofessional 
communication as opposed to unchallenged prevalence of the hierarchical dominance 
(Warelow, 1996). The social process of consent has a function in achieving the necessary 
relationship between professionals and diverse cancer patients to break down the known 
communication challenges enabling and improving informed consent to CCTs. It is hoped that 
this thesis not only contributes to the sociology of the professions but can also impact 
improvements in interprofessional communication and practice needed to enhance informed 
consent to CCTs.  
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The possibility of valid consent if relied solely on patient autonomy is seen to be 
subordinated by the relational component of informed consent wherein patient trust in 
professionals above all else obtained informed consent to CCTs. I leave you with the words of 
Stephen R Covey (1932-2012): 
“Trust is the glue of life. It’s the most essential ingredient in effective communication. 
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Appendix C4.1 Cumulative Literature Search History 
Limits applied (2003- 2018; refined to last 3-5 years if yield too large, peer reviewed, adults, 
English speaking, exclude meta-analysis, include literature reviews & discussion papers if 
relevant) 
Search 











selected for initial 
review (new) 
S1 24 9 0 15 
S2 16 12 0 4 
S3 29 17 5 12 
S4 29 0 20 9 
S5,6,7 23 13 7 3 
S8 22 8 7 7 
S9 14 11 3 0 
S10 0 0 0 0 
S11 100 67 1 32 
S12 17 15 0 2 
S13 34 30 1 3 
S14 52 49 0 4 
S15 47 44 1 2 
S16 88 73 3 12 
S17 279 274 1 4 
S18 57 53 3 1 
S19 46 28 11 7 
S20 42 33 6 3 
S21 81 74 7 5 
S22 2 0 2 0 
S23 81 47 31 2 
S24 27 20 3 4 
S25 51 35 10 6 
S26 1 0 1 0 
S27 48 35 6 7 
S28 3 0 2 1 
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Appendix C4.3 Synthesis of Literature- (Using adapted CASP tool) 
(Focus on interprofessional qualitative)  
Nursing research / Interprofessional/ Nursing practice (From search history & referenced) x 24 
Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 
Limitations  Strengths  
Kao et al. (2017) 
 
European Journal 






Varied- Qualitative & quantitative Literature review- Communication strategies for 
informed consent (IC) to CCTs 
 
(Good assessment of patient knowledge & 
understanding; showed post communication 
skills- no more knowledge, but more time for 
decisions given, & more patient satisfaction 
CCTs). 
 
Time was an important component in 
reassessing patient understanding of 
information. 
Few studies that looked 
at qualitative data to 






Nursing – invalid tools 
for measuring 
Good filtering system 
 
Filtering driven by patient 
understanding outcomes 







nursing and math’s. 
 
Search C1- Ref 
study & C3 
Surveys to 446 members of 
Oncology society- 43% 
participation. SPSS- exploratory 
factor or related themes. 
To ascertain the perceptions of oncology 
nurse’s perceptions of CCT conduct- 
(physicians’ conduct).  
 
Predominance of patient hope and unrealistic 
expectations & lack of understanding of trial 
 
Willingness of patients to participate even if 
limited efficacy 
 
Consent mostly misunderstood, freely consented 
Care of trial patients-better as supported- not 
assessed 
Perspectives of nurses 
only examined 
 
Did not seek their own 
experiences of their 
practice 
Good-Nurses who were 
mainly  
involved with trial patients 
 








Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 














patients/ 20 carers- intervals before, 
80 days post, 365 days post 
To examine how patients and carers decide to 
participate in stem cell transplant research 
studies / treatment options.  
 
Majority decided to participate before consent 
consultation. 
 
Pts felt no other option, followed Doc’s 
recommendation, not wanted to hear all 
information, Altruism x 4 as reason for choice. 
Nurses only discernment 
Only those who decided 
to participate were 
discussed 
Nurses identified key themes- 




content, usefulness of 
paperwork.  










Observation in clinics, and semi-
structured interviews with patients 
(37) & providers (15). 
 
To provide ethnographic insight into the ways 
in which research is discussed and related to 
standard treatment.  
Communication struggles with initial 
presentation of RCT, patient not remembering, 
Initial purpose to ascertain if patient interested, 
no % outcomes given- likened to assenting.  
 
Pt showing therapeutic misconceptions. 
Immediate patient concerns and questions re 
doses pushed aside. Doctors –lack of 
information clarity.  
Role of navigator to give more information and 
act as advocate- competing ethics between 
roles.  
Participants were paid 
Do not know for sure if 
navigators were nurses. 
 
Done in specific clinic-? 
if generalizable.  
Qualitative themes identified  
 
Different roles identified  
(unclear how many nurses) 
 
Objective view from outside 
the professions. 
Strength in the quality of 
observation.  
 
Pts from all demographics –




Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 









Search C2  
Quantitative- 
 
Questionnaires- assessing activities: 
frequency and importance of role 
components. 
 
Analysed by SPSS, Likert, Chi-
square. 
To assess the role of the clinical trial nurse- 
30 participants. 
 
Role highly valued by physicians and team. 
 
IC- thought to be most important, but 3rd most 
frequent activity 
Roles included 3 advocacy components -balance 
of rights, study quality,  
Nurses gave appropriate language, verifying 
information, oversaw form signing.  
Given options to choose 
from 
 





Gave CTN role clarity by 
frequency of tasks  
 
Gave importance as per 
nurses’ view 
 
Approved data collection tool 
(CTNQ) 
 
Referred to Ocker & Plank 
(2000) 
-similar findings- role 
advancing to include 
organisational, clinical & 
ethical 
Davis et al. (2002) 
 












3 vignette focus group interviews: 




To assess the challenges of protecting subjects 
 
(From the perspective of the CTN) 
Study coordinator encompasses several roles , 
centrality in relationships, complexity of 
relationships, role expectations and conflict of 
role 
 
Key advocacy role components identified: 
Patient advocate- for needs, interests & welfare 
Subject advocate- to enrol, understanding, risk & 
safety, lawyer-like- protecting rights 
Study advocate- research goals, clean data, 
career less, police 
Conflicts- re caring & detachment, hope v 
realism, resonate with duality of physician, less 
trained 
Would they have been 
less outspoken if 
medical professionals 
included 
Sought the nursing 
perspective of consent to 
CCTs 
 




Conflicts within role 
 




Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 
Limitations  Strengths  













Using CTNQ to quantify. 
 
Themes derived from quantitative 
date and analysis 109 survey 
participants 
To define the role of the CRN (research 
nurse) 
 
Most likely to be involved in the SIV and not in 
the developmental stage and in IC and 
recruitment 
CTN- assessed IC- mostly verification, patient 
satisfaction, goal and purpose, continued 
consent, Act as advocate-ensuring IC 
Recruitment- not a view, except communicate 
information, barrier factors,  
IC- did use appropriate language, explained, 
helped decision making (DM).  
Given options as 
opposed to relaying 
narrative 
 
No assessment of trust 
 
Poor for assessing social 





Recognised tool used to 
assess 
 
Nursing role clarity- for 
themselves. Self- affirming 












67 CTNs surveyed (cross sectional).  




Themes derived from quantitative 
date and analysis used 
To ascertain the role of the CTN 
Showed complex role – due to the combination 
of contractual and accountability arrangements 
 
Encounter practical and ethical issues 
 
Frequency and importance of role assessed 
Involved in IC- higher frequency, 2nd- 
implementation, 3rd –data, 4th- recruitment 
Importance- 1st IC, 2nd- Data, 3rd- Investigational 
procedure, 4th- Protocol planning 
Professional issues- undervalued, lacked 
education and confidence 
Given options as 
opposed to relaying 
narrative 
 
No assessment of trust 
 
Poor for assessing social 
dimension of the 
relationship 
Tool used was effective 
Correlation between 
frequency and importance of 
role in IC 
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Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 














Testing of CTNQ (Clinical Trials 
Nursing Questionnaire) n=40 
 
Focus group assessment 
Reliability of tool verified  
Assessed by focus groups and expert judges 
Met the desired outcome 
Has responsibility to ethics 
Recruitment in approaching patients and 
information giving 
Small group Significant for nursing role in 
research 
 









done by nurses, US 
 





Cross sectional descriptive model 
for 197 pts 
Themes identified 
To describe factors and outcomes related to 
the decision-making process regarding 
participation in CCTS. 
 
SDM (shared decision making was most 
frequently preferred) v patient autonomy-83% v 
17%. 
Examining disease and socio-economic factors 
Multiple other factors assessed that influence. 
Hope & Trust were predictors; more trust in 
healthcare system than doctors 
Decisional conflict reported after the decision 
Suggested- Shared family DM is preferred  
Validity of the tool may 
be questionable 
 
Assessed after the 
decision to enter trial- 
may have skewed data 
New model not used before 
so innovative 
 




economic factors in DM 
 
Leaning towards the social 
dimension of consent 












Focus group, N=9 
 
Explores the potential contribution of CRNs 
to clinical trials. 
 
Showed role in transition- lack of confidence, 
role conflict between clinical and research role, 
challenges for nursing staff with patient 
compliance- gaining consent but not 
cooperation, wide range of skills and knowledge 
identified, RCT issues and self-motivation. 
Not focused on CCTs- 
general Clinical trial 
focus 
Small study of 9 
Focus groups could 
have impeded flow of 
conversation 
Still relevance for CCTs 
 
Lack of confidence in like in 
Wilkes study in Australia 
Similar to Davis; Mori & 
Mullen; Catania for conflict 
and advocacy respectively 
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Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 
Limitations  Strengths  
Easter et al. 
(2008) 
 












Mixed to find themes Quantified the 
thematic findings- helpful for 
thematic priorities 
 
Interviews closed and open- ended 
Coded and electronically divided 
into codes- themes 
 
Telephone interviews 
To find out a normative model of care in 
research- what physicians perceive of their 
research role, plus study coordinators 
(nurses), and patients.1/2 pts saw Docs and SC 
as taking care of them, ½ Docs said they were 
conducting research, 1/3 SC said they were 
conducting research.  
Pts considered research care differently, 
although as care,  
Research activities considered as care- i.e., 
monitoring side effects, Docs said care of 
research pts involved ‘two hats’, Docs made the 
distinction, SC appeared uncomfortable with 
just the research role. 
Many pts thought research happened elsewhere.  
 
Care described in positive terms; research in 
negative terms, SC said different to Doc as pts 
more comfortable- closer relationship, 
Research care was improvement on standard 
care.  
Not analysed by nurses 
 
Half the studies were 
cancer (9) 
 
Small size (37) 
 
Possible leading 
questions re care and 
title of study 
 
Telephone interviews 
curtailing quality  
Reasonably objective 
analysis, although doctors 
assessing own practice 
 
Takes account of study 
coordinators 
 
Two hats identified-Docs 
 




Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 
Limitations  Strengths  













4 focus groups, comprising data 
managers, 14 nurses 
 
Thematic analysis 
To ascertain views of data managers 
(sometimes nurses) of the nature and 
challenges of their role and differences 
between physician’s role.  
 
3 roles identified: 
 
Information provision-clarification of 
questions post consultation, RCT explained as 
level of detail not provided by doctor i.e.: 
logistics and practicalities, but unable to provide 
some info,  
 
Gave quality assurance-ensured true IC, 
verifying understanding, non-coercive, rights 
confirmed, gave balanced view, comfortable 
speaking to pts, felt IC still medical prerogative, 
pts valued on-going nursing support & QL 
discussions, inconsistent messages from team,  
 
Negotiated time-to discuss difficult patient 
issues, needs, cultural, language, 
misconceptions, ethical concerns if trial was 
disadvantage to pt.  
No doctors’ views on 
their perception of 
nurses’ roles 
Views of nurses heard 
 
Possibility of patient 
autonomy reduced, hence 
nurse role 
 
Highlighted need for more 
education and training for 
research 
 
Showed Docs limited time 
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Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 
Limitations  Strengths  
Kass et al. (2009) 
 












12 audiotapes of patient oncologists 
with 84 pts agreed to be taped.  
30 pts were offered ph 1 and 35 ph 
2.  
Patient surveys 45- 60mins 
structured surveys on purpose & 
benefits of CTs. Pts were re-
contacted after 1-2 
To find out what patients understand from 
oncologists’ clinical trial discussions.  
 
Options discussion- almost all oncologists stated 
safety and dosing re phase 1. Then quickly 
moved to discussion about the therapeutic 
intent using ‘therapy’ and ‘medicine’, one of the 
efficacy for the research purpose, or another 
treatment option 
 
Ph 2- more on the efficacy discussed 
Survey-54% said purpose was to see if trial 
worked / benefits- more with ph 2, 11% to cure. 
Ph 2 more likely to mention dosing. Only 12% 
said purpose was safely & dosing from both. In-
depth interviews- 18/27 described purpose.  
Most joined because good chance of survival. 
Docs re-enforced the therapeutic intent- ph 1 
‘might work for you’ 
Decision 68% planned to join 
58% said trial had promise 
Audiotaped discussions 




explored with doctors 
 






week after the survey 
 
 
Key themes identified from 
discussions- much hope given 
in early phase trials, mixed 
messages about trial benefit 
 
May lead to pts therapeutic  
Misconception 
 
Good data management-  
Coding by 2 staff members  
Random selection of tapes 
Interviews coded & entered 
into electronic system 














455 primary care NPs, 53% 
response, 173 unusable, Attitudes 
measured on Likert scale assessing 
if comfortable discussing CCTs, 
Ethical 8 points on a scale, high 
risk, RCTs, Beliefs,  
Nurse practitioners’ attitudes and beliefs 
towards CCTs, and if they would recommend 
to a patient.  
 
2/3 in favour of recommending, 1/3 time was an 
issue, ½ wd prefer themselves on trial, Issues 
with RCTs,  
 
50% comfortable discussing, 2/3 wanted to 
maintain a relationship- agreed would leave to 
doctor, ½ felt would get better care on trial, 50% 
ethical concerns over RCTs- high risk and 
guinea pig worry.  
Large lack of response 
 
NP do refer to tertiary 
centres 
 




Is the discomfort more 
related to cancer trials? 
Highlighted important themes 
- 50% not comfortable 
discussing 
 
¼ were positive re trials 
 
Unlikely to recommend 
 
Ethical concerns  
Leave to doctors 
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(highlighted relevant themes) 
Limitations  Strengths  












Did not explore the experience of 
IC 
Amalgamation of 2 roles- no data 
on same from UK perspective 
To evaluate the oncology nurse navigator role 
in terms of CCTs recruitment & cost 
effectiveness 
 
39% increase in black breast ca recruited 
patients of the 86% that were eligible 
Only cost / role analysis 
 
Showed nurses role in 
eligibility, screening of pts, 
and nurses’ definite 
involvement in IC 
 
Good focus on the cultural 
deficits in recruitment- 
benefits of community 
navigation  
Hussain-Gamble 




Health policy and 






In depth interviews with 60 South 
Asian women; topics were- 
terminology, DM, WTP, 
recruitment and trial involvement 
 
25 HCPs (mix of docs and nurses, 
Coordinators, academics); topics- 
barriers to trials, the way forward. 
 
Thematic analysis 
Exploration of Asian population view of 
research to include the professionals view of 
the population 
Pts showed no antipathy towards trials 
Motivation was altruism/helping community 
Tension between personal responsibility and to 
community / worried about who would look 
after family 
Deterrent- testing drugs and long -term side 
effects, Not being approached as a concern, not 
being referred, felt ethnicity of doc mattered 
HCPs- more than ½ said language was a 
problem- causing extra burden on staff, 
interpreters- not readily available and can distort 
information, lack of time, poor organisational 
support, Age-worse language problem, young 
people not always available, felt at risk signing, 
often declined. HCPs shocked if these pts were 
excluded, thought ‘passive’ lack of inclusion- 
due to institutional racism/problems, pts were 
‘cherry-picked’.  
Lack of familiarity & cultural insensitivity-
stereotyping i.e., poor time keeping, women lack 
of interest, mistrust, that doc looked down on 
patients, women were not intelligent, Muslim 
women would not seek care. 
These people had not 





patients included –context 
specific 
 
Both nurses and docs 
interviewed 
 
HCPs –gate keeping 
highlighted and stereotyping 
these women 
 
Language as huge problem 
 
Highlighted value of ethnic 
minority doctors 
 




Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 
Limitations  Strengths  
Corrigan (2003) 
 
Sociology of Health 
and Illness 
 







Participants as in aims and semi-
structured interviews.  
 
Thematic analysis. 
To analyse the social process involved when 
ph 1 patients and healthy volunteers consent 
to clinical trials.  
She examines the process of consent, from 
perspectives of patients, volunteers (26), nurses 
and doctors (7).  
Not a ‘one-time event’ 
Main focus- events leading up to consent, 
reasons to participate, factors influencing, 
benefits, risks, understanding of trial. 
Informed subjects- unclear re RCTs and 
misunderstood, struggled with complexity of 
information. Pts understanding based on 
previous experiences.  
Generalisation of side-effects were unclear- 
‘smaller number’ 
Terminology used was important- this one uses 
‘study’- loaded with positive connotations.  
Few were concerned re side-effects / mainly 
subjects did not express a great deal of concern 
re side-effects.  
Subjects tended to believe that drugs tested were 
safe- possible therapeautic misconceptions 
implied. 
Subjects showed trust in doctors, nurses and the 
authorities- felt reassured drugs were tested on 
animals.  
Pt used term guinea pig- illustrates he was object 
of research.  
Choice- pts felt they were not coerced, but 
unclear about an alternative. Consented because 
wanted better treatment, and willingness to 
please the doctor.  
Doctors- felt mutual participation, equipoise is 
satisfied by genuine uncertainty. Pt when offered 
is looking for advice & reassurance. Volunteers 
had no prior expectations. Pts asked for more 
time.  
Limits -Pts may have 
been influenced to join 







Key parts of the lead up to 
consent examined 
 




positive statements leading to 
lack of understanding and 
therapeutic misconception 
 
Trust of patients 
 










Author & Journal  Design Aim & Findings 
(highlighted relevant themes) 



















16 informed consent discussions 
observed.  
Transcribed and coded using 
descriptive coding. 
To argue that the one factor overlooked in the 
theoretical paradigm that guides the practice 
analysis of IC- where the paradigm poses an 
ideal model of communication falls to include 
the social dimension.  
 
Overview of IC-mostly 100%, 81% no 
disclosure of alternatives, 6% no statement about 
withdrawal or confidentiality.  
 
Time was not a problem. 
Framing identified- over elevating the benefits, 
confused purpose of the trial, positive 
statements, confused therapy & experimental 
part, dosing schedule not clear, risks & benefits, 
FDA detracted from toxicity arm.  
Small amount of 
participants 
 
Only phase 1 observed 
 
Unclear arm of study 
 
Gave % for the 
statements observed 
(gives prioritisation of 
the themes identified) 
Coded, recorded and checked 
3 times 
Qualitative statement 
explained to discern the 
social meaning of the content 
Good data for phase 1 trial 
communication issues 
Refers in discussion to 
transmission mode of 
communication (Shannon & 
Weaver, 1949)- 
sender/receiver which fails to 







Search C1- referred 
to study, UK 
 
Nursing Research  
Qualitative- 
 
55 patients assessed 
Via constant comparison of semi-
structured interviews 
To identify the psychosocial impact of 
participating in early anti-cancer drug trials 
 
Patients are ‘desperate’- (phase 1 and 2) the 
offer of a trial was seen as the ‘turning point’ 
Reasons for participating was that the offer was 
in their best interests 
Nearly 80% of pts wanted the HCP to decide/ 
DM was passive; 20% were active and 
collaborative inc families 
Deciding- ‘found it lonely’, active role- do not 
welcome responsibility 
Could weigh up 
Influenced by initial trial presentation in positive 
terms (‘study’ not ’trial’) 
 
Autonomy ‘over-ridden’ by positive approach 
Seeks the patient 
experience as opposed 
to the professionals  
 
Gave % of themes 
identified- giving 
priority to consent 
problems 




neutral person presents the 
trial 
Pts interviewed more than 
once (pre- and post-
recruitment) 
Insightful of pts perspectives 
Language used highlighted 
for its influence 
Could assess the 
communication of Docs and 
Nurses via pts perspective 
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(highlighted relevant themes) 
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Semi-structured interviews / in-
depth, audio recording of 
appointments, thematic analysis, 
Topics were rationale for trial, 
views on the arms, patient 
eligibility, patient preferences, 
recruitment difficulties, to measure 
the information provided and 
whether the patient participated 
actively. 
To explore the views and experiences of 
nurses recruiting patients into CTs in terms 
of their patient- centredness and patient 
empowerment. 
Nurses had keen sense of being clinicians & 
advocates, many practices made it difficult for 
pts to play active role in IC- undermining 
quality,  
Nurses had empathetic preferences, view of as 
intervention burdensome. 
Ethical unease re recruitment- due to patient 
misconceptions. 
Nurses scrutinised decisions made by MDT. 
Recruitment interactions- struggles to have their 
voice heard & the ‘silenced patient’. Active 
engagement confirming understanding,  
partially informed patient.  
Small number of 
participants 
 
The nursing experience; not 
only cancer trial nurses 
 
Dual roles identified 
MDT issues highlighted 
 
Unable to voice 
 
That nurses’ data was 
independent of the 
management team 
 
Two- pronged data collection 
















A hermeneutic phenomenological 
study 
Participants -25 patients, 20 nurses, 
patient advocates- 6 focus groups 
Interpretative 
Researchers were active participants 
in the interpretative process 
To point of saturation 
Had ethical approval 
 
 
To find out the meanings of ‘quality nursing’ 
care through the experiences of pts with 
cancer, their carer, and their nurses.  
 
How was quality assessed 
1-Easily accessible care 
2-effective communication- two-way, off set 
complaints, helped cultural 
3-empowered pts by giving information 
when often pts did not have enough, was vague 
or misleading, better than doc communication 
4- clinical competence engendering trust 
relationship, professional meant std of care and 
dedicated, 
5- Attention to spiritual, beliefs 
6- enabled SDM- promoted clinical 
effectiveness, key to SDM was relationship with 
patient,  
7- Family presence- physical and emotional 
supportive role 
NOT specific to CCTs 
 
Only the nursing 




Small size- may not be 
generaliseable 
Useful for the importance of 
certain experiences denoting 
quality of care 
 
Could be generalizable 
because off concepts raised as 
relationship social dimension 
of care 
 
Empowered patient to SDM 
(Shared decision making) 
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Limitations  Strengths  














 91-interviews- 5 US centres 
4 stakeholder groups 
Cancer centre leaders, PIs (doctors), 
research staff, referring clinicians 
 
Coders used grounded theory 
To find out the perspectives of CCT 
personnel on the barriers & facilitators for 
clinical research pertaining to minority 
recruitment. 
1-Minority groups are influenced by scepticism. 
Facilitators at institutional level & participant 
level encourage participation-opportunities 
varied 
2- Potential barriers of offering – insurance, 
language discordance, non-English speaking 
forms, unmet needs, time issues, competing 
responsibilities 
3-Faciliators- developing rapport with groups, 
tailor made approach, assistance at institutional 
level, -built by individuals  
4- Internal & external means- nurses reviewed 
clinics for eligible pts, explicit by informing 
centres about trials, giving feedback as 
important 




Combination of professional 
views- multi-centre 
Interviewers were trained 
over 2 days, independent 
review of codes 
Power in individual rapport 
Nurses roles in discerning 
eligibility 
Main themes evidenced 
Distrust, Scepticism  
Language and education 
Level of skill and data 
collection excellent to include 
pilot and reviews 
Could apply to ethnic 
minority clinical setting 










Groups of items identified from 
statements 
 
Positive snowballing approach, 
consisting of 3 rounds of online 
surveys  
Participants- 5 groups, 222 in total, 
28 patients, 15 family members, 32 
physicians, 58 HCPs (including 
CCT nurses)  
Round 1- list the essential 
information 
2& Refinement  
Identifying essential information to support 
patient DM regarding participation in CCTs: 
A Delphi approach 
In order to improve IC 
Generated into 8 headings: purpose of trial, 
understanding of trial, participation in trial, risks 
and discomforts, benefits to future patients, 
ethics and governance, communicating the 
result.  
3 as essential (80%) 
Risks in relation to risk/benefit, ethics & 
governance, future pts, differences in care, 









Included nurses and doctors 
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For purpose of illustration of the 
points 
Data is the description of the case  
Limits to relational autonomy 
Palliative care case study of pain killer denied 
Nursing views on family (relational) influence 
on patients' autonomy 
Family denied on grounds that takes away pts 
autonomy because causes drowsiness 
Not CCT focused 
Significance of the case 
–showing how family 




This case circumnavigates 
patient autonomy 
Referred to Yang et al. 
(2010)- 80% docs prefer 
patient autonomy although as 
per Foo et al. (2013) – 60% 





Appendix C4.4 Synthesis of Literature Medline 8 Search 
Search Table 8 (Layout adapted from NICE, 2014). sequence = Search Trust, CCTs, Doctors 
13 hits of which 4 were discarded, leaving 9. Of these 4 were overlaps from previous searches; Madsen et al, 2007;Yang et al, (2017); 
Daughterty et al, (2005); Brown et al, (2011). The 5 new studies are presented below: 




Papers in Ref lists 
1- Fracasso et al. 
(2013) 
Coaching 








Screened 268 patients- a coaching 
intervention was evaluated v usual 
care (UC). (the coach gave extra 
education and support to pts 
allocated).  
End point to include those enrolled to 
trials.  
 
Assessing the efficacy of a coach in the impact on 
ethnic group recruitment. 
 
Findings: 
Higher quality of life (FACT- G QOL) and positive 
attitudes towards CCTs improved enrollment. 
Analysis of trial enrollment during or after 
intervention made no difference than UC for 
enrolment.  
Poor adherence related to depression 
Not usual care 
provision – so poor 
value add.  
 
Role of physician not 
assessed.  
.  
Barriers to CCTS for minority 
groups.  
Comis et al. (2009) 
Ford et al. (2008)- barriers to 
recruitment in under -
represented populations.  
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Papers in Ref lists 
2- Lee et al. (2016) 
Barriers and 
facilitators for CT 
participation among 
diverse Asian 
patients with breast 







16 participants, 5 focus groups, open 
ended questions, 2 moderators, 
coders 
Thematic analysis with NVIVO 
To examine the barriers and facilitators to CT 
recruitment in patients- with a particular focus 
on Asian breast cancer women.  
 
Findings: 1. Prevalent knowledge/attitudes- 1/3- 
lack of understanding, sought more info, range of 
attitudes (anxiety-optimism). 
2. Factors - Individual: family influences, ‘last 
resort’, more benefit, altruism. Barriers- previous 
bad experience with doctors and drugs, health 
care system, conservative/cautious- ‘less 
adventurous’. 
3. Factors related to CCTs- majority motivator was 
hope in trial, then lower cost, Trust in care, trial 
conduct- ethical, monitoring. Majority barrier 
was fear and uncertainty / and chance factor / 
stress of therapy. Main motivating factor= Trust 
in doctor/ local governance. In polite manner 
/pictures etc.  
Limitations: 
Small numbers 
No men interviewed 
But could be 
transferrable to other 




the barriers for ethnic 
groups for IC to 
CCTs 
Referred to literature: 
Mills et al. (2002)- difficulties 
with recruitment in ethnic- 
minority groups.  
Grandfield et al. (2002)- 
barriers classified as 
physician-related and system 
factors.  
Russell et al. (2008)- health 
care professionals’ attitudes  
Murthy et al. (2004)- mistrust 
and inconvenience as major 
barriers.  
 





phase 1 and phase 2 
clinical trials of 
cancer 
chemotherapy 
British Journal of 
Cancer 
Cancer research UK 
Quantitative- 
Questionnaires- open and closed 
ended questions. 
38 phase 1/11 patients participated.  
SPSS analysis was done 
 To examine the motives of patients to enter 
early clinical trials of novel cancer therapies. 
 
Findings: 
Asking their motivation- 17% said altruistic, 58% 
gave hope of therapeutic response. 82% - helping 
future pts, 89%- possible benefit, 66%- trust in 
doctors, 76% trust in nurses, treated by latest 
treatment- 66%, 61%- better follow up, 58%- closer 
monitoring. Men more positive, 47%- said 
alternatives explained, info sources- mainly 
oncologist-82%. 
 Referred to literature: 
Appelbaum et al. (1987)- 
patients lack of understanding 
of the therapeutic benefit.  
Self- interest as motivating 
factor- Daugherty et al. 








Papers in Ref lists 







Participate in CCTs: 




and Religiosity.  
 







898 respondents.  
2/3 Caucasians 
Monthly on-line or phone survey for 
a year randomly selected based on the 
knowledge networks panel. 




Distrust -Corbie- Smith on a 5 point 
Likert scale. 
 
Religious beliefs on a 1-5 Likert 
scale.  
 
WTP- measured by 3 parameters;  
1- might improve length of life, 2- 
improve  
QL, 3- might help others. All 3 on a 
1-10 scale of likeliness.  
 
Barriers to CTP scale 1-10. 
To explore the effects on individuals’ WTP in 
seeking trial information from doctors, 
interpersonal relationships and the internet- 
comparing as per title.  
And religiosity in influencing CT participation 
according to ethnicity. 
Knowledge and distrust – considered baseline 
predictors 
 
Findings: Distrust hugely reduced WTP.  
Caucasians- much higher levels of WTP 
AA- higher levels of religious belief, distrust in 
medical professions religious activity and distrust in 
medical professionals.  
For both distrust was negatively related to WTP. 
Concerns around RCTs. Factual knowledge was 
needed for WTP.  
For Caucasians seeking info from doctors was 
positively associated with WTP  
 
Religious was not a significant factor in WTP. 
Religious activity for Caucasians was associated 
with lower levels of WTP v AA from sources 
through the church. 
Not got the 
experiential instances 
that give these results 
Byrne et al. (2014)- why pts 
not participating- distrust in 
medical profession. 
Frank (2004)- knowledge of 
CT- important for WTP. 
O’Hanlon (2013)- African- 
American distrust due to past.  
More info re risks and 
benefits- Tanner at al (2014). 
Advanci et al. (2003)- AAs’ 
more likely to hold religious 
belief God would determine 
fate and decreased WTP or 
provides CT resources. 
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Papers in Ref lists 
5- Townsley et al. 
(2006) 
‘Understanding the 








Survey – analysis by stats and semi-
structured interviews analysed as per 
grounded theory approach  
Pt research – 94 elderly pts.  
To assess the attitudes of elderly pts to CCTs 
 
70% would participate if nothing else available 
Reasons to participate-Role 
1- Cancer physicians’ recommendation or for ALL 
participants or doc should decide, 2- to feel better, 
3- benefit others. 
Strengths- QC as per 





reduced question list 




paid ? increase 
possibility 
to enter the trial 
Cox (2003) – as above 




     
 
 224 




Papers in Ref lists 
Possible Related 
study x 3- 





















To assess pts comprehension of RTCs 
49 pts: Appalachian pts 
 
Uncertainty:-2 types of uncertainty; cognitive and 
affective (neutral and negative)  
 
RTC- increases uncertainty- as doc cannot choose 
treatment 
Regardless of level of comprehension, uncertainty 
still existed,  




Affective uncertainty- affected perception i.e. 




of labelling of codes 
as per 1-4 
investigators, memo 








Brown et al. (2004) 
Sinha (2007) 
Joffe et al. (2001) 
Featherstone & Donovan 
(1998) 
Brashers (2001) 
Avis (2010) – re 
advocates were 
previous trial or 
cancer patients 
    
Dellson (2011)- Not 
focus of current 
study as written 
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Appendix C5.1 IRAS Approval 
Full Set of Project Data IRAS Version 5.0.0  
Welcome to the Integrated Research Application System  
IRAS Project Filter  
The integrated dataset required for your project will be created from the answers you give to the following 
questions. The system will generate only those questions and sections which (a) apply to your study type and (b) 
are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding 
with your applications.  
Please complete the questions in order. If you change the response to a question, please select ‘Save’ and review 
all the questions as your change may have affected subsequent questions.  
Please enter a short title for this project (maximum 70 characters) The interprofessional experience of 
informed consent to cancer trials. A single centre case study. 
1. Is your project research?  
Yes No  
2. Select one category from the list below:  
Clinical trial of an investigational medicinal product  
Clinical investigation or other study of a medical device  
Combined trial of an investigational medicinal product and an investigational medical device  
Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical 
practice  
Basic science study involving procedures with human participants  
Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative 
methodology  
Study involving qualitative methods only -Yes 
Study limited to working with human tissue samples (or other human biological samples) and data (specific 
project only)  
Study limited to working with data (specific project only) Research tissue bank 
Research database  
If your work does not fit any of these categories, select the option below:  
Other study   
2a. Please answer the following question(s):  
a) Does the study involve the use of any ionising radiation? No 
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b) Will you be taking new human tissue samples (or other human biological samples)? No 
c) Will you be using existing human tissue samples (or other human biological samples)?   
No 
3. In which countries of the UK will the research sites be located?(Tick all that apply)  
England / Scotland 
Wales 
Northern Ireland  
UK 
3a. In which country of the UK will the lead NHS R&D office be located:  




Scotland Wales  
Full Set of Project Data IRAS Version 5.0.0  
Northern Ireland  
= UK 
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network 
(CRN) support and inclusion in the NIHR Clinical Research Network (CRN) Portfolio? Please see 
information button for further details.  
2  
No 





This study does not involve the NHS  
4. Which review bodies are you applying to?  
HRA Approval 
NHS/HSC Research and Development offices 
Social Care Research Ethics Committee 
Research Ethics Committee YES 
Confidentiality Advisory Group (CAG) 
National Offender Management Service (NOMS) (Prisons & Probation)  
 
For NHS/HSC R&D offices, the CI must create SiteSpecific Information Forms for each site, in addition to the 
study wide forms, and transfer them to the PIs or local collaborators.  
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It looks like your project is research requiring NHS R&D approval but does not require review by a REC 
within the UK Health Departments Research Ethics Service – is that right?  
Yes 
4b. Please confirm the reason(s) why the project does not require review by a REC within the UK Health 
Departments Research Ethics Service:  
Projects limited to the use of samples/data samples provided by a Research Tissue Bank (RTB) with generic 
ethical approval from a REC, in accordance with the conditions of approval.  
Projects limited to the use of data provided by a Research Database with generic ethical approval from a REC, in 
accordance with the conditions of approval.  
Research limited to use of previously collected, nonidentifiable information  
Research limited to use of previously collected, nonidentifiable tissue samples within terms of donor consent  
Research limited to use of acellular material  
Research limited to use of the premises or facilities of care organisations (no involvement of patients/service users 
as participants)  
Research limited to involvement of staff as participants (no involvement of patients/service users as 
participants)  
5. Will any research sites in this study be NHS organisations?  
  Yes  
5a. Are all the research costs and infrastructure costs for this study provided by an NIHR Biomedical 
Research Centre, NIHR Biomedical Research Unit, NIHR Collaboration for Leadership in Health Research 
and Care (CLAHRC) or NIHR Research Centre for Patient Safety & Service Quality in all study sites?  
No 
If yes and you have selected HRA Approval in question 4 above, your study will be processed through HRA 
Approval.  
If yes, and you have not selected HRA Approval in question 4 above, NHS permission for your study will be 
processed through the NIHR Coordinated System for gaining NHS Permission (NIHR CSP).  
If yes, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form immediately after  
If yes, and you have not selected HRA Approval in question 4 above, NHS permission for your study will be 
processed  
IRAS Version 5.0.0 through the NIHR Coordinated System for gaining NHS Permission (NIHR CSP).  
Full Set of Project Data  
5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network 
(CRN) support and inclusion in the NIHR Clinical Research Network (CRN) Portfolio? Please see 
information button for further details.  
No  
If yes, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form immediately after 
completing this project filter and before submitting other applications. If you have selected HRA Approval in 
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question 4 above your study will be processed through HRA Approval. If not, NHS permission for your study will 
be processed through the NIHR Coordinated System for gaining NHS Permission (NIHR CSP).  
6. Do you plan to include any participants who are children?  
No 
7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity 
to consent for themselves?  
No  
Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the 
study following loss of capacity. Intrusive research means any research with the living requiring consent in law. 
This includes use of identifiable tissue samples or personal information, except where application is being made 
to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. 
Please consult the guidance notes for further information on the legal frameworks for research involving adults 
lacking capacity in the UK.  
8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM 
Prison Service or who are offenders supervised by the probation service in England or Wales?  
No  
9. Is the study or any part of it being undertaken as an educational project?  
Yes  
Please describe briefly the involvement of the student(s): 
This is part of a Professional doctorate in Health and Social Care based at Royal Holloway University of London. 
The student (myself) will interview nursing and medical staff involved in cancer care and deploy thematic 
qualitative data analysis to extrapolate themes useful for interprofessional working. The student will examine the 
documentary evidence surrounding cancer clinical trials and will keep an observation diary of interprofessional 
working.  
9a. Is the project being undertaken in part fulfilment of a PhD or other doctorate?  
Yes 
10. Will this research be financially supported by the United States Department of Health and Human 
Services or any of its divisions, agencies or programs?  
No  
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of 





Appendix C5.2 CEU Approval 
 
Clinical Effectiveness Unit  
9 Prescot Street London E1 8PR  
Switchboard: 020 3416 5000 General fax: 01234 567 890 www.bartshealth.nhs.uk  
Prof Jon Gabe  
12th October 2015  
Dear Prof Gabe,  
Laura O’Regan’s Evidence of Quality Improvement Project Registration  
The following Quality Improvement Project:  
What is the interprofessional experience of communication that impacts on obtaining 
informed consent to cancer clinical trials? : A single centre qualitative case study.  
...was registered by Laura O’Regan on the 1st October 2015 and subsequently endorsed by 
the appropriate Clinical Effectiveness Lead on the 9th October 2015.  
Ms O’Regan is now free to begin her project. Yours sincerely,  
Clinical Effectiveness Unit 






Appendix C5.3 RHUL Approval  
Department of Social Work 
Dr Frank Keating, Director of 
Research 
Royal Holloway, University of 
London 
Egham, Surrey TW20 0EX 
Department of Social Work 
Department • +44 (0)1784 414964 
frank.keating@rhul.ac.uk  
www.rhul.ac.uk    
 
 
9th June 2015 
Laura O’Regan 
(via email) 
Dear Laura  
RE: Upgrade Outcome 
Thank you for attending the upgrade meeting and I can confirm that your proposal 
has been approved and you can now proceed with the next stage of your project, 
i.e., seeking the necessary ethical approvals and arranging a meeting with your 
supervisor to plan future steps. I attach the ethics form which has to be signed by 
your supervisor before submission to the departmental research committee (via me). 









Appendix C5.4 (a) Self- Certification  
(Both sent to Supervisor prior to data collection) 
 
Ethics Review Details  
You have chosen to self- certify your project.  
Name:  O'Regan, Laura (2013)  
Email:  RXJD002@live.rhul.ac.uk  
Title of research 
project or grant:  
What is the interprofessional experience of communication that 
impacts on obtaining informed consent to cancer clinical trials? : 
A single centre qualitative case study.  
Project type:  Royal Holloway postgraduate research project/grant  
Department:  Social Work  
Academic 
supervisor:  
Professor Jon Gabe  






No external funder  
Funding Body:   
Start date:  30/12/2015  
End date:  30/12/2018  
Research question summary: 
The purpose of this study was to explore and analyse the interprofessional 
experience of communication that impacts on obtaining informed consent to cancer 
clinical trials. 
What am I trying to find out? 
1. The professional perspective on why so few potentially eligible cancer patients are 
recruited to CCTs? The recruitment rates, documentary review and known patient 
barriers that impact on obtaining consent provide background rationale. 
2. To identify how the interprofessional discourse impacts on obtaining informed 
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consent to CCTs, identifying elements of and gaps pertaining to interprofessional 
working. 
3. To identify how different professionals perceive their role and the role of others in 
the phenomenon. Professional values and motivations are sought. Documentary 
evidence on competencies and policies informing practice are explored. 
4. To identify the professional developmental needs that can improve obtaining 
informed consent to CCTs. The aim is to identify the potential for process and 
interprofessional communication improvements ultimately improving patient 
outcomes. 
5. To address the knowledge gap on the interprofessional experience of this 
phenomenon.  
Research method summary: 
This study falls into the qualitative research family. Blaxter et al. (2010) further 
describe qualitative as a naturalistic phenomenological mode where the subjective 
experiences of individuals are sought in the real life setting. Giving meaning to the 
structure is referred to by van Manen (1990) as the lived experience. Qualitative is 
preferred over quantitative research as it is the most appropriate methodology 
because it examines personal meanings (Poger and Thomas, 2000). It seeks depth 
as opposed to a breadth of information. It is preferable in the natural and practice 
setting as a case study where the researcher was also a practitioner. The study 
neither seeks to change not is it experimental. 
The Research design uses an instrumental local institution case where the subject is 
the interprofessional experience and the object is the impact on informed consent to 
CCTs. 
The data collection methods are semi-structured interviews, diaries (reflective diary) 
and documentary evidence.  
Risks to participants  
Does your research involve any of the below? Children (under the age of 16), 
No  
Participants with cognitive or physical impairment that may render them unable to 
give informed consent, No  
Participants who may be vulnerable for personal, emotional, psychological or other 
reasons,  
No  
Participants who may become vulnerable as a result of the conduct of the study (e.g. 
because it raises sensitive issues) or as a result of what is revealed in the study (e.g. 
criminal behaviour, or behaviour which is culturally or socially questionable), 
No  
Participants in unequal power relations (e.g. groups that you teach or work with, in 




Participants who are likely to suffer negative consequences if identified (e.g. 




If in the instance that participants feel uncomfortable by any of the questions asked 
because of their role, it is made clear to them that all information is non-identifiable, 
and only issues that could be at risk to patient care would need reporting. There is 
on site counselling available for professional supervision if needed. 
This poses none to minimal risk to any participants.  
Design and Data  
Does your study include any of the following?  
Will it be necessary for participants to take part in the study without their knowledge 
and/or informed consent at the time?, No  
Is there a risk that participants may be or become identifiable?, No  
Is pain or discomfort likely to result from the study?, No  
Could the study induce psychological stress or anxiety, or cause harm or negative 
consequences beyond the risks encountered in normal life?, 
No  
Does this research require approval from the NHS?, Yes  
If so what is the NHS Approval number, 6397  
Are drugs, placebos or other substances to be administered to the study participants, 
or will the study involve invasive, intrusive or potentially harmful procedures of any 
kind?, 
No  
Will human tissue including blood, saliva, urine, faeces, sperm or eggs be collected 
or used in the project?, No  
Will the research involve the use of administrative or secure data that requires 
permission from the appropriate authorities before use?, No  
Will financial inducements (other than reasonable expenses and compensation for 
time) be offered to participants?, No  
Is there a risk that any of the material, data, or outcomes to be used in this study has 
been derived from ethically-unsound procedures?, No  
Details,  
Risks to the Environment / Society  
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Will the conduct of the research pose risks to the environment, site, society, or 
artifacts?, No  
Will the research be undertaken on private or government property without 
permission?, No  
Will geological or sedimentological samples be removed without permission?, No  
Will cultural or archaeological artifacts be removed without permission?, No  
Details,  
Risks to Researchers/Institution  
Does your research present any of the following risks to researchers or to the 
institution?  
Is there a possibility that the researcher could be placed in a vulnerable situation 
either emotionally or physically (e.g. by being alone with vulnerable, or potentially 
aggressive participants, by entering an unsafe environment, or by working in 
countries in which there is unrest)?, No  
Is the topic of the research sensitive or controversial such that the researcher could 
be ethically or legally compromised (e.g. as a result of disclosures made during the 
research)?, 
No  
Will the research involve the investigation or observation of illegal practices, or the 
participation in illegal practices?, No  
Could any aspects of the research mean that the University has failed in its duty to 
care for researchers, participants, or the environment / society?, 
No  
Is there any reputational risk concerning the source of your funding?, No  
Is there any other ethical issue that may arise during the conduct of this study that 
could bring the institution into disrepute?, No  
Details,  
Declaration 
By submitting this form, I declare that the questions above have been answered 
truthfully and to the best of my knowledge and belief, and that I take full responsibility 
for these responses. I undertake to observe ethical principles throughout the 
research project and to report any changes that affect the ethics of the project to the 
University Research Ethics Committee for review.  
Certificate produced for user ID, RXJD002  
Date:  03/11/2016 21:11  
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Signed by:  O'Regan, Laura (2013)  
Digital 
Signature:  
Laura J O'Regan  
Certificate 
dated:  
11/3/2016 9:19:08 PM  
Files 
uploaded:  
Full-Review-314-2016-11-03-21-11-RXJD002.pdf Laura O'Regan 












Appendix C5.5 Letter of Invite 
Dr/Nurse. XXX 
Cancer Clinical Trials team 
/Cancer services (Daycare /Ward)  
London Cancer Clinical Trials Office  
Xxxxx Hospital 
London 
Re: Research Study: What is the interprofessional experience of communication that 
impacts on obtaining informed consent to cancer clinical trials? : A single centre 
qualitative case study. 
Dear Sir/Madam, 
I am currently undertaking a research study as part of my Professional Doctorate in Health and 
Social Care at Royal Holloway University. I am working as a Senior Research Nurse in the 
Haemato-Oncology section of the Cancer Clinical Trials Office and have been as a specialist 
nurse in the Haemato-Oncology specialty for some years.  
Recruitment of patients to cancer clinical trials is one of the primary objectives of the 
clinical trial team. I am interested in how professional communication and collaboration can 
impact on informed consent and how different professions view the roles and responsibilities. 
This study aims to answer the question: What is the interprofessional experience of 
communication that impacts on obtaining informed consent to cancer clinical trials? : A 
single centre qualitative case study. 
The purpose of this case study is to use a phenomenological approach to gain an 
understanding of how different professionals (both clinical and non-clinical) experience 
interprofessional communication that leads to obtaining informed consent. The researcher is 
particularly interested in how different professions conceptualise their role and the role of 
others and how all professionals experience interprofessional discourse and how that impacts 
on informed consent. My hope is that this study will identify the main themes in relation to the 
challenges for professions and interprofessional challenges that preclude recruitment or that 
recruit non-compliant patients. This may have a positive educational and practice impact on 
the cancer clinical trial local delivery team and other centres in the future. 
This is a generic invite which aims to recruit a minimum of 25 participants collectively 
from the medical and the nursing profession. I am inviting consultants and registrars, research 
nurses and specialist nurses some of whom may not be clinical. I am not writing to each staff 
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member individually. Therefore this letter can be passed on to a colleague who might be 
interested.  
Anyone who chooses to take part will be requested to sign a Consent Form. The 
participant commitment will be partaking in a 45 minute audio taped interview (interview can 
be terminated earlier at request) and is held in a private clinic room. A second short interview 
of ten minutes approximately 2 weeks after transcription gives participants to add any further 
comments. All participants complete a demographic details form used to categorise the 
professions and grades. 
Data collected from you at the time of interview and via the demographic form is treated 
with the strictest confidence and is anonymous. You have the right to take part or at any stage 
withdraw your consent without penalty.  
Thank you for taking the time to read this letter. Should you wish to find out more about 
the study before you take part and/ or part take in the study, please feel free to contact me on 
my work phone or email below.  
Email:l.oregan@sgul.kingston.ac.uk 
If you are happy to proceed and part take in the study please sign the consent form attached, 
and return it to me in the pre-stamped envelope. I have enclosed the information sheet for you 
to retain for your reference. Should I not hear from you I will assume that you do not want to 
take part and I will not contact you again. 
Yours sincerely, 




Appendix C5.6 Consent Form 
 
I ______________ have read and understand the letter of invitation to take part in the 
research study: What is the interprofessional experience of communication that impacts 
on obtaining informed consent to cancer clinical trials? : A single centre qualitative case 
study. 
I have received sufficient information about the study and I understand that I will need 
to answer a demographic form and will be interviewed to obtain my experiences. 
I am aware that I can withdraw at any time without penalty. I understand that I will be 
asked to meet for a second short interview for the verification purposes at which time a 
transcription of my interview can be kept.  
I agree to the researcher communicating to the authorities any governance concern that 
has or may have a negative impact on patient care while making all attempts to maintain 
confidentiality.  
Should I have any concerns about the study or conduct of the researcher the research 
supervisor, Professor Jon Gabe can be contacted at j.gabe@rhul.ac.uk 
I hereby consent to participate in this research study. 
Please indicate: 
I have read the information sheet about this study (Yes/No) 
I have had an opportunity to ask questions (Yes/No) 
I have received satisfactory answers to my questions (Yes/No) 
I understand that I am free to withdraw from the study at any time, without giving a reason 
(Yes/No) 
I agree to participate in this study (Yes/No) 









Appendix C5.7 Participant information sheet 
Royal Holloway University of London 
Department of Health and Social Care 
Re: Research Study:  
What is the interprofessional experience of communication that impacts on obtaining 
informed consent to cancer clinical trials? : A single centre qualitative case study. 
I am currently undertaking a research study as part of my Professional Doctorate in 
Health and Social Care at Royal Holloway University. I am working as a Senior Research 
Nurse in the Haemato-Oncology section of the Cancer Clinical Trials Office and have been as 
a specialist nurse in the Haemato-Oncology specialty for some years.  
Recruitment of patients to cancer clinical trials is one of the primary objectives of the 
clinical trial team. I am interested in how professional communication and collaboration can 
impact on informed consent and how different professions view the roles and responsibilities. 
This study aims to answer the question: What is the interprofessional experience of 
communication that impacts on obtaining informed consent to cancer clinical trials? : A 
single centre qualitative case study. 
The purpose of this case study is to use a phenomenological approach to gain an 
understanding of how different professionals (both clinical and non-clinical) experience 
interprofessional communication that leads to obtaining informed consent. The researcher is 
particularly interested in how different professions conceptualise their role and the role of 
others and how all professionals experience interprofessional discourse and how that impacts 
on informed consent. My hope is that this study will identify the main themes in relation to the 
challenges for professions and interprofessional challenges that preclude recruitment or that 
recruit non-compliant patients. This may have a positive educational and practice impact on 
the cancer clinical trial local delivery team and other centres in the future. 
This is a generic invite which aims to recruit a minimum of 25 participants collectively 
from the medical and the nursing profession. I am inviting consultants and registrars, research 
nurses and specialist nurses some of whom may not be clinical to attend the interview in a 
private clinic room as convenient for you within the hospital. I am not writing to each staff 
member individually. Therefore this letter can be passed on to a colleague who might be 
interested.  
Anyone who chooses to take part will be requested to sign a Consent Form. The 
participant commitment will be partaking in a 45 minute audio taped interview (interview can 
be terminated earlier at request) and is held in a private clinic room. A second short interview 
of ten minutes approximately 2 weeks after transcription gives participants to add any further 
comments. All participants complete a demographic details form used to categorise the 
professions and grades. 
Data collected from you at the time of interview and via the demographic form is treated 
with the strictest confidence and is anonymous and the consent form is separated and stored 
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separately from your answers. You have the right to take part or at any stage withdraw your 
consent without penalty or impact on your position, and you can choose to not answer a 
question if you so wish. You may retain this information sheet for reference. 
Should you have any concerns or queries about the study or conduct of the researcher 
the research supervisor, Professor Jon Gabe can be contacted at j.gabe@rhul.ac.uk 
Thank you for taking the time to read this letter. Should you wish to find out more about 
the study before you take part and/ or part take in the study, please feel free to contact me on 
my work phone or email below. 
Email: l.oregan@sgul.kingston.ac.uk 
If you are happy to proceed and part take in the study please sign the consent form 
attached, and return it to me in the pre-stamped envelope. Should I not hear from you I will 
assume that you do not want to take part and I will not contact you again. 
 
Yours sincerely, 
Name: Laura O’Regan 
Senior Research Nurse  
Cancer Research Delivery Group 




Appendix C5.8 Full Demographics 
Demographic details collected from the Nurse Participants at Interview 
RN= Research Nurse N= Registered Nurse (in Haemato-Oncology) 
P PN1 PN2 PN3 PN4 PN5 PN6 PN7 PN8 PN9 
MN 













30-39 50-59 30-39 20-29 
Gender F F F F F F F F F M M F 
Job RN RN RN RN N N RN RN N RN RN/N N 
Take 
consent 





No No No No No No No No Yes No Yes No 
Education BSc BSc BSc MSc BSc BSc BSc BSc Diploma BSc BSc PGDip 
/BSc 
 
Demographic details of Doctor Participants 
Con= Medical Consultant     MD= Medical Degree 
Prof= Professor of Medicine (Haem-Oncology)  PHD=Doctorate 
SpR= Specialist Registrar     MSc=Master of Science 
F2- Senior House Officer Doctor Day-care 
P PD1 PD2 PD3 PD4 PD5 PD6 PD7 PD8 PD9 PD10 
Age 30-39 30-39 30-39 20-29 30-39 60+ 40-49 30-39 30-39 30-39 
Gender F M F F M M F F M M 
Job Con SpR SpR F2 SpR Prof Con SpR Con SpR 
Take 
consent 
Yes Yes Yes No Yes Yes Yes Yes Yes No 
Formal 
Training 
No Yes Yes No Yes Yes Yes No No Yes 
 
Demographic details of Manager Participants 
OPM= Outpatient manager  CM= Clinical manager  
BTM=Blood Transfusion Manager   Dip= Diploma 
P PM1 PM2 PM3 PM4 
Age 40-49 20-29 30-39 20-29 
Gender M F M F 
Job CM CM BTM OPM 
Take 
consent 
No No Yes No 
Formal 
Training 
No No No No 





Appendix C5.9 Interview Schedule 
(a) Interviewee Data Collection Schedule 
Study Title: What is the interprofessional experience of communication that 
impacts on obtaining informed consent to cancer clinical trials? : A single centre 
qualitative case study. 
Demographic Section 






2. Please tick are you  
Female 
Male 
3. Please tick one of the following 
Are you a Consultant? 
Are you a Specialist Registrar? 
Are you a research nurse? 
Are you a specialist nurse? 
Are you a manager who is professional but non clinical? 
4. Do you undertake consenting patients to cancer clinical trials? 
Yes 
No 














(b) Interview Guide 
Q1 - How is a patient consented to a Cancer Clinical Trial? 
Probes 
When does the process of obtaining consent start? 
Who are the professionals involved? 
Do you think that has significance? 
Would that be the general view? 
Tell me your experience of this? 
Q2- What is the role of the physician in obtaining consent? 
Probes 
Is this the general view? 
Explain what your experience has been? 
What are the most important motivating aspects for you? 
Please feel free to give examples for above points. 
Q3 - What is the role of the research nurse in obtaining consent? 
Probes 
Is this the general view? 
Explain what your experience has been? 
What are the most important motivating aspects for you? 
Please feel free to give examples for above points. 
Q4 - What is the role of the wider team regarding obtaining consent to cancer 
trials? 
Probes 
Does the wider team have an impact on clinical trial consent? 
Explain what your experience has been? 
Please feel free to give examples for above points. 




How do different professionals respond to these barriers? 
Should professionals respond differently? 
Explain why? 
What is your experience? 
How can staff influence/ impact clinical trial consent? 
Q6- How do patients experience cancer clinical trial consent? 
Probes 
What does this mean? 
Has this significance in terms of decision making? 
Explain examples from your own experiences. 
Is this the general view?  
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Appendix C5.10 SOP for Consent taking  
Local Standard Operating Procedure: Informed Consent for Clinical Research  
(main points / unable to duplicate due to copyrights). 
Referenced from:  
Declaration of Helsinki (2008): that physician or another qualifying individual 
must seek the potential subjects freely given informed consent, preference in writing 
and witnessed.  
General Medical Council (2008): Consent Guidance. 
Nursing and Midwifery Council (2015): Consent Guidance.  
Good Clinical Practice (2008): Consent Guidance.  
3 Steps Process which includes:  
1- The giving of information 
2- The discussion and clarification of the information 
3- Taking the subjects verbal and written consent 
Effective communication is the key to participants enabling informed decisions 
about participation in a clinical trial. When providing information, researchers should 
do their best to find out about participants condition and treatment beliefs, culture, 
occupation or other factors that may have a bearing on the information they require. 
Confirms that the practice of IC is an on-going process performed by all members of 
the clinical trial team.  
Legally acceptable representative (according to GCP 1.37): 
“An individual or juridical or body authorised under the applicable law or 
consent, on behalf of a prospective subject, to the subjects participation in the Clinical 
Trial”.  
Impartial Witness: 
“A person who is independent of the trial, who cannot be unfairly influenced by 
people involved in the trial, who attends the IC process if the acceptable legal 
representative cannot read the Informed Consent Form and any other written 
information supplied to the subject.”  
Other staff responsibilities: 
• If agreed to suitably qualified number of the research team and is considered 
on a trial-by-trial basis, taking into account the local circumstances, sponsor 
requirements and GCP.  
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• Staff are prepared to take on the additional responsibility and feel confident to 
take informed consent in line with the relevant code of professional conduct.  
• Has a comprehensive understanding of the study and all training is 
documented. 
• An effective line of communication is maintained back to the Principle 
Investigator.  
Time: 
All participants are given ample and sufficient time to make an informed 
decision with regard to the trial entry. IC is gained before the start of the trial.  
Reading and Writing: 
If the subject is unable to read or write; an Impartial Witness should be present 
(to read and explain) or the Legally Acceptable Representative. 
Non-English speaking: 
Every effort is made to not exclude non-English speaking speakers. Access to 
CCT is enabled by incorporating an impartial interpreter or Impartial Witness- they 




Appendix C5.11 Colaizzi’s 7 steps of analysis (as adopted by Sanders, 2003) 
1. Each transcript should be read and re-read in order to obtain a general sense about the whole content.  
 
2. For each transcript, significant statements that pertain to the phenomenon under study should be 
extracted. These statements must be recorded on a separate sheet noting their pages and lines 
numbers.  
 
3. Meanings should be formulated from these significant statements.  
 
4. The formulated meanings should be sorted into categories, clusters of themes, and themes.  
 
5. The findings of the study should be integrated into an exhaustive description of the phenomenon 
under study.  
 
6. The fundamental structure of the phenomenon should be described.  
 
7. Finally, validation of the findings should be sought from the research participants to compare the 





Appendix C5.12: Transcript 
I: Welcome xxx and we have gone through the background. So, can you describe how 
a patient is consented to a cancer clinical trial? 
CD1: So, I suppose the first step is informing the patient of the potential options relating 
to the clinical trial and then we start by having an informal discussion about what the trial is 
and why they would be suitable to go into that trial, why we think it is a good treatment option 
at that stage. So, informal discussion around and why we think a clinical trial is a good option 
as opposed to the standard treatment if there is one. And then give them an opportunity to ask 
any questions at that very early stage and then probably the next step is to give them more 
details if it is something they are interested in pursuing, then we give them written information 
in the form of a PIS and we would allow them to take that away and read that and give them at 
least 24 hours to go through it and let the information assimilate and come back to us with any 
questions they might have relating to the information that they have read. 
I: So, at that point in time it is the patient who is involved with you. Are there any other 
professionals involved up until that point?  
DC1: Yeah, I suppose on a basic level we would generally discuss in the context of the 
MDT so already discuss at that level and the clinical trial has been suggested as a 
recommendation coming out from the MDT and probably before I see the patients I (myself) 
would make myself familiar with the trial that is on offer. I might liaise with whoever is leading 
the research from a nursing point of view just to make sure that the trial is open and that I am 
allowed to give out information to the patient. 
I: So, the role of the physician, how would you see the role of the physician yourself? 
DC1: I suppose I see my role as being a / I am the patient’s advocate so I would be 
informing the patient about the trial to the best of my ability, giving them a balanced overview 
and what the trial involves but also if they decide to not go for the trial what treatment is on 
offer. So, giving them a fairly/ recommending the best course of action regarding the trial but 
also laying out the other options so that they can come to an informed decision on their own 
really.  
I: So, what /so you would rely on the patient to make the decision? 
DC1: Well I would see it as / ultimately it would be their decision but it would be my 
recommendation, and a clinical recommendation would be a trial at this stage but I wouldn’t 
decide, I can’t dictate that that’s going to happen. So, they would have to willingly consent. 
I: So, you mention about the role of being an advocate, so what would be the most 
motivating aspect from you as a physician?  And how would you conceptualise that and what 
is the thing that motivates you? 
DC1: To enter the clinical trial?  
I: Yes, with regard to the consenting of patients to clinical trials? You can be honest. 
DC1: Ask me again? 
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I: What motivates you to consent patients to cancer clinical trials? 
DC1: So, because if I think it is a trial that has shown great promise like a phase 2 or 3 
trial and there is good data coming out of it from other institutions or from other trials that have 
gone before and if there is standard or care or there is no standard of care at that stage. I suppose 
if I think obviously there are issues around recruiting patients to trials and we are active in this 
institution and we are always trying to consent people to trials as much as possible but it has to 
be in the best interests of patients and we wouldn’t put patients into trials because we need to 
make up numbers. Primarily it is that it has to be in the best interest of patients when there is 
no standard and the alternative is more attractive I suppose. 
I: And so, the general view would be similar to your view.  
DC1: Yes, and in amongst that is the general drive to find newer or better approaches 
to patient care but you still can /make sure that you were selecting patients that it was in their 
best interests over and above everything else. 
I: Even if it was a phase one trial? 
DC1: Well I think that would come down to a discussion with the patient as to what 
was their best interests again they might decide that having no treatment is preferable than 
having it. And you would have to have that discussion with them but obviously I think a lot of 
patients would view even phase one trials as a good opportunity maybe not necessarily 
knowing what is going to come out of it for them because they know that it is going to help to 
gain more information for other patients in the future. But you would have that discussion 
openly with them that they would know going into it that there would be no guarantees about 
what the outcomes would be.  
I: So, I mean irrespective of what phase the trial is what would you say the role of the 
wider team is, nursing as a profession in that process? Do you think they have a role? 
DC1: Yes, so I think that /well from a nursing perspective/the role is primarily to 
support the patient once they are in the trial/whether that is helping to give them more 
information they have read about and reiterating like with chemotherapy. So, whenever I 
consent for chemotherapy then one of the CNSs would go through it again and make sure they 
have the information and ask any questions and so certainly to support my role in consolidating 
any information we discussed in the case of informed consent, but also in trials facilitating the 
screening process. 
I: Ok really helpful yes. And does the wider team outside of the clinical trial team/ 
cancer research delivery team have a role here and if they do what is their role like the CAG 
the rest of the people do they have a role in terms of accrual of patients, consent? Do you see 
them as having any impact? 
DC1: I suppose some of the more senior consultants might have more of an opinion 
about that but I think in general you want to work within a supportive dept so as dept who is 
very active in recruiting patients to clinical trials and if you don’t have that support from the 
broader infrastructure then I think that the work and effort that goes into setting up and running 
a trial / it becomes very difficult unless you have that/ those people in the broader team. 
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I: So, it is the ideal is to have the support from both sides from within and outside the 
clinical trial team? 
DC1: Yeah    
I: Let’s suppose there are sometimes barriers to recruiting or consenting patients to 
clinical trials what do you think that those might be in your experience? 
DC1: So on occasions it takes a long time to get trials open so there might be trials that 
we have accepted or that we want to open and that have been through the process of set up but 
that set up can take a long time so it can be frustrating when you know that you have a patient 
whom you know can be very suitable and you can’t quite/ and don’t know what the time line 
is going to be and obviously you are going to have at some point but you don’t know when and 
so then it becomes very difficult to make decisions about does the patient have time to wait or 
should we be looking at other treatment options so that can be a big challenge I think. 
I: so how do the physicians and people at your level respond to that challenge? Can you 
respond to that? 
DC1: Am, I mean I think if you are the PI in charge of the trial you probably have a 
little more weight in terms of what the issues are in terms of the set up and trying to identify 
ways to resolve those issues but then that involves the support of the infrastructure and the 
support of the wider Dept and that is not always forthcoming. 
I: Do you think that’s just your experience here or everywhere or is it just here? 
DC1: I think that is really difficult for me to answer because this is the only place that 
I have been a consultant and I am not in a position where I have had so much exposure to 
recruiting patients to a clinical trial and also consenting for clinical trials so I think I don’t 
know was I am aware of the issues in the other places that I have worked. 
I: And so apart from delays in getting a trial open what other obstacles have you 
encountered in getting patients recruited or consented to clinical trials? 
DC1: Getting patients consented to trials?  
I: Because on trials are a much smaller percentage than patients who are not on trials 
so there is a much smaller percentage of patients but then there are a lot of trials that maybe 
patients could have access to so where are the other challenges or obstacles in getting those 
people that are the larger percentage the opportunity to join a trial? 
DC1: mm.  
I: From your experience do you know of any other issues that you have encountered 
here? 
DC1: I suppose before you actually get to the stage of consenting patients it is 
identifying patients who are suitable to go into the trials can be a challenge so I think we have 
gotten better at it in the year that I have been here. I think unless the trial is in the forefront of 
people’s minds and that everybody knows it is open or you have got one person who is 
advocating for that trial and they are very proactive in looking for patients who might be 
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suitable to enter. I think it is very difficult sometimes you might forget or miss patients who 
could be eligible. I think it has gotten better here since we have had a research presence at the 
mdt and we discuss / and can go through new diagnosis and we can go through any trials that 
might be suitable or just having the forum/ the trials meeting once a week keeping people up 
to date about what is active and what is out there so that you can and everybody is aware of 
what is available so you are always thinking about it whenever you see patients so I think 
before it wasn’t quite as forthcoming. 
I: So those meeting are interprofessional meetings; there is representation from doctors 
and nurses at those 2 meetings. 
DC1: Which I think is really important. 
I: Would that be a more joint approach to what pathway of care that patient actually 
takes? 
I: So, the fact that they are definitely multi professionals at those meeting; would you 
say that everybody communicates what their perspective is at those meetings and that it is 
useful in making a decision? 
DC1: Yeah definitely. I think haematology is a good example of how every professional 
works together as every patient with a diagnosis or relapsed diagnosis is discussed within the 
context of the MDT so we are used to doing that that is the Gold Standard and that is how 
patients should be managed and with that same structure should be in place with regard to 
clinical trial options so I think there has to be in the same forum because that is how our patients 
are discussed and that is how we make treatment decisions for patients. We don’t ever really 
do that unilaterally so .. 
I: So, this is quite new this involvement of different professionals along with the 
medical profession her is quite a new thing? 
DC1: Yeah, I guess it is and it has been a more recent thing with regard to clinical trial 
recruitment potentially. So, we have been doing it for a long time with standard treatments. 
I: That’s really helpful and that takes me through what your perspective of what other 
people’s role is and what your role is and then the wider team and if they have an impact as 
well so that is generally what we have talked about so did you want to add anything else at all? 
DC1: I suppose my overriding impression of the clinical trial activity here is that as a 
kind of team as clinicians we all have the same ethos to clinical trials and all are very 
encouraging of active recruitment to trials but in order for that to flourish it has to be in the 
right environment / with the wider institution and that does not always necessarily feel. 
I: Why is that the case? 
DC1: I am not sure. I think trial activity within haematology is not prioritised whereas 
it might be prioritised in other departments. I think that there is not a brilliant infrastructure in 
terms of staffing levels for running clinical trials here so I think we suffer because we don’t 
have/ we need a bigger team essentially, I think to promote clinical trial recruitment and 
activity. I think the willingness is there but it is not necessarily backed up by the ability to 
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deliver on a basic numbers level. I think research staff are really stretched and they are thinly 
spread. 
I: Why is that/ is that just the state of play in the NHS anyway or is it here? 
DC1: I think it is here. I think other places that I have worked have had more / better 
recruitment and more nursing staff /more visible research nursing teams that can help you 
facilitate getting patients into trials whereas here I think it is really difficult because it falls to 
a very small number of individuals and there are a lot of trials that we want to have open. 
I: Yes, there is a huge portfolio here. 
DC1: Yes, and the numbers don’t match up. 
I: Compared to other centres; trials that are open or opening up. 
DC1: It needs to be matched by the resources to deliver that to help recruit and to help 
support patients into the trials and into the process but I don’t think that it necessarily matches 
up at the moment. 
I: And am but do you think that the physicians have a say in this obstacle that you have 
raised? 
DC1: I don’t know. I don’t know that I have been here long enough to determine that 
but I think probably I think they are kind of Here cancer institute doesn’t have as much 
representation within haemato-oncology as it could do. JG is a big advocate obviously for the 
clinical trials and what we do here but it is a kind of high level within the BCI but I don’t think 
there is enough haem-Onc clinicians that can help kind of shape what we need from a resources 
point of view so it falls to one person which is JG. He is only one person and there is a limit to 
the time as to what he can achieve. 
I: It is really helpful to see as it is a single centre case study and what are the problems 
here and maybe they are similar to problems elsewhere and we know that there are obstacles 
and so it is just about hearing what everybody has to say and what they have to say and what 
their experience is here. So, I think there is lots of useful information here in what you have 
said. Thank you very much name. 
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Appendix C5.13 Code Manual (Steps 3 and 4 of analysis) 
Significant statements Step 1 and 2 (linkage to 
phenomenon) 
Formulated meanings Code bank (Manual in 
NVIVO 10) 
CN5: They (patients) might have been 
propositioned by the doctor about it. If doctors are 
able to, they will give them (patients) time to think 
about it and come back to decide and agree to it. 
 
Doctors obtaining consent 
Doctors’ communication 
Doctors offers trial and gives information 
More than offers- makes a proposal (language used) 
The possibility of giving time to patient to deliberate 
Giving time is uncertain 
Information giving 
Timing of offer 
Time to patient 
Language used to offer 
RD10: It would be really difficult for doctors, 
because they (research nurses) are experts in the 
trial. They (research nurses) are experts, and they 
have a lot more time to sit down with the patient 
and go through. They are prompting everyone to 
make sure that they are sticking to the trial. 
Doctors’ constraints within 
informed consent 
Nurses’ communication in 
obtaining informed 
consent  
How the nurse augments the doctor’s role due to 
doctor’s difficulties (? time constraints) 
Doctor’s (not consultant) highlighting nursing role as 
trial expert and go through (information) 
The relaxed manner in which nurse communicate 
with patient to include body language 
The nursing role to ensure quality control 
Nurses’ as information-giver 
Nurse as social 
communication 
 
Formulated meanings Theme clusters / sub-themes Interpreted theme (related to obtaining informed consent) 
Doctors offers trial and gives information 
More than offers- makes a proposal (language used) 
The possibility of giving time to patient to deliberate 
Giving time is uncertain 
Decision-making role 
Timing of initial offer 
Timing of consent 
Doctors’ information-giving role 
The way responsibility is experienced by doctors (this quote is nurse’s 
view) 
The impact of time on how the doctors’ role is undertaken 
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Formulated meanings Theme clusters / sub-themes Interpreted theme (related to obtaining informed consent) 
Doctor’s (not consultant) highlighting nursing role due to 
constraints- as trial expert and goes through (information) 
The relaxed manner in which nurse communicate with 
patient 
The nursing role to ensure quality control 
Information-giving 
Time as a factor 
Social dimension of 
communication 
Doctors’ is responsible, constraints- knock on effect on nurse role 
Nurses’ role -responsibility has developed form difficulties the doctor 
experiences i.e. lack of time 
Out of this nurses’ role has emerged as a different way of 
communicating  
Nurses can still be experts 
 
 
